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Thesis Summary
The presence of a-smooth muscle actin (a-SMA) containing myofibroblasts are 
responsible for closure of wounds and formation of the collagen-rich scar. The current 
study demonstrated a failure of TGF-pi-mediated fibroblast-myofibroblast 
differentiation associated with in-vitro aging. This was associated with age-dependent 
attenuation of hyaluronan (HA) synthase (HAS) 2 dependent HA induction and its 
assembly into a pericellular coat.
Removal of the HA coat by hyaluronidase (Hyal) digestion led to abrogation of 
dependent induction of a-SMA in young cells. Whilst this illustrated the importance of 
the HA coat during phenotypic activation, its restoration in aged cells as a result of 
HAS2 over-expression, did not lead to the acquisition of a myofibroblast phenotype. 
The HA pericellular coat was necessary but not sufficient to correct for the age- 
dependent defect in phenotypic conversion.
In addition to HAS2 there was loss of EGF receptor (EGF-R) in aged cells and both 
were required for normal fibroblast functionality. The data demonstrated that the HA 
receptor, CD44, co-localises with EGF-R following activation by TGF-Pi. This 
interaction was HA-dependent as disruption of the HA coat abrogates the association 
and inhibits downstream ERK1/2 signalling, required for phenotypic conversion. In 
aged fibroblasts the association was lost with resultant suppression of ERK1/2 
activation. Forced over-expression of EGF-R and HAS2 in aged cells restored TGF-pi- 
mediated HA-CD44/EGF-R association and a-SMA induction.
Collectively, the data demonstrated that HA can serve as a signal integrator by 
facilitating TGF-pi-mediated CD44-EGF-R-ERK interactions and ultimately regulate 
fibroblast phenotype. I propose a model to explain this novel mechanism and the 
functional consequence of age-dependent dysregulation. This mechanism may have 
direct implications for modifying the wound healing response, particularly for 
developing therapeutic strategies to improve healing in the elderly.
v
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Chapter 1 
General Introduction and 
Project Overview
1,1 Aging and Wound Healing
Alterations in response to injury in the aged occur in virtually every system of the body 
from the musculoskeletal system to the central nervous system. The analysis of 
impaired skin wound healing provides a powerful and accessible route to address the 
link between cellular changes (proliferation, differentiation, senescence - all amenable 
to in-vitro dissection) and alterations at the whole tissue level in-vivo. In addition to 
these practical scientific considerations impaired wound healing in the skin represents 
an important health issue with corresponding morbidity and mortality [1].
Put simply, wound healing is impaired with advancing age. The morbidity associated 
with age-related impaired wound healing presents a major clinical and economic 
problem [2]. The financial burden for treatment o f age related acute and chronic wounds 
has been estimated to be in excess of £1 billion per year [3]. In the U.S trauma is the 
fifth leading reason for death of people over the age of 65 [4]. Unless improved wound 
care strategies are developed, the projected relative and absolute increases in the elderly 
population will further exacerbate this problem. Despite the obvious clinical impact 
however, the basic cellular and molecular mechanisms underlying impaired human 
wound healing are largely unknown.
Impaired wound healing in the aged is due partly to comorbidities common among the 
elderly, but evidence also suggests that inherent differences in cellular structure and 
function may impair tissue repair and regeneration as well [5]. Progress in 
understanding the role that growth factors play in wound healing and the ability to 
synthesise adequate quantities of these factors for clinical use has led to clinical trials 
evaluating their use in wound healing. The results of these studies however have been 
disappointing.
The aim of this thesis is to try further the understanding of the mechanisms involved in 
wound healing but critically, how these processes falter with age. Continuing progress 
in understanding the complex interaction between the aging cell and the wound healing
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process is essential in order to explore and develop focussed therapeutic strategies to 
improve healing in the elderly.
1.2 Phases o f  Wound Healing
The response to injury is a primitive but essential, innate host immune response which 
comprises a closely orchestrated cascade of biochemical events that lead to tissue 
reorganisation and restoration of its integrity and function. The molecular interactions 
that underlie wound healing involve the collaborative efforts of many different tissues, 
cell lineages, signalling molecules and matrix proteins. The literature has been 
comprehensively reviewed by Martin [6] and Singer and Clark [7]. Although the wound 
healing process is a continuum it is classically separated into four sequential, yet 
overlapping, phases which are defined as hemostasis, inflammation, proliferation, and 
remodelling.
During hemostasis a fibrin clot is formed at the site of endothelium injury and platelets 
aggregate. Platelets adhere to the injured endothelium and release chemokines, thereby 
attracting the cellular components of the inflammatory phase [8, 9]. The inflammatory 
phase of wound healing is characterised by the presence of neutrophils, macrophages, 
and lymphocytes [9]. The inflammatory cells then serve to release pro-inflammatory 
cytokines and growth factors, ingest foreign materials, increase vascular permeability, 
and promote fibroblast activity [10]. The proliferative phase begins several days after 
the initial injury. In this phase, capillary growth and granulation tissue formation occur. 
Cellular proliferation and abundant collagen synthesis by fibroblasts lead to re- 
epithelialization and construction of a preliminary dermis. The final phase of wound 
healing resolution is a long process of tissue remodelling and increasing wound 
strength. During this phase, type I collagen synthesis and turnover continues and 
fibroblasts differentiate into myofibroblasts, allowing further wound contraction. An 
acellular vascular scar is the final result o f the wound healing process. However this 
fibrous scar does not contain the same proportion of strength and functionality of 
uninjured tissue.
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All four phases of healing (hemostasis, inflammation, proliferation and remodelling) 
exhibit characteristic age-related changes (Table 1). Impaired/delayed healing in the 
elderly is associated with decreased levels of growth factors, diminished cell 
proliferation and migration, an excessive inflammatory response and matrix 
degradation, suggesting that the process of in-vivo aging is a dynamic, complex process 
in which the balance of synthesis and degradation are disrupted [3].
Hemostasis Proliferation
Enhanced platelet aggregation Delayed re-epithelialisation
Increased release of alpha- Delayed angiogenesis
granules
Delayed collagen deposition
Inflammation Resolution
Decreased vascular aggregation Reduced collagen turnover and
remodelling
Increased secretion of Delayed wound strength
inflammatory mediators
Delayed infiltration of Decreased wound strength
macrophages and lymphocytes 
Decreased secretion of growth 
factors
Table 1. Summary of age-related changes in wound healing phases. [2].
1.2.1 Alterations in Hemostasis and Inflammation
Specific age-related changes in the coagulation and immune systems which influence 
healing processes include alterations in cell adhesion, migration, and functional 
responses. Exposure of collagen promotes platelet adherence following endothelial 
damage. Enhanced platelet release [11], adherence [12], and their secretion of alpha-
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granules, which contain transforming growth factor (3 (TGF-p), TGF-a, and platelet- 
derived growth factor (PDGF) [11] have been shown to increase with advanced age.
Nitric oxide is an important vasoactive mediator and its secretion has been shown to 
decrease in aged endothelial cells [13], leading to reduced capillary permeability at the 
injury site. Evidence for the alteration of the inflammatory response in aged individuals 
has also been demonstrated. Cohen et al have reported increased numbers o f wound 
inflammatory cells in aged mice, when compared to young mice, particularly with 
regards to neutrophil infiltration during the early stages of wound healing [14]. 
Conversely, whilst neutrophil numbers increase with age their ability to undergo 
respiratory burst activity and phagocytose bacteria is impaired [15]. Age related changes 
in macrophages appear to be critical in defective wound healing. Whilst matrix 
adherence of peritoneal macrophages may be delayed [16], animal studies demonstrate 
that influx is amplified in aged subjects [17]. Wounded young mice subjected with 
rabbit anti-macrophage serum exhibited impaired healing compared to untreated aged 
mice [14] and moreover, accelerated wound healing following application of young 
peritoneal macrophages was demonstrated in cutaneous wounds of aged mice [18]. 
Studies demonstrate that macrophage function in terms of phagocytic ability [17], 
maturation [16,19] and growth factor release [20], is also defective with age.
1.2.2 Alterations in Proliferation
Angiogenesis, collagen synthesis and re-epithelialization display an age-related delay in 
aged animals [20]. The proliferative response of fibroblasts, endothelial cells and 
keratinocytes is impaired in aged animals [21]. With increasing age, there is a decrease 
in the number and size [22] and proliferative response [21, 23] of fibroblasts. Aged 
fibroblasts have also been shown to exhibit a diminished response to growth factors and 
diminished replicative capacity [22, 24]. These changes result in an age-related delay in 
wound closure in animal models as well as in human wounds [25, 26]. Whole wound 
studies have shown decreased rates of epithelialisation and contraction in older animals 
[27, 28] and humans [29].
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The process of angiogenesis is altered with age although the literature is inconsistent in 
method. The more popular standpoint associates aging with reduced angiogenesis [20]. 
The process of angiogenesis is mediated by release of substances such as Fibroblast 
Growth Factor -2 (FGF-2), vascular endothelial growth factor (VEGF) and PDGF 
secreted by platelets and macrophages and it is thought that an age-related decline in 
secretion of these mediators may be responsible for delayed angiogenesis and 
subsequent impaired wound healing in aged subjects [13, 24]. Data has demonstrated 
that wound capillary ingrowth is reduced with age [30, 31] and that restoration of such 
growth factors specifically reversed impaired microvessel growth in aged mice [31]. 
Some authors, however, have reported an increased angiogenic response with age [16]. 
Whilst Ashcroft et al report delayed angiogenesis, they ultimately demonstrate an 
amplified response in aged mice when compared with young mice [3]. In line with this 
notion one study showed that thrombospondins, proteins with antiangiogenic abilities, 
were abundant in matrix produced by newborn cells but virtually undetectable in the 
matrix of adult cells [32]. By their own admission, Ashcroft et al recognise that 
conflicting data may reflect differences in animal model used, the differences in 
validation o f ‘aged’ animals and differences in the time course of angiogenesis used [3]. 
It would seem, however, that further enquiry is needed to fully realise the specific role 
of angiogenesis in age-related impaired wound healing.
Despite there being no difference in the overall content of collagen in a young or aged 
mature wound, its synthesis is certainly delayed with aging [20] and this delay (with 
type 1 collagen production in particular) can have a negative effect on deposition of 
connective tissue [21]. Degradation of the ECM is necessary for deposition of a new 
collagen scaffold, a process mediated by the matrix metalloproteinases (MMPs). The 
activities of MMPs are kept in check by tissue inhibitors of metalloproteinases (TIMPs). 
Studies have revealed that induction of MMPs and suppression of TIMPs, have been 
attributed to age-related delayed wound healing [33, 34]. In addition, a loss of 
responsiveness of in vitro and in vivo aged human fibroblasts to a variety of cytokines 
and hormones including insulin, epidermal growth factor (EGF), keratinocyte growth 
factor (KGF) and PDGF has been reported [3,19].
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Studies have reported reduced EGF responsiveness due to preferential loss of EGF 
receptors in aging fibroblasts [35]. Furthermore, a marked delay in expression levels of 
EGF and its receptor were observed in aged mouse cells, compared to young expression 
[36]. With age, cells lose responsiveness to PDGF and require increased PDGF 
concentrations to restore proliferative capacity of younger phenotype and moreover, in 
humans, secretion of TGF-(3 is attenuated with increasing age [19, 37]. Dysregulated 
expression of cytokines at the wound site together with reduced levels of fibroblast and 
inflammatory cell-associated TGF-P and PDGF have been observed in aged mice [38]. 
The keratinocyte expression of cytokines and their receptors were found to alter 
dramatically in an aging mouse model o f acute wound healing [36].
1.2.3 Alterations in matrix deposition
In the aging human dermis the fibroblast takes on a quiescent state, with poorly 
developed endoplasmic reticulum [39]. Pienta and Coffey [40] have demonstrated that 
when comparing 20 year old fibroblasts with 66 year old fibroblasts, the aged 
phenotype was characterised with a global decline in all aspects of human fibroblast 
motility. It has also been reported that aging cells are less responsive to chemotactic 
cues from matrix constituents such as fibronectin [41]. Although the observation was 
only made in females it was reported that serum from aged individuals (but not young 
individuals) had an inhibitory effect on the migration of lung fibroblasts [42].
Shevitz et al [43] documented that deposition of fibronectin, one of the main 
components of the provisional matrix, is advanced in late passage fibroblasts. Aged 
fibroblasts exhibit impaired migration, actin cytoskeletal organisation and integrin 
function, [23, 44]. In-vitro wounding experiments demonstrated that, with increasing 
donor age patients, the ability of human skin fibroblasts to re-establish a confluent 
monolayer is decreased [44].
7
1.2.4 Alterations in Remodelling Phase
Late passage human diploid fibroblasts demonstrate an increased contractile phenotype 
on a collagen gel and filamentous actin (f-actin) content. Gibson et al postulate that 
increased f-actin in aged cells facilitates increased contractile strength through 
interactions with the fibronectin integrin receptor [45].
Tissue remodelling inevitably results in formation of a scar with reduced mechanical 
strength from that of normal skin. Animal models have described variable results with 
respect to the effect of age on wound breaking strength [3]. Studies have shown that 
older animals gain wound strength at a slower rate [46]. A significant delay in wound 
closure by old rats was documented during the early phases of repair, after which 
closure rates were equivalent and in-vitro studies showed that despite differences in 
contraction by skin fibroblasts there are no changes in apoptotic or myofibroblast cells 
[3]. A 20% to 60% delay in healing rates has been reported in aged animals when 
compared to their young counterparts [47]. Intriguingly, despite non-healing wounds 
being more prevalent in aged skin, there is now a consensus that rather than being 
defective, healing in elderly patients not suffering from concomitant diseases is simply 
delayed and the final result is qualitatively similar to that of the young. In fact, Ashcroft 
et al [16, 38] demonstrated that acute wounds heal with an enhanced quality of scarring 
in aged individuals. Associated with this was an increased level of elastin and fibrillin 
expression (particularly in females) leading to regeneration of the dermal architecture 
and enhanced macroscopic and microscopic scar quality. The phenomenon of enhanced 
scar quality with age may reflect upregulated type III collagen [48] and reduced levels 
of TGF-p [3], properties which distinguish the regenerative ability of foetal over adult 
wound healing.
1.3 Replicative Senescence
It is universally accepted that human aging has, at least in part, a cellular origin. The 
principle changes that occur in the resident cell populations within the dermis have been 
suggested to result from the accumulation there of senescent cells with an altered 
cellular phenotype and a decreased ability to divide in response to damage or cell loss
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[49]. While a number of these changes may relate to environmental factors such as 
photodamage [50], the inverse relationship between donor age and replicative lifespan 
suggests that the histochemically observed accumulation of senescent cells within the 
dermis represents a component of organismal aging [51, 52].
The phenomenon ‘replicative senescence’ is the term used to describe cells that have 
lost the ability to divide yet remain metabolically active [53]. It is well established that 
in replicative senescence, with the exception of ‘immortal’ embryonic germ and tumour 
cells [54], all human cells exhibit a limited number of population doublings before they 
enter a non-dividing state, which is characterised by irreversible growth arrest of cell 
proliferation within the G1 phase [49], even if stimulated with mitogens [55]. This 
limited replicative potential is also associated with increased cell size and distinct flat 
morphology, senescence associated (3-galactosidase activity, a wide change in gene 
expression [49, 54-56] and synthesis of growth factors, cytokines and ECM components 
[57]. It has been reported that such changes in gene expression may occur much earlier 
in the replicative lifespan[56].
Cellular senescence can be brought about by a number of factors, including oxidative 
stress [49, 54, 58] radiation [58] and may be induced experimentally by repeated 
subdivision in culture, a model developed by Hayflick in the 1960s and for this reason 
replicative senescence is sometimes referred to as Hayflick’s Limit [53]. Gradual 
telomere erosion with successive cell division is thought to be the primary intrinsic 
trigger of replicative senescence in many somatic cell populations [57, 59] and may 
have the potential to contribute to organismal aging [57, 60]. However, in-vivo cellular 
senescence which seems to increase with age may result from stresses that the cells 
sustain through their lifetime and not because they are replicatively exhausted and the 
term stress-induced premature senescence rather than true replicative senescence could 
account for impairment of fibroblast function in non-healing wounds [54]. Accordingly, 
in one study, telomere length in fibroblasts did not correlate with donor age, as 
fibroblasts from centenarians still undergo many population doublings in-vitro [61] and 
telomere independent senescence has been described [49]. Senescence may be an 
underlying cause of aging that evolved to prevent the uncontrolled growth of cells,
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known as cancers and accordingly senescence plays an important role as a tumour- 
suppressor mechanism [62-64].
It was proposed early on that replicative senescence in culture mimics organismal aging, 
particularly aspects of aging, such as delayed wound healing, declining immune 
response, and thinning of the skin [59]. The general assumption that the aging process is 
mirrored by cellular senescence in vitro is based on lower replicative capacity of human 
fibroblasts from patients with accelerated aging syndromes [65], patients with age 
related diseases such as diabetes mellitus, and donors of higher chronological age [54]. 
However, these inverse relations have not been reported unequivocally [54, 66], 
particularly when health status and biopsy conditions were controlled [55]. The 
relationship between cellular senescence and aging in vivo is still not clear but given the 
duration of aging in humans, cell culture studies are a promising approach to the study 
of human aging.
1.4 The Fibroblast
This thesis is principally concerned with the activities of the fibroblast. Fibroblasts 
within the dermis play a pivotal role in controlling wound healing responses; both age- 
and site-specific variations in fibroblast phenotype have been related to the observed 
wound healing phenotype [49]. Within each wound healing phase, fibroblasts execute 
critical tasks dependent upon the fibroblast capacity to migrate to the wound bed and 
proliferate. The fibroblasts capacity to migrate and proliferate basally and in response to 
growth factors has been shown to be decreased markedly as fibroblasts near senescence 
both in vivo and in vitro [35, 67]. This is likely to be a major causative reason for the 
delay and decrease in wound healing in aged individuals, a phenomenon which is the 
main tenet o f this thesis.
Fibroblasts are the most abundant cell-type in physiological connective tissue [68] and 
their prime function relates to the disposition of the extracellular matrix (ECM) and its 
remodelling during normal and pathological processes, such as wound healing [69]. 
Like other cells from the connective tissue, fibroblasts are derived from the embryonic
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mesoderm and thus express the intermediate filament protein, vimentin. Fibroblasts are 
mesenchymal cells and are generally considered to have a uniform morphology and are 
bipolar and spindle-shaped [68] and their actin cytoskeleton is organised into a cortical 
network mostly concentrated just beneath the plasma membrane and they display 
immature focal adhesions
1.4.1 Fibroblast Origin
Depending on the type of tissue to be remodelled, myofibroblast precursor cells are 
recruited from different sources; among these locally residing fibroblasts seem to be the 
most common [70]. Other mesenchymal cells that serve as fibroblastic progenitors are 
pericytes and smooth muscle cells (SMCs) from the vasculature; they seem to play an 
important role during vessel repair and have been suggested to contribute to fibrosis in 
scleroderma [71]. In addition, bone marrow derived cells or fibrocytes have been 
suggested to represent an alternative source for fibroblastic cells during skin wound 
healing and in liver, lung, and kidney fibrosis and represent an important source of 
fibroblasts during healing o f extensive bum wounds where it might be difficult for 
fibroblasts to migrate from the edges of the injury [72]. This large spectmm of 
precursors further underlines the cmcial function of the fibroblast in maintaining tissue 
homeostasis.
1.4.2 Role of Fibroblast in Wound Healing
After tissue injury, cytokines locally released from inflammatory and resident cells [6] 
induce fibroblastic migration into the provisional matrix formed by the fibrin clot, 
whereupon the fibroblasts proliferate and restore ECM components [68] to initiate and 
perpetuate the wound healing processes. Gradually, fibroblastic cells replace the 
provisional fibrin matrix with a loose matrix called granulation tissue, composed of new 
blood vessels, fibroblasts, inflammatory cells, endothelial cells, myofibroblasts, and the 
components of a new, provisional ECM which supports further ingrowth of cells and 
are essential for the repair process. Cmcial interactions between the ECM and 
fibroblasts help regulate further ECM synthesis and its subsequent remodelling.
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Fibroblasts produce the matrix components fibronectin, hyaluronan (HA) and later 
collagen and proteoglycans.
Once within the wound site, fibroblasts proliferate and differentiate into an activated 
phenotype called myofibroblasts. These differentiated fibroblasts are the main cell type 
involved in deposition and remodelling of ECM and ultimately they undergo 
contraction [73], decreasing the size o f the wound and bringing the wound edges into 
closer proximity. The formation of granulation tissue in an open wound allows for re- 
epithelialization and construction of a preliminary dermis. Whilst the age-related 
changes in proliferative and migrative capacity have been well documented [35], less is 
known regarding alterations in phenotypic transformations that accompany aged 
fibroblasts. This thesis attempts to clarify these changes.
In normal conditions, fibroblastic cells exhibit few or no actin-associated cell-cell and 
cell-matrix contacts and little ECM production [74]. Within the ECM, fibroblasts are 
under resting mechanical tension, thus ensuring that the connective tissue maintains its 
shape. Fibroblasts are also stress shielded by the ECM preventing development of stress 
fibres [70, 75] On a cellular level, mechanical strain on the ECM is transmitted through 
integrins to intracellular focal adhesion complexes and the actin cytoskeleton, to alter 
cell signalling [76]. This process, termed mechanotransduction, integrates mechanical 
cues and growth factor-induced intracellular signals to modulate cell functions 
important for wound healing. Fibroblasts in intact tissue are generally stress-shielded by 
the crosslinked ECM and do not develop contractile features and cell-matrix adhesions. 
In the continuously remodelled ECM of injured tissue this protective structure is lost. 
Numbers of fibroblasts increase within the wound and continuous synthesis of ECM 
components [77] enhances matrix rigidity by applying small transitional forces to the 
newly formed granulation tissue [78].
In response to mechanical challenge following injury fibroblasts become activated and 
acquire a migratory phenotype termed the proto-myofibroblast that contain initially only 
P- and y-cytoplasmic actins [68, 70].
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1.4.3 Myofibroblastic Differentiation
With increasing stress in the ECM resulting from their autocrine remodelling activity, 
proto-myofibroblasts further develop into differentiated myofibroblasts (see figure 1.1). 
Their actin skeleton reorganises to form large bundles that run in parallel and terminate 
at the cell periphery and they display an increase in the thickness and number of stress 
fibres [79]. In addition to pre-existing 0- and y-cytoplasmic actins they are characterised 
by expression of a-smooth muscle actin (a-SMA) [72], a mechanosensitive protein [70] 
normally found in smooth muscle cells. Hence, myofibroblasts have structural 
properties between those of a fibroblast and a smooth muscle cell [80].
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Figure 1.1: Two step process of myofibroblastic differentiation in-vivo. Following an increase in 
mechanical tension fibroblasts become activated and acquire a migratory phenotype termed the proto- 
myofibroblast. Proto-myofibroblast are characterised by the presence of stress fibres containing 
filamentous actins and synthesis of ED-A fibronectin. In the presence of prolonged mechanical tension, 
ED-A fibronectin and TGF-pl further differentiation occurs to a contractile phenotype, termed a 
differentiated myofibroblast, characterised by the expression of a-SMA. Taken from [74].
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Morphologically, myofibroblasts have characteristic flattened, irregular shapes and 
well-developed cell matrix interactions and intracellular gap junctions [81]. They can 
also be recognized by the ability to express other smooth muscle cell contractile 
proteins such as desmin, calponin and smooth muscle myosin [74, 82]. Nevertheless, 
incorporation of a-SMA into stress fibres remains the most reliable marker of the 
myofibroblastic phenotype [72].
Expression of a-SMA in stress fibres confers to the differentiated myofibroblast at least 
a two-fold stronger contractile activity compared with a-SMA negative fibroblasts in 
culture [70]. The cellular mechanisms responsible for the a-SMA mediated increase in 
contraction are largely unknown. What is certain is that generation of a-SMA-positive 
differentiated myofibroblasts is dependent on the production by inflammatory cells of 
biologically active transforming growth factor-p, the most accepted stimulator of 
myofibroblastic differentiation [72]. TGF-p neutralizing monoclonal antibody strongly 
reduces a-SMA induction in dermal fibroblasts [83]. The action of TGF-P is dependent 
also on the local presence of the cellular fibronectin splice variant ED-A [72]. ED-A 
fibronectin is expressed in the initial stages o f wound healing and along with collagen I 
is positively regulated by TGF-p [84]. In the absence of TGF-p and/or the ED-A 
fibronectin, fibroblasts can differentiate into the proto-myofibroblast but not to the 
myofibroblast phenotype [74, 85].
Myofibroblasts are involved in the remodelling and deposition of new ECM and 
ultimately granulation tissue contraction and wound closure [68, 70, 72, 86]. They are 
also responsible for subsequent wound contracture and formation of a collagen rich scar 
[86] . They produce the matrix proteins fibronectin, and later collagen types I and III, 
elastin, glycosaminoglycans and proteoglycans [79, 87]. Myofibroblasts also secrete 
various enzymes such as MMPs and tissue inhibitor of the ECM [88], which are capable 
of altering the composition of the ECM. In addition, myofibroblasts can function as 
immune cells and play a significant role in modulating wound repair through the release 
of chemokines, growth factors, and cytokines such as monocyte chemotactic protein-1 
(MCP-1), interleukin-1 (IL)-l, IL-6, IL-8, hepatocyte growth factor (HGF), TGF-p and 
EGF, reviewed in [89].
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Although both fibroblasts and myofibroblasts contribute to normal wound repair the 
latter are present for a finite period and when contraction stops and the wound is fully 
epithelialized few if any a-SMA-containing myofibroblasts are found in the scar [90]. It 
is still unclear whether, during healing, all myofibroblasts undergo apoptosis [68] and 
hence represent terminally differentiated cells [86] or if some revert back becoming 
fibroblasts suggesting that these fibrotic cells in fact represent alternate phenotypes [91]. 
It should be noted that whilst massive apoptosis has been demonstrated in-vivo reversal 
of the myofibroblast has not [68]. Whilst the signals leading to mass suicide are still 
unclear, at the end of tissue repair, the reconstructed ECM once again takes over the 
mechanical burden and this stress release appears to be a powerful promoter of cell 
death and myofibroblast removal [68, 70].
1.4.4 Fibroblast Heterogeneity
Fibroblastic cells represent a heterogeneous group of cells that show functional 
subpopulations during normal conditions in-vivo [92]. Fibroblasts differ between organs 
and also within tissues and show intrinsic differences with respect to size, morphology, 
proliferation rates and collagen turnover [93]. Fibroblasts derived from non-glabrous 
versus glabrous skin (e.g. palms and soles) demonstrate differential proliferative 
capacity and myofibroblastic differentiation [84]. It has been suggested that some 
pathological conditions could be due to the recruitment of fibroblast subtypes, leading 
to the predominance of a particular population or alternatively to the modulation of 
phenotypic features of fibroblasts. For example, distinct fibroblast subpopulations in the 
human reproductive tract contribute differently to the development of inflammation by 
their secretion of soluble mediators [93]. Wall et al demonstrated that, compared to 
healthy skin normal fibroblasts, chronic wound fibroblasts aberrantly express genes that 
regulate the ECM and cytoskeleton, show a decreased ability to repopulate wounds and 
an impaired ability to produce the correct stromal address code required to drive an 
acute-phase inflammatory response [94]. In the same study, chronic wound fibroblasts, 
from different patients, demonstrated very different proliferative capacities. By the 
authors’ own admission this was an indication of the heterogeneous wound
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environments that the cells were derived from, despite the wounds demonstrating 
clinical parallels.
In most cases, repair involves a healing process that is imperfect, producing a fibrotic 
scar rather than flawless regeneration of the original tissue architecture. In contrast to 
the scarring observed in adult dermal wounds, wound healing in the oral mucosa is 
clinically distinguishable by an increased ability to migrate and repopulate a wound 
with no discemable scar formation [95]. The oral mucosal healing process includes the 
same basic steps as cutaneous wounds, however, the unique outcome in the mucosa 
suggests that an altered series of events occurs in response to injury [96]. Several 
studies have demonstrated that the differences in these two tissues in healing potential 
may be a direct result of distinct phenotypic differences between respective fibroblast 
populations [95]. As with wounds in the oral mucosa, human foetus cutaneous wounds 
heal rapidly and perfectly with no scar formation [69, 97]. Foetal fibroblasts are the 
major effector cells responsible for this phenomenon [98]. However, it is unclear as to 
whether myofibroblasts play a role during foetal wound healing. Some authors report 
that there is no apparent conversion from fibroblast to myofibroblast in embryonic 
healing [6], whilst others maintain that fibroblasts do indeed differentiate into 
myofibroblasts, but that this response is altogether more rapid and short lived [99].
The fibroblast lineage is thus not a homogeneous population of cells but rather one that 
is typified by an enormous degree of phenotypic plasticity. A delineation of the role of 
each fibroblast subpopulation may provide insight into the development of treatments 
for pathological conditions such as age-related chronic wounds. The question this thesis 
attempts to answer is whether fibroblast phenotypic plasticity extends to cellular aging? 
Numerous studies have investigated embryonic and oral tissue repair in a search for 
molecular differences that could explain the near “perfect” manner in which they heal 
when compared to their adult dermal counterparts. It has been demonstrated that site- 
specific differences in TGF-p production may contribute to their superior healing.
16
1.5 Transforming Growth Factor beta
Previous work has demonstrated the importance of TGF-p 1 in controlling wound 
healing and mediating the “scarring” phenotype of adult dermal wounds. Furthermore, 
alterations in the migratory and signal transduction responsiveness to TGF-P 1 have 
been postulated to explain the age-related defects in human wound healing [100]. Many 
factors influence repair and one factor that has been intimately linked to wound healing 
and scar formation is TGF-p. TGF-p is an extracellular protein ubiquitously produced 
by all cells [101]. Major sources o f TGF-p include activated macrophages, 
lymphocytes, bone, kidneys, fibroblasts, smooth muscle cells and due to the influence 
of mechanical tension, myofibroblasts themselves [78,101].
The TGF-p family of proteins consists of several structurally related but functionally 
distinct isoforms. In mammals, three isoforms, TGF-pl, - p2 and -  P3, have been 
identified [78, 102]. These isoforms are known to play distinct roles in cell growth, 
differentiation and ECM formation [78] migration and angiogenesis [101]. All of these 
processes are important in tissue development and wound healing [102]. They are 
encoded by different genes but share the same receptors and intracellular signalling 
pathways [103,104].
TGF-pl is synthesised as an inactive precursor. Following translation the inactive 
propeptide is secreted as a large latent complex, covalently bound with latency 
associated peptide (LAP) and is stored in this inactive form in the matrix. Activation of 
TGF-P 1 occurs by proteolytic cleavage of the LAP from the latent molecule, allowing 
the bio-active TGF- pi to interact with specific receptors at the cell surface [105].
1,5.1 TGF~p in Wound Healing
A central event in tissue repair is the release o f cytokines in response to injury. A wealth 
of evidence points to TGF-P as a key cytokine that initiates and terminates tissue repair. 
Upon cutaneous injury, TGF-p is rapidly induced [106]. Expression of TGF-p receptors 
are also elevated [106]. Immediately after injury, degranulating platelets release TGF- 
pl that is chemotactic for the inflammatory cells neutrophils and macrophages and
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mitogenic for collagen-producing fibroblasts [102], which in turn release more TGF-pl 
[106]. TGF-pl is also known to promote fibroblast proliferation [107]. In addition, 
production and activation occur during the wound healing process through autocrine 
and paracrine feedback loops [102]. In injured tissue, TGF-pl continues to be produced 
and activated during all phases o f wound healing and in response to several stimuli 
including plasmin, thrombospondin and reactive oxygen species [102]. TGF-P 1 is 
known to induce the formation of granulation tissue and has been shown to stimulate 
fibroblast collagen synthesis in vitro [108].
TGF-pl inhibits the expression of MMPs, proteases that regulate ECM degradation 
[78]. TGF-pl also enhances the expression of protease inhibitors, including 
plasminogen activation inhibitor-1 (PAI-1) and TIMPs and also increases the expression 
of the ECM components collagen, laminin, and fibronectin [78]. Hence TGF-P 1 not 
only enhances collagen and ECM production, it also inhibits their degradation. Also, 
focal adhesions are known to mature in response to TGF-P 1, resulting in increased cell- 
matrix adhesions and ECM deposition [109]. This control of the ECM has implicated 
TGF-pl as an important factor in fibrotic tissue formation, and scar formation, 
suggesting a central role for TGF-pl in wound healing. [68, 70, 102]. Significant to this 
body of work, TGF-P 1 is also the main promoter of fibroblast-myofibroblast 
transdifferentation, associated with enhanced a-SMA expression [72,110-112].
Dysregulation of TGF-P 1 action has been implicated in a variety of pathological 
processes including cancer [113], autoimmune disease and inflammatory disorders 
[114]. Mice over-expressing or lacking specific TGF-P family members or their 
receptors demonstrate profound effects in the development or homeostasis of many 
organs [115, 116]. Dysregulated TGF-P receptor (TGF-PR) signalling has been shown 
to play a role in chronic fibrotic disease such as scleroderma [106]. Alterations in the 
ratio between TGF-P RI and TGF-p RII may contribute to sustained fibrosis [117].
TGF-pi is responsible for accumulation of myofibroblasts and ECM deposition [118- 
120], making the prolonged release of TGF-pl a candidate for fibrotic disorders [121]. 
TGF-P 1 itself is insufficient to result in persistent fibrotic responses in vivo or in vitro,
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and synergy between other extracellular ligands such as connective tissue growth factor 
(CTGF) was shown in a mouse fibrotic model [122]. Increased levels of TGF-pl have 
been reported in a variety of diseases associated with renal fibrosis including 
glomerulonephritis [123] and diabetic nephropathy [124]. Furthermore, the over 
expression of TGF-pl has been shown to induce chronic kidney disease [125]. TGF-pl 
null mice showed a decreased rate of granulation tissue formation and increased rate of 
epithelialisation compared to wild-type controls suggesting that TGF-pl may act to 
increase inflammation and delay wound closure [126]. That said the administration of 
TGF-pl greatly enhances the repair of injured tissues in several studies. When applied 
topically, healing is improved in a variety o f wound models, including incisional and 
excisional wounds, punch wounds and ulcers [101].
1.5.2 TGF-p Signalling
TGF-pl is known to be involved in a wide range of cellular processes, and for TGF-P 
signalling to occur TGF-P must bind to one of its receptors. There are three types of 
TGF-pR termed type I, type II, and type III. These are located on the cell membrane of 
virtually all cells [127]. The type III receptor (TGF-PRIII), also known as Betaglycan, is 
a membrane anchored proteoglycan that has no signalling structure but acts to present 
TGF-p to other receptors. The type I and type II receptors are trans-membrane serine- 
threonine kinases that interact with one another and appear to be directly involved with 
TGF-p signalling [128]. For signalling to occur binding of active TGF-P 1 to the TGF 
receptor type II serine/threonine kinase receptor (TGF-pRII), leads to the 
phosphorylation and recruitment of TGF-P type I receptors (TGF-pRI) into a 
heteromeric receptor complex. The serine/threonine kinase activity of the activated 
complex propagates signals inside the cell leading to transcription of various genes. 
This occurs principally through activation of the Smad signalling pathway although 
TGF-p signalling can also occur via a number of Smad independent pathways.
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1.5.2.1 Smad Related TGF-pl Signalling
The serine/threonine kinase activity of the activated complex propagates signals inside 
the cell through phosphorylation of receptor-activated (R)-Smads, a family of 
transcriptional factors which can be subdivided into two branches: those which are 
activated by TGF-P and activin (Smad2 and Smad 3) and those which are activated by 
bone morphogenetic protein 7 (BMP-7) signalling (Smadl, Smad5 and Smad8) [129, 
130].
Once phosphorylated, Smads associate as heterodimeric complexes with Smad4, enter 
the nucleus, and bind to specific DNA sequences where they initiate target gene 
transactivation, either alone or in association with other transcriptional partners [131]. 
The inhibitory Smads, Smad6 and Smad7, have the ability to form stable associations 
with TGF-PRI and to interfere with both phosphorylation of Smads and 
heteroligomerization with Smad4 [78].
As earlier mentioned, TGF-P 1 is the main mediator of myofibroblastic differentiation, 
characterised by the up-regulation of a-SMA. The major pathway through which 
TGFpi regulates expression of a-SMA in fibroblastic cells is via Smad signalling [112,
132]. Transcription of a-SMA in lung myofibroblasts and in myofibroblast-like 
activated hepatic cells was reportedly predominantly mediated by the binding of Smad3 
to the Smad-binding element 1 upstream of the a-SMA core promoter sequence [132,
133]. In contrast, another study demonstrated that overexpression of Smad2 but not 
Smad3 induces myofibroblastic differentiation in lung fibroblasts [112]. This 
discrepancy may be due to different roles of Smad2 and Smad3 depending on the level 
of myofibroblast differentiation [134]. Interestingly Ashcroft showed that Smad3 null 
mice present enhanced cutaneous epithelialisation and wound healing [135], whereas 
overexpression or exogenous application of Smad3 was found to accelerate 
myofibroblast differentiation and subsequent wound healing in rabbit dermal fibroblasts 
[136]. Targeted deletion of Smad2 or Smad3 genes in mice and in embryonic fibroblasts 
revealed distinct non-redundant roles for each of these transcription factors [137].
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Whereas Smad2 null mice die in early gestation from defects in gastrulation and 
mesoderm formation, mice with homozygous deletions in the Smad3 gene are viable but 
display impaired immune function and defective neutrophil chemotaxis [138]. These 
observations suggest that there are fundamental differences in the processes mediated 
by Smad 2 and Smad3 in-vivo. Currently, it is debatable as to which of the R-Smads is 
the most important in terms of myofibroblastic differentiation; this thesis will attempt to 
clarify Smad signalling in dermal fibroblasts.
TGF-pl-induced a-SMA expression during myofibroblastic differentiation has been 
shown to proceed in a Smad-independent manner under certain circumstances [68,139]
1.5.2.2 Non-Smad Related TGF-P 1 Signalling
Smad proteins are critical to many of the actions of TGF-P 1. Alternatively, TGF-P 1 can 
regulate fibroblast gene expression independent from Smad signalling [129, 140]. In 
one study Smad-independent TGF-P 1 mediated induction of myofibroblastic 
differentiation was shown to be regulated via activation of phosphatidylinositol 3-kinase 
(PI3K) and the downstream effector p21-activated kinase-2 [141] and regulated through 
the TGF-pl control element [142]. The mitogen-activated protein kinase /extracellular- 
signal-regulated kinases (MAPK/ERK) pathway is required for fibroblast spreading and 
actin stress fibre formation in fibroblasts [139]. Chen et al showed that syndecan 4 is 
required in fibroblasts to integrate TGF-p/ERK signals to induce a-SMA expression 
[139].
Non-Smad signalling proteins have several general mechanisms by which they 
contribute to physiological responses to TGF-P 1. Non-Smad signalling proteins can 
directly modify Smad activity either positively or negatively [106]. TGF-P 1 activation 
of the PI3K pathway has been shown to phosphorylate Smad3 and enhance its 
transcriptional activation of the collagen I gene in mesangial cells [129]. In contrast, the 
absence o f Smad3 confers radioprotection in primary dermal fibroblasts through 
enhanced MAPK-ERK signalling [143]. Such ‘lateral signalling’ by Smad and non- 
Smad interactions helps to explain the diverse array of responses, sometimes conflicting
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(i.e. apoptosis or differentiation), that can result from binding of TGF-P 1 to a single 
receptor complex.
Secondly, Smads can directly interact and modulate the activity of non-Smad proteins 
which transmit signals to other pathways. ERK-MAPK has been shown to directly 
affect Smad3 phosphorylation and vice versa [140]. TGF-P receptors can directly 
interact with or phosphorylate non-Smad-proteins, thus initiating parallel signalling that 
cooperates with the Smad pathway [129].
ERK, p38 MAPK (p38) and c-Jun N-terminal kinases (JNKs) have all been implicated 
in TGF-pl signalling [129]. Chondrocyte differentiation involves Smads and non-Smad 
effectors such as Protein Kinase A (PKA), p38 and ERK [129, 144]. One study 
demonstrated that antagonising either MAPK/ERK or TGF/ALK-5 suppressed matrix 
contraction by dermal fibroblasts, suggesting that integrating TGF-P and ERK signals is 
essential for contraction [139].
Overall, these studies point to the potential complexity of the interplay among Smad 
and non-Smad signalling interactions in the control of wound healing processes.
1.5.3 TGF-fi 1 Signalling and aging
Wound healing is critically affected by age and growth factors such as TGF-P 1. The 
combined effect of these factors on fibroblast migration proliferation and 
differentiation, essential components of wound healing, are poorly understood. Mogford 
et al have demonstrated that alterations in the migratory and signal transduction 
responsiveness to TGF-pl may explain the age-related defects in human wound healing 
[100]. They demonstrate that age-dependent differences in TGF-P 1 responsiveness are, 
in part, supported by a depressed expression of TGF-P receptors and activation of 
downstream effectors. This might explain why application of TGF-pl has failed to, 
[145] or only partially [146], reversed the healing deficit associated with wounds in 
aged animals because of intrinsic cellular deficits. Failure of TGF-P 1 to stimulate an
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increase in age-related wound healing correlates with a failure of growth factors to 
produce favourable clinical trials [147].
1.6 Extracellular Matrix
One emerging theme in aging research is that a number of changes may not have their 
origins in age-related cellular changes but rather in the cellular microenvironment, 
including the local structural architectures. Each can influence the other in a manner 
where cause and effect are difficult to separate. Thus, an understanding of age-related 
changes in the structural microenvironment of the skin is an important factor in any 
discussion in aging and wound healing.
It is beginning to be appreciated that the materials that lie between cells, the matrix 
components, have major instructive roles for cellular activities. This extracellular matrix 
(ECM) is the principle component of connective tissue but its functions extend from its 
role as a scaffold to include tissue homeostasis and it is implicated in cell migration, 
growth, differentiation, wound healing and a variety of disease states. ECM components 
are synthesised by a variety of mesenchymal and parenchymal cells. Its extracellular 
distribution can be in the form of cell-associated pericellular matrices and structures that 
surround the periphery of the cells. Synthesis and remodelling of the ECM is necessary 
for scar tissue formation, however, excessive synthesis and remodelling of the ECM can 
lead to progressive fibrosis, characteristic o f numerous fibrotic disorders. The 
components of the ECM, although appearing amorphous by light microscopy, form a 
highly organised structure of glycosaminoglycans (GAGs), proteoglycans, 
glycoproteins, peptide growth factors and structural proteins such as collagen and to a 
lesser extent, elastin.
In terms of morphology, aged skin is characterised by reduced dermal thickness, 
reduced number of cells, and a disorganised microcirculation [3]. The thickness of the 
epidermis, which functions as a barrier to water, remains the same with age but is 
associated with flattening of the dermal-epidermal junction, giving the appearance of 
atrophy [148]. GAG and collagen levels not only fall but the physical properties of
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collagen itself changes with age [3]. Elastin levels appear to remain constant but as with 
collagen it is functionally different with age, leading to decreased elasticity of the skin
[149]. Such changes may lead to modified cellular responses resulting from altered 
matrix binding of growth factors, impaired cellular migration/proliferation in response 
to changes in matrix structure, quantity and/or adhesion molecule expression and altered 
signalling between matrix and cells leading to downstream changes in gene expression 
[3]. Changes in the composition of the ECM and matrix receptors occur under 
physiological and pathological conditions such as the menstrual cycle, the development 
of diabetes, tumour progression and, significantly, the aging process and wound healing
[150]. During wound healing, particularly the early stages, the ECM is rich in HA [151] 
where it functions as an organiser of the ECM; as a scaffold about which other 
macromolecules o f the ECM orient themselves.
1.7 Hyaluronan (HA)
1.7.1 Structure and Biology o f HA
HA is a high-molecular-weight, anionic linear polymer [151] composed of repeating 
alternating units of glucuronic acid and N-acetylglucosamine, all connected by 13- 
linkages (See Figure 1.2), that can reach a molecular mass of several million Daltons 
[152]. HA is unusual among the GAG family because it is not sulphated or covalently 
linked to a core protein throughout its length [152, 153]. HA is, hence, the only non­
proteoglycan GAG. Furthermore, unlike other macromolecules, which are synthesised 
in the Golgi apparatus, HA is synthesised at the inner leaflet of the plasma membrane 
which allows for extrusion of HA chains of unconstrained size [154].
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Figure 1.2: The chemical structure of hyaluronan.
HA is present throughout the body, identified in virtually every vertebrate tissue. The 
total amount of HA in an adult human has been estimated to be 20 g, the highest 
concentrations occurring in the vitreous o f the eye, (where it was first found), soft 
connective tissues (synovial fluid of articular joints and the intercellular space of the 
epidermis) and in the umbilical cord as Wharton jelly [152, 153]. More than 50% of 
total body HA is present in the skin, of which the majority is found in the dermis as 
opposed to epidermis [155].
Physicochemical studies indicate that the polymer can take on a vast number of shapes 
and configurations, dependent on polymer size, pH, salt concentration and associated 
cations. HA also occurs in a number of physiologic states, circulating freely, tissue- 
associated by way of electrostatic interactions but easily dissociated and in equilibrium 
with the HA in the rest of the body [151].
Despite the simplicity of its composition, without branch points or apparent variations 
in sugar composition, HA has a great number of diverse functions which fall into three
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overlapping categories: Firstly, HA greatly influences the hydration and physical 
properties of tissues. The molecular domain of HA encompasses a large volume of 
water that expands extracellular space, hydrates tissues and, in high concentrations, as 
found in the ECM of the dermis is responsible for skin moisture [151, 156, 157]. Due to 
its moisturising effect it has also widely been used as an ingredient in skin care products 
and has been used as a space-filling complex in cosmetic surgery [158]. Secondly, HA 
acts as an organizer of the ECM; it is not only the central scaffold about which other 
macromolecules of the ECM orient themselves [151], it also interacts with other ECM 
macromolecules (including the proteoglycans aggrecan and versican), which are 
essential to the structure and assembly of several tissues [157]. Finally, HA interacts 
with cell surface receptors, notably CD44, and thereby influences cell behaviour [158]. 
The ability o f HA to form a pericellular coat, a unique environment in which many cell 
types reside, illustrates the interrelation of these three functions. Formation of 
pericellular coats depends on the large hydrodynamic domain occupied by HA, its 
interaction with extracellular proteoglycans, and its interaction with the cell surface
[157] (see HA Pericellular Coats below). Furthermore, HA promotes cell motility, 
regulates cell-cell and cell-matrix adhesion, promotes proliferation and influences 
differentiation [159-162]. It participates in such fundamental processes as 
embryological development and morphogenesis [163], wound healing [164], repair and 
regeneration and inflammation [165]. HA levels increase in response to severe stress 
and in tumour progression and invasion [166]. The tight regulation required for HA 
deposition in association with these multiple and diverse processes depends on net 
levels of synthesis and degradation.
1.7.2 Synthesis and Catabolism
In vertebrates, the HA cytoplasmic product is produced on the inner face of the plasma 
membrane of fibroblasts and directly extruded through the plasma membrane into the 
extracellular space permitting unconstrained polymer growth. This is unlike other 
extracellular polysaccharides that are synthesised in the Golgi [152]. Synthesis occurs 
by hyaluronan synthase (HAS) sequentially adding sugars to the reducing terminus
[152]. HAS are glycosyl transferases that occur in vertebrates, bacteria, and algal
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viruses [167]. There are three synthase genes in the mammalian genome, coding for 
HAS1, 2, and 3 [153]. They have distinct expression patterns controlled, in part, by 
various growth factors and cytokines [168]. Expression of the HAS genes also appear to 
be tissue specific [168], each producing a different size polymer [169]. HA is very 
metabolically active, with a t\n  o f 3 to 5 minutes in the circulation, less than 1 day in 
skin and even in an inert a tissue as cartilage, the HA turns over with a t\n of 1 to 3 
weeks [151]. The turnover of HA in mammalian tissue is astonishing. There are 15 g of 
hyaluronan in the 70-kg individual, of which 5 g are cycled daily through this pathway
[153]. This rapid turnover is due in part to lymphatic removal of HA from the tissues 
and subsequent degradation in lymph nodes and liver [170]. It is proposed that 
scavenger receptors expressed on liver endothelial cells are responsible for part of this 
degradative process [171]. The principle enzymes involved in turnover of HA are the 
hyaluronidases (Hyals), endoglycolytic enzymes with a specificity in most cases for 
the/?-l,4-glycosidic bond that break down the HA polymer into smaller fragments. Six 
homologous Hyals genes have been found in the human genome. Recent work has been 
focused on elucidating the function of these Hyal proteins. The two primary mammalian 
Hyals, Hyal-1 and Hyal-2 are involved predominately in HA catabolism in somatic 
tissues and have different activities and degrade HA to either oligosaccharides or larger 
fragments [172].
Degradation begins when extracellular high mass HA polymers of the ECM are tethered 
to the cell surface through the combined action of CD44 and Hyal-2 [167]. This 
metabolic cascade begins in lipid raft invaginations at the cell membrane surface. Hyal- 
2 interacts with CD44 and with a Na+-H+ exchanger termed NHE1 that creates an acidic 
microenvironment for the acid-active Hyal enzyme [173]. Endolytic cleavage by the 
Hyal occurs in a series of discreet steps generating HA chains of decreasing sizes. The 
enzyme makes the initial cleavage generating 20 kDa sized products of approx 100 
saccharides [174]. The Hyal-2-generated HA fragments are internalised, delivered to 
endosomes and ultimately to lysosomes, where Hyal-1 degrades the 20kDa fragments to 
small disaccharides [153]. Despite their exceedingly simple primary structure, HA 
fragments have extraordinary wide-ranging and often opposing biological functions. 
The biological functions of the oligomers at each quantum step differ widely. The very
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large HA polymers are among the largest of matrix molecules and depending on tissue 
source and physiological conditions can reach sizes of 105 kDa. [175]. They are space 
filling, hydrating, anti-angiogenic, [176] anti-inflammatory and immunosuppressive 
[177, 178] extracellular polymers [151, 153, 165, 167, 179]. This derives in part from 
the ability of the space-filling polymers to prevent ligand access to cell surface 
receptors. The foetal circulation and amniotic fluid contain high concentrations of HA. 
This may account for some of the immunosuppression in the developing foetus [153]. 
High molecular HA can also have an array of regulatory and structural functions. 
Additional functions include ovulation, embryogenesis, protection of epithelial layer 
integrity wound healing and regeneration [167].
20-kDa intermediate polymers are highly angiogenic, inflammatory and 
immunostimulatory [153]. They stimulate endothelial recognition of injury [180], 
induce inflammatory gene expression in dendritic cells [181] attracting inflammatory 
cells, and also induce expression of inflammatory cytokines in such cells [165]. HA 
degradation products are reported to contribute to scar formation [182]. Foetal wounds 
heal without scar formation and wound fluid HA is high molecular weight [183]. When 
Hyal is added to generate fragments, there is increased scar formation [182]. 
Collectively, these data support the concept that while high molecular mass HA 
promotes cell quiescence and tissue integrity, HA breakdown products act as 
endogenous “danger signals” and alert the body that injury may have occurred, 
initiating an inflammatory response [184]. Hence whilst turnover of HA is high in 
mammals, the presence of abnormally high levels of oligosaccharide fragments signal 
tissue damage or invasion, which can elicit defence mechanisms, cellular differentiation 
and tissue morphogenesis (e.g. angiogenesis).
Degradation into yet smaller oligomers induces expression of heat shock proteins which 
are anti-apoptotic [185]. So fragments of HA in the course of catabolism generates 
products with size-specific and widely differing biological activities; fragments that are 
involved in essential processes. Wound healing serves as a fine example of the precise 
regulation required of HA catabolism (see HA and Wound Healing below).
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1.7.3 HA Binding Proteins and Receptors
The wide range of biological actions of HA is postulated to derive in part from its 
interaction with a wide number of hyaladherins, a term coined by Toole [186] to 
describe a heterogeneous group of proteins with the ability to bind HA. The 
hyaladherins associate with HA through electrostatic or covalent bonds [187]. Growth 
factors, collagen and a myriad of other proteins have been identified, are widely 
distributed in the body and have diverse functions [151]. Most of the known HA 
binding proteins and receptors couple to HA through a 100 amino acid globular binding 
domain called the “link module”. The link module region is comprised of an 
immunoglobulin domain and two adjacent link modules. The immunoglobulin domains 
are most likely responsible for the link protein-proteoglycan interaction, whereas the 
link modules mediate binding to HA [188, 189].
Extracellular hyaladherins are a group of HA-binding proteoglycans that include 
aggrecan, neurocan, and brevican, constituting a gene family collectively termed 
‘hyalectins’ [158]. These proteoglycans are components of the ECM and each 
proteoglycan has a characteristic distribution, with versican present in different soft 
tissues, aggrecan prominent in cartilage, and neurocan and brevican prominent in the 
central nervous system.
1.7.3.1 TSG-6
Tumor necrosis factor-stimulated gene 6 (TSG-6) is an extracellular hyaladherin closely 
related to the hyaluronan receptor CD44, the expression of which is tightly regulated 
[190]. There is little or no constitutive expression of TSG-6 in adult tissues, but the 
protein is synthesised by fibroblasts, chondrocytes, monocytes and vascular endothelial 
and smooth muscle cells in response to stimulation with pro-inflammatory mediators or 
certain growth factors [190, 191], where it has been shown to have anti-inflammatory 
and protective functions in arthritis and asthma [191]. TSG-6 has been implicated in the 
stabilization of ECM structure, particularly by supporting the formation o f cross-linked 
HA networks [192]. TSG-6 catalyses the transfer of inter-a inhibitor (Ial) heavy chains 
to HA forming a stable, covalently linked complex which has an important role in
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formation of the pericellular matrix [193, 194] and is detected in several inflammatory 
disease states and in the context of inflammation-like processes, such as ovulation, by 
influencing the expansion of the HA-rich cumulus ECM in the preovulatory follicle 
[195].
1.7.3.2CD44
Cellular hyaladherins that are responsible for attaching HA to the cell surface constitute 
the HA receptors. HA binds to cells via three main classes of cell surface receptors: 
Cluster of Differentiation 44 (CD44), receptor for HA-mediated motility (RHAMM) 
and Intracellular adhesion molecule-1 (ICAM-1) [151, 196]. CD44 is the most 
prominent among these and is, therefore, considered the principle receptor for HA
[151]. It is a multifunctional single-pass transmembrane glycoprotein that is encoded by 
a single gene that consists of 19 exons [197] consisting of four functional domains
[158]. It is very widely distributed in the body being found on virtually all cells except 
red blood cells [151]. The appearance of HA in the dermis and epidermis parallels the 
histolocalization of CD44 [151]. Alternate slicing and variations in CD44 polypeptide 
sequence, glycosylation and oligomerization generates different isoforms and confers 
specific functions to the CD44 protein and its affinity for HA binding [197].
The precise biological role of CD44 in-vivo in various tissues remains to be determined 
but has been shown to be critical in maintenance of local HA homeostasis. HA-CD44 
interactions participate in a wide variety of cellular functions, including cell-cell 
aggregation, retention of pericellular matrix, matrix cell and cell-matrix signalling, 
receptor mediated internalization/degradation of HA, cell migration and proliferation 
[151, 198]. For this reason HA-CD44-mediated interactions are critical in wound 
healing. For example, CD44 plays an important part in regulating leukocytes 
extravasation into inflammatory sites [199] and mediates phagocytosis [200]. CD44 
plays an important role in resolution of inflammation and regulation of fibroblast 
function. CD44nul1 animals exhibited enhanced and prolonged infiltration followed by 
reduced myofibroblast infiltration. The healing defect in CD44-/- mice was associated
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with impaired fibroblast function and markedly diminished collagen deposition in the 
scar [198].
Furthermore, CD44 is important in maintaining the integrity of the actin cytoskeleton 
[201]. The cytoplasmic tail o f CD44 can interact with the actin cytoskeleton, through 
interaction with a number of membrane-associated cytoskeletal proteins, such as 
ankyrin [202, 203] and cortactin [204] which are expressed in a variety of biological 
systems. Such interactions cause, cytoskeleton activation and result in several important 
HA-mediated functions such as cell adhesion, proliferation and migration and appear to 
have important roles in activation of a number of signalling pathways, particularly in 
tumour progression [173, 205-208]. CD44 can also function as a co-receptor, physically 
co-localising with receptors such as TGF-p type I and type II receptors and resulting in 
the modulation of intracellular transduction pathways involved in TGF-P signalling 
[161,203,209,210].
The ability of HA to associate with itself, with its receptor CD44, with proteins, or with 
other GAGs [211] speaks to the versatility of this molecule, qualities which are 
particularly advantageous for the assembly of HA-dependent pericellular coats.
1.7.4 HA Pericellular Coats
When retained at the cell surface, HA can generate a voluminous pericellular matrix or 
“coat”. The HA-dependent coat has multiple important roles, from serving structural 
and mechanochemical functions, to the regulation of cell division and motility. 
Prominent HA coats are observed during embryogenesis, tissue remodelling, wound 
healing and tumour invasion [194, 212-214]. The particle exclusion assay is the most 
widely used technique to visualise the HA-dependent pericellular coat [215]. In this 
assay, a suspension of particles, usually fixed erythrocytes, is allowed to settle and a 
clear zone surrounding the cell is made apparent by virtue of the exclusion of the red 
blood cells by negatively charged pericellular HA present. Treatment of cells with HA- 
specific Hyal removes the pericellular coat, indicating that matrix integrity is HA- 
dependent [216]. HA can be tethered to the cell surface by the HAS synthases or cell
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surface receptors such as CD44 (See Figure 1.3). HA crosslinking occurs with several 
proteoglycan molecules, which are highly negatively charged and repel each other, 
causing HA to extend out from the cell surface in a bottle brush-like configuration 
[213]. The aggregating proteoglycans interact with HA via the link module in the N- 
terminal globular G1 domain [213]. In chondrocytes, aggrecan is the predominant 
proteoglycan in the pericellular matrix, while in fibroblasts and smooth muscle cells, 
versican is the major HA binding proteoglycan [217, 218]. The expression of individual 
pericellular coats in culture has been shown to mimic the extracellular volume of cells 
in-vivo [219].
CD44
O Matrix 
HyaladherinPlasma
membrane
HA Synthase
Hyaluronan
Peri-cellular coat
Figure 1.3 Representation of HA-dependent pericellular coat. Adapted from [219].
The HA coat is thought to regulate the assembly of the ECM by serving as a scaffold or 
through interactions of pericellular constituents with other matrix proteins. For example, 
fibronectin and collagen were found in the pericellular matrix of fibroblasts. The HA- 
versican pericellular coat has been shown to play a role in maintenance of proliferative 
and migratory phenotypes in various cells following growth factor treatment or injury 
[218]. HA coats promote proliferation by enabling cell detachment and rounding during 
mitosis and facilitate migration by separating cellular and fibrous barriers. The
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pericellular HA coat has been shown to inhibit cell-cell contact essential for subsequent 
cellular differentiation [175].
Other HA-binding molecules such as TSG-6 can also be retained within the coat [193- 
195, 214], creating higher order levels of structural HA that regulate important 
biological processes [213]. Studies from this laboratory have demonstrated that TSG-6- 
mediated formation of heavy chain-HA complexes is critical in the formation of a 
pericellular HA coat in proximal tubular epithelial cells [194].
In addition to pericellular coats, HA can form cable like structures in association with 
HA binding proteins which promote monocyte binding independent of TSG-6 [193]. 
HA cables are distinct from HA coats most notably in their differential regulation by 
HAS; over-expression of HAS2 was shown to promote HA coat assembly but inhibit 
cable formation [194], over-expression of HAS 1 led to increased cable formation [213] 
and over-expression of HAS3 was associated with induction of both HA pericellular 
structures in proximal tubular epithelial cells [193]. This is a fine example of how 
different HAS isoforms can regulate opposing cellular responses.
L 7.5 HA and Wound Healing
HA has an important biological role in skin wound healing, by virtue of its presence in 
high concentrations in skin [179]. Tissue injury and repair is characterised by synthesis 
and degradation of extracellular matrix components. One of the earliest components of 
the newly formed temporary matrix is HA [220]. Many of the biological processes 
mediated by HA are also central in the wound healing process. The wound tissue in the 
early inflammatory phase of wound repair is rich in HA, probably as a result of 
increased synthesis [221]. Changes in HA expression that occur in injured tissues can 
have profound effects upon the migration and activation of inflammatory cells, 
including monocytes and macrophages [222]. Therefore, injury induced changes in HA 
are likely to be critical for regulating the influx of inflammatory cells that occur 
immediately after wounding of the skin. Upregulation of HAS gene expression has 
been found in tissue injury [179], consistent with the observation that HA accumulation
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occurs following injury. HAS2 mRNAs are increased following rat lung injury by 
irradiation [179]. Epidermal trauma in adult mice is associated with increased epidermal 
HA [223]. Higher expression of HAS have been demonstrated in autoimmune [224] and 
mechanical renal injury [225].
HA has two multiple roles in inflammation. Whether HA is bound to cells or to 
extracellular matrix components, its hydrophilic nature creates an environment 
permissive for migration of cells and early on in the response to tissue injury the HA- 
rich environment supports the influx o f fibroblasts and endothelial cells into the 
provisional wound matrix and subsequent formation and organisation of granulation 
tissue [156]. Fibroblasts isolated from granulation tissue synthesise increased HA levels 
compared to fibroblasts isolated from normal skin, suggesting they are an important 
source of HA generation during early tissue repair [226]. HA degradation products can 
stimulate inflammatory cells to produce chemokines and cytokines that recruit 
inflammatory cells to the site of injury to modulate and resolve tissue injury. HA 
fragments are responsible for induction of proinflammatory cytokines such as Tumour 
Necrosis Factor-a (TNF-a), IL-lp and IL-8 [156]. Cell proliferation is also an essential 
part of tissue repair and increased HA is essential for fibroblast detachment from the 
matrix and mitosis [156].
Moderation of the inflammatory response is required to stabilise the granulation tissues 
matrix and in a somewhat contradictory role to its inflammatory stimulation functions 
HA can also serve to offer protection to cells and extracellular matrix molecules against 
free-radical and proteolytic damage mediated through a free-radical scavenging and 
protein exclusion property [227]. This property is believed to confer HA a healing 
promoting ability in chronic wounds such as venous leg ulcers where damage is a result 
of prolonged inflammation by free radical [228]. TSG-6 expression is induced 
following generation of the inflammatory cytokine TNF-a in fibroblasts and 
inflammatory cells. TSG-6 is thought to bind with HA and serves as a potent negative 
feedback loop to moderate inflammation and stabilise granulation tissue in the latter 
part of the inflammatory process [229].
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HA is also critical in the regulation o f angiogenesis. Low molecular weight HA 
promotes whereas high molecular HA inhibits angiogenesis [156]. HA and its fragments 
may play crucial roles in the skin wound-healing process, by modulating the expression 
o f fibroblast genes involved in remodelling and repair of ECM. Through its ability to 
enhance type III collagen synthesis and TGF-p3 expression in dermal fibroblasts, high 
molecular weight HA promotes the creation o f a foetal-like cell environment, which is 
known to favour scarless healing, whereas low molecular weight HA might favour a 
fibrotic phenotype through stimulation of type I collagen [230].
Although the exact mechanisms through which HA and enzymatically derived 
fragments, affect the ECM metabolism during wound repair remain unclear, much has 
been elucidated: The earliest phases following injury is characterised by induction of 
high molecular weight HA, synthesised by platelets [231], which binds fibrinogen, one 
o f the first reactions in clot formation [232]. A combination of increased synthesis and 
impaired clearance by hyal-2 inhibitors maintains accumulation of large HA polymers. 
Its anti-angiogenic and immunosuppressive properties opens up tissue spaces, 
facilitating access of neutrophils to the wound site for removal o f dead tissue debris and 
bacteria. During the inflammatory phase inhibitors would then have to be removed for 
the lager HA molecule to be fragmented by Hyal-2. Smaller HA fragments induce 
inflammatory cytokines leading to infiltration by monocytes and lymphocytes. 
Following inflammation, further HA fragmentation leads to angiogenesis [233] and 
subsequent proliferation of fibroblasts and synthesis of collagen for reparative processes 
[234]. Inhibition o f Hyal-1 activity must be invoked temporarily at this stage o f wound 
healing in order for intermediate sized HA fragments to accumulate. Whilst HA 
breakdown products are integral for the cascade events essential to normal wound 
healing mechanisms, their subsequent removal in tissues is paramount for resolution of 
injury as demonstrated following experimental lung injury [235]. It is clear that the 
relative proportion of HA molecular sizes exerts a fine regulation of matrix state, from 
the early inflammatory steps to the final tissue recovery.
Many reports have verified the effects o f exogenous hyaluronan in producing beneficial 
wound healing outcome. In animal experiments, topically applied hyaluronan has been
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shown to accelerate skin wound healing in rats [227] and hamsters [236]. Corneal 
epithelial wound healing is also reported to be stimulated by exogenously applied 
hyaluronan [237]. An increased and prolonged presence o f HA has been reported to be 
associated with the scarless quality of foetal tissue repair [230]. In contrast, its 
accumulation is reduced in adult tissues where wound healing is characterised by 
scarring [179].
HA has been reported to inhibit scar formation in healing adult wounds when applied 
topically and to reduce the packing density o f collagen bundles [69] and, therefore, lead 
to reduced scarring [164], These suggestions are in agreement with the work of Laurent 
et al. [238] who showed that applied HA resulted in scarless healing of tympanic 
membranes and with Balasz and Denlinger [239] who hypothesized that a HA-rich 
environment inhibits the matrix cells responsible for fibrous scars. In chronic wounds, 
such as venous leg ulcers, HA application has been shown to promote healing [156].
ECM HA is prominent in development and in the early phases o f wound healing, 
especially in the foetus where the repair process is scar free [240]. In contrast its 
accumulation is reduced in adult tissues where wound healing is characterised by 
scarring [241]. These observations have led to the suggestion that HA may lead to 
reduced scarring [156] and reduce fibrosis. Conversely, work by Jenkins et al and 
Meran et al in this laboratory propose that increased HA associated with fibroblasts may 
promote differentiation into myofibroblasts and, therefore, facilitate the formation of 
scar tissue and promote the fibrotic response. They demonstrated that inhibition of HA 
synthesis in dermal fibroblasts significantly attenuated the capacity for cells to 
differentiate and proliferate in response to TGF-(31. These studies indicate HA plays a 
pivotal role in regulating TGF-pi driven cellular differentiation in that it facilitates 
fibroblast-myofibroblast transition [242, 243].
1.7.6 HA and Aging
The majority o f papers that evaluate HA regulation as a function of age are confined to 
those differences exhibited between foetal and adult fibroblasts, whilst a limited number
36
of studies centre on differences exhibited by cellular aging. Some o f these are now 
reviewed.
Ellis et al demonstrated that foetal fibroblasts assemble large HA pericellular coats and 
show no alterations in HA synthesis with age. In complete contrast, their adult 
counterparts failed to package HA into a coat, associated with an age-related decline in 
HA synthesis [244]. Chen et al indicated that foetal dermal fibroblasts display an 
elevated level o f migratory activity compared to adult cells and that this may result from 
inherent differences in the production of HA, specifically that foetal cells synthesis 
higher levels o f HA in-vitro compared to adult cells [245]. Ellis et al expand on these 
observations and demonstrate that, in addition to differential migratory capacity and HA 
generation, foetal and adult fibroblasts differ in their response to TGF-|31. In foetal 
fibroblasts both cell migration and HA synthesis were inhibited by TGF-pl, whereas 
adult fibroblasts were unaffected by TGF(31 [69].
Matuoka et al demonstrated differential GAG production associated with aged human 
diploid fibroblasts in-vivo and in-vitro [246]. They specifically demonstrated in one 
study that cultured normal human fibroblasts during in vitro aging exhibited increased 
proportions o f heparan sulfate GAG associated with marked depletion of HA, through a 
decrease in HA synthase activity [247]. They suggested that the change in HA synthesis 
was responsible, at least to some extent, for the observed growth reduction, during 
aging, o f normal human fibroblasts.
Vigetti et al established an in-vitro model consisting of sequential passages o f human 
aortic smooth muscle cells and in contrast showed that cell migration and HA synthesis 
significantly increases in aged cells, when compared to young cells, as does HAS2 and 
HAS3 and the HA receptor CD44 [248]. Associated with this was an age-related 
increase in CD44 signalling mediated ERK1/2 phosphorylation. Addition o f HA 
oligosaccharides or an anit-CD44 blocking antibody inhibited ERK1/2 activation and 
cellular migration. In contrast, age-related reduction in the deposition of the ECM and 
in particular HA levels have been reported in humans [249].
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HA contributes to the viscoelastic properties o f the vocal fold lamina propria in elderly 
humans. Butler et al reported decreased HA levels in the vocal fold propria in elderly 
humans [250]. In a rat model decreased density o f extracellular HA was shown to be 
associated with an age-dependent attenuation o f expression of genes coding HAS. The 
authors propose that accumulation o f dysfunctional senescent cells may contribute to 
the observed mRNA changes associated with aging.
In evaluating alterations in GAG biosynthesis during in-vitro aging by dermal 
fibroblasts Isnard et al demonstrated biphasic modifications in HA levels; from passage 
5 to passage 13, incorporation o f HA was decreased, only then to increase through 
passages 17-27 [251].
Meyer et al [252] tested the hypothesis that decreasing levels of HA deposition might 
underlie the changes associated with the aging process. They concluded that neither the 
concentration nor polymer size o f HA changes as a function o f age, however, enhanced 
association with tissues occurs, through HA-binding proteins and alterations in the 
histolocalization o f HA, with a shift o f HA towards the lower dermal layers.
Despite the extensive previous research on HA, there have been few studies that have 
assessed the impact o f HA in regulating fibroblast-myofibroblast differentiation in the 
context o f aging.
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Project Aims
Fibroblastic differentiation into myofibroblasts is a key event during normal wound 
repair and previously this laboratory has demonstrated that TGF-pl -driven phenotypic 
activation is associated with accumulation o f HA and its assembly into a pericellular 
coat. The overall purpose o f this work is to understand the effects of in-vitro aging on 
dermal fibroblast differentiation in the adult. Specifically, this thesis will determine the 
regulatory role that HA may play in fibroblastic behaviour and the phenotypic changes 
associated with aging.
My specific objectives were:
1) To characterise phenotypic alterations o f dermal fibroblasts associated with in 
vitro aging under basal and TGF-pi stimulated conditions.
2) To characterise age-related changes in HA homeostasis and determine what role 
this has on wound healing outcomes.
3) To compare TGF-pi signalling in young and aged dermal fibroblasts and 
determine the regulatory role HA plays
4) To determine the functional significance o f the alterations in HA associated 
with the myofibroblast phenotype. How does this change with age?
5) To perform interventional experiments to control cellular HA levels to 
specifically direct cellular wound healing responses. Is it possible to influence 
the fibroblast response by altering their synthesis o f HA?
Crucially an understanding of how HA levels are controlled within cells and whether 
this alters with aging, together with understanding how this impacts on cellular 
responses and wound healing outcomes, is important in the future targeting of HA 
therapy/manipulation for dysfunctional wounds in the aged.
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Chapter 2 
Materials and Methods
2.1 Materials
All general and tissue culture reagents were purchased from Sigma-Aldridge (Poole, 
Dorset, UK), Fisher Scientific (Leicestershire, UK) and GIBCO/BRL Life Technology 
(Paisley, UK) unless otherwise stated. PCR and QPCR reagents and primers were 
purchased from Invitrogen Life Technologies (Paisley, UK) and Applied Biosystems 
(Cheshire, UK). Radioisotopes were purchased from Amersham Pharmacia Biotech 
(Little Chalfont, Bucks, UK). Other reagents used were: recombinant TGF-P, EGF, goat 
anti-human EGF antibody from R&D Systems (Oxford, UK), Mouse monoclonal anti- 
CD44 blocking antibody from Ancell (Bayport, MN); MAP Kinase (MEK) inhibitor 
PD98059, p38 kinase inhibitor SB203580 and KN-92/93 were from Calbiochem 
(Nottingham, UK). The EGF-R inhibitor AG 1478 was from Invitrogen, the ALK5 
inhibitor SB431542, Cytochalasin B, bovine testicular hyaluronidase (H3884) IL -lp 
and 4-methylumbelliferone (4MU) were from Sigma (Poole, UK).
2.2 Patient Samples
All experiments were performed with dermal fibroblasts obtained by biopsy from 
consenting adults undergoing routine minor surgery. The biopsies were obtained from 
normal uninjured skin o f patients and were attained with the support o f Professor D. 
Thomas, Wound Biology Group, Dental School and ethical approval for the samples 
was obtained from the South-East Wales Local Research Ethics Committee (Ref No: 
02/4836). Clinical details o f patients involved are provided in Table 2.1
Table 2.1 Patient Details.
Patient
number
Sex Date of 
birth
Age biopsy 
obtained
Site of 
skin biopsy
Relevant medical 
History
Patient I F 06.06.1946 56 Arm Smoker; low haemoglobin; 
mild hypertension
Patient II M 18.06.1925 77 Arm Non-smoker; hypertension;
Patient III M 06.06.1955 48 Arm Smoker; nil significant
Patient IV F 17.03.1914 89 Arm Non-smoker; 
moderate atherosclerosis
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2.3 Tissue Culture
2.3.1 Isolation o f Fibroblasts
Fibroblast isolation was performed by the Wound Biology Group according to their 
previously established techniques [86]. Tissue biopsies were transported immediately to 
the laboratory in sterile phosphate buffered saline (PBS) in a sterile universal container 
(Greiner Bio-one, Gloucester, UK) for isolation o f cells. Cultures were established 
by a single-cell suspension technique following enzymatic degradation o f the 
specimens. Specimens were washed thoroughly in PBS under aseptic conditions in a 
class II biological safety cabinet. The tissues were trimmed of all excess fat and washed 
in a 53 mm diameter bacteriological grade petri dish (Fahrenheit Laboratory Supplies, 
Milton Keynes, UK). Specimens were then immersed in 70% (w/v) ethanol for 30 -  45 
seconds to surface sterilize them. The tissue was then transferred to another petri dish, 
washed again in PBS and then dissected with a scalpel into 2 mm2 portions. The pieces 
o f tissue were then added to a universal containing Fibroblast-Containing Serum 
Medium (F-SCM) [Dulbecco’s Modified Eagles Medium (DMEM) and F-12 medium 
supplemented with L-glutamine (2mM), non-essential amino acids (lx), antibiotics (100 
U/ml penicillin G; 100 jig/ml streptomycin sulphate), anti-mycotics (0.25 pg/ml 
amphotericin B) and 10% (v/v) foetal calf serum (FCS) (Biologic Industries Ltd., 
Cumbernauld, UK)] and Dispase (2 mg/ml; Boehringer Mannheim, Lewes, UK) which 
had been filter sterilised and incubated overnight at 4°C. The tissues were then brought 
to room temperature, and the epidermal and the dermal layers o f the skin were carefully 
separated using a pair o f fine-toothed forceps. The dermal tissue was then transferred to 
a 1 mg/ml solution o f bacterial Clostridium histolyticum A collagenase (Boehringer 
Mannheim) made up in F-SCM which had been previously filter sterilized. The tissue 
was then minced and incubated at 37°C overnight.
Subsequently, the cell suspension was pipetted through a 21-gauge needle to fragment 
any remaining tissue and centrifuged in a conical based tube at 1,500 revolutions per 
minute (RPM) for five minutes. The supernatant was carefully removed and the pellet 
washed twice with PBS. The pellet was then re-suspended in 2 ml o f F-SCM and plated 
in 12.5 cm tissue culture flasks.
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2.3.2 Fibroblast Culture
The cells from 12.5 cm2 tissue culture flasks were transferred to 75 cm2 flasks once they 
attained confluence, and cultured in Dulbecco’s modified Eagles medium supplemented 
with L-glutamine (2mM), lOOunits/ml penicillin and 100pg/ml streptomycin and 10% 
foetal calf serum (FCS) (Biologic Industries Ltd., Cumbernauld, UK). The cultures 
were maintained at 37°C in a humidified incubator in an atmosphere of 5% CO2 and 
fresh growth medium was added to the cells every 3 to 4 days. At 90% confluence, 
fibroblasts were trypsinized and 1.5 x 105 cells were re-seeded into T75’s each time 
and either utilised for experiments, cultured further to senescence or cryo-preserved as 
described below.
2.3.3 Calculation o f population doubling levels
At each passage, the total number o f viable cells was determined by direct counting 
using a haemocytometer. Population doublings (PDs) were calculated using the 
following formula as previously described [253] :
logio (total cells harvested at passage) -  logio (total cells reseeded)
PD =
logio(2)
Cumulative population doubling levels were calculated by adding the derived increase 
to the previous PD level (PDL) and fibroblast populations were cultured and cryo- 
preserved at various passages until senescence. Senescence was determined when the 
population doubling/week was <0.5 [254]. Previously, work by Dr Stuart Enoch in the 
dental school has extensively characterized the growth kinetics and entry into 
replicative senescence using dermal fibroblasts taken from the four patients [254]. 
From this work, typical population doubling data based on the replicative lifespan for 
each patient was calculated (Table 2.2).
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Patient
Passage
I II III IV
Number of Population Doublings 
(PDs)
Early pass 6.76 6.65 7.5 6.64
Mid-pass 22.7 26.03 33.74 35.93
Senescent 45.63 49.61 63.09 70.05
Table 2.2 Population doubling Data. Num ber o f  population doublings undergone by 
dermal fibroblasts for each patient throughout their replicative lifespan [254].
Senescence varied for each patient, occurring over the range PDL 46-70. For the 
purpose o f this project it was decided that the PDs at which cells reached mid­
passage would be selected for ‘aged’ cells. Based on the data, in the experiments, 
10-15 PDL and 23-36 PDL are used and referred to as young and aged dermal 
fibroblasts, respectively. Prior to experimentation all cells were growth-arrested in 
serum-free medium for 48 hours to allow cell-cycle synchronisation. All 
experiments, unless otherwise stated, were performed in serum-free medium to 
avoid any influence o f serum factors. Furthermore all experiments were performed 
on equivalent cell numbers.
2.3.4. Fibroblast Sub-culture
Confluent fibroblasts were sub-cultured by treatment with Trypsin/ 
ethylenediamineetetraacetic acid (EDTA) diluted 1:1 with PBS. The trypsin was evenly 
distributed over the base of the flask and incubated at 37°C for 1-3 minutes, after which 
the cells became detached from the base o f the flask and appeared rounded when 
examined under light microscope. The resulting cell suspension was treated with an 
equal volume o f FCS to neutralise the protease activity. The total volume was then 
transferred to a centrifuge tube and the suspension centrifuged at 1500 RPM for 7
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BSA in HBSS and then incubated with the appropriate secondary antibody (DAKO, 
Cambridgeshire, UK) (Table 2.4), diluted in 0.1 % (wt/vol) BSA in HBSS, for 1 h at 
room temperature. The cells were washed extensively with 0.1 % (wt/vol) BSA in 
HBSS, mounted in Vectashield fluorescent mountant (Vecta Laboratories, 
Peterborough, UK) and examined under UV-light on a Leica Dialux 20 fluorescent 
microscope (Leica Microsystems (UK) Ltd, Milton Keynes, UK).
2.4.2 FITC-Phalloidin Staining
Following stimulation, cells were fixed in 4 % (wt/vol) paraformaldehyde for 15 min at 
room temperature. Cell were left to air dry, and permeabilised in 0.1 % (vol/vol) 
Tween-20 in PBS for 5 min at room temperature. Non-specific binding sites on the cells 
were blocked with 5 % (wt/vol) BSA in PBS for 20 min at room temperature. The cells 
were washed thoroughly in 0.1 % (wt/vol) BSA in PBS. Cells were incubated with the 
phalloidin (Table 2.5), diluted in 0.1 % (wt/vol) BSA in PBS, for 1 h at room 
temperature whilst avoiding light. The cells were washed repeatedly in 0.1 % (wt/vol) 
BSA in PBS and then mounted in Vectashield fluorescent mountant and examined 
under UV-light on a Leica Dialux 20 fluorescent microscope.
2.5 Analysis o f  Cell Proliferation
Fibroblast proliferation was assessed by the incorporation of D-[3H]-Thymidine into 
DNA. Cells were grown in 35mm dishes and assessed at sub-confluence (~ 50% 
confluence). Metabolic labelling was performed by incubation with 1 pCi/ml D-[3H]- 
Thymidine for 24 hours. The medium was then discarded and the cells washed 
repeatedly with PBS containing ImM Thymidine prior to fixing with 500pl o f 5% 
trichloracetic acid containing ImM Thymidine at 4°C for 1 hour. The cell layer was 
extracted by incubation with 1ml o f 0.1 M NaOH at 20°C for 24 hours and neutralised 
with 0.1M HC1. Radioactivity was determined by p-counting on a Packard Tri-Carb 
1900 liquid scintillation analyser and the results represented as disintegrations per 
minute (dpm).
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Table 2.3: Primary Antibodies for Immuno-Fluorescence
Antibody Cat. no Host Type Dilution
Anti-Hum an Vim entin (Dako) M0725 M ouse M onoclonal
IgG,
1:50
Anti-Hum an Cytokeratin (Dako) M 0717 M ouse M onoclonal
IgG!
1:50
Anti-Hum an a-SM  Actin (Sigma) A5691 M ouse M onoclonal
IgG2a
1:30
Anti-Hum an CD44 (Calbiochem) A020 Rat M onoclonal
IgC 2b
1:200
A nti-Hum an EGF-R (Santa Cruz 
Biotechnology)
1005: sc- 
03
Rabbit Polyclonal
IgG
1:50
Table 2.4: Secondary Antibody for Immuno-fluorescence
Antibody Cat. no Host Type Dilution
Fluorescein Isothiocyanate (FITC)- 
C onjugated Anti-M ouse IgG (Dako)
F0261 Rabbit Polyclonal 1:40
Fluorescein Isothiocyanate (FITC)- 
Conjugated Anti-Rabbit IgG (Dako)
F0205 Swine Polyclonal 1:40
A lexa Fluor® 555 Anti-rat IgG 
(H+L) (Invitrogen)
A21434 goat Polyclonal 1:10,000
Table 2.5: Phalloidin FITC-Conjugate
Reagent Cat. no Biological
Source
Dilution
Phalloidin FITC-Conjugate (Fluka, 
Sigm a-Aldrich)
77415 Amanita
phalloides
1:50
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2.6 Reverse Transcription (RT)
Dermal fibroblasts were grown to confluence in 35mm dishes and washed with PBS 
prior to lysis with 200pl Tri-reagent and RNA purification according to the 
manufacturer’s protocol. Briefly, 200 pi of chloroform was added to the sample and 
agitated by inversion until completely emulsified. The sample was incubated at 4°C for 
3 min to allow the phases to separate then centrifuged at 130,000 RPM for 20 min at 
4°C. The colourless aqueous layer was pipette and mixed with an equal volume of 
isopropanol. The mixture was incubated at 4°C for 24 hours then the precipitate was 
pelleted by centrifugation at 130,000 RPM at 4°C for 20 min. The supernatant was 
removed and the pellet was washed repeatedly in 0.5 ml ice-cold 70 % (vol/vol) ethanol 
by briefly vortexing then centrifuging at 130,000 RPM for 20 min at 4°C. The RNA 
pellet was air dried at room temperature then dissolved in 10 pi o f H2O. One pi o f the 
RNA sample was diluted in 99 pi o f H2O and the absorbance was measured at 260 nm 
and 280 nm using a Beckman UV-DU64 spectrophotometer (Beckman Instruments Ltd, 
High Wycombe, UK). The ratio o f 260:280 gave an indication of protein contamination 
(>1.6 was considered to indicate sufficiently pure RNA). The concentration of RNA 
was calculated from the absorbance at 260 nm:
Abs26o x dilution factor (100) x RNA coefficient (40) = RNA in pg/ml
The RT was performed using the random primer method. The RT was carried out in a 
final volume o f 20 pi per reaction, containing 1 pg of RNA sample, 2 pi o f lOx RT 
random primers, 2 pi o f lOx RT buffer, 0.8 pi o f 25 mM dNTPs (deoxynucleotide 
triphosphate) (mixed nucleotides: dATP, dCTP, dGTP and dTTP), 1 pi o f Multiscribe™ 
reverse transcriptase, and 1 pi o f RNase inhibitor. All reagents used were supplied as a 
high-capacity cDNA reverse transcriptase kit (Applied Biosystems). The RT was 
performed using an Applied Biosystems “Gene Amp PCR System 9700” thermocycler. 
As a negative control RT was performed with sterile H20  replacing the RNA sample. 
The solution was incubated at 25 °C for 10 min to allow the random hexamer primers to 
anneal to the RNA. The primers were then extended using the reverse transcriptase in 
the presence o f the four dNTPs by heating the solution to 37 °C for 2 h, thus generating 
cDNA. The cDNA is then heated to 85 °C for 5 s, thus separating the hybridised
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complexes consisting of the RNA template and the newly synthesised cDNA and 
deactivating the reverse transcriptase. The resulting single stranded complementary 
DNA (cDNA) was stored at -2 0  °C.
2.7 Quantitative PCR (Q-PCR)
Q-PCR was carried out in a final volume o f 20 pi per reaction, containing 1 pi of 
cDNA, 10 pi o f TaqMan Fast Universal Master Mix (20X) (Applied Biosystems), 8 pi 
o f H2O, and 1 pi of a TaqMan gene expression assay primer and probe mix (Applied 
Biosystems) (Table 2.2). A negative control (-PCR) was prepared with H2O substituted 
for the cDNA. PCR was simultaneously done for ribosomal RNA (primer and probe 
commercially designed and purchased from Applied Biosciences) as a standard 
reference gene.
Quantitative PCR was performed using the 7900HT Fast Real-Time PCR System from 
Applied Biosciences using Taqman Universal PCR Master Mix (Applied Biosystems) 
following the manufacturer’s instructions. The Taqman gene expression assays used are 
shown in Table 2.6.
The comparative CT method was used for relative quantification o f gene expression. 
The CT (Threshold cycle where amplification is in the linear range o f the amplification 
curve) for the standard reference gene (ribosomal RNA) was subtracted from the target 
gene CT to obtain the delta CT (dCT). The mean dCT for similar samples were then 
calculated. The expression of the target gene in experimental samples relative to 
expression in control samples was then calculated using the formula:
2 “( dC T (l) -  dCT(2))
where: dCT(l) is the mean dCT calculated for the experimental samples and dCT(2) is 
the mean dCT calculated for the control samples.
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Table 2.6: TaqMan Gene Expression Assays (Applied Biosystems)
Primer Catalogue Number
a-SM A Hs_00426835_gl
HAS 1 H s_00155410_m l
HAS 2 H s_00193435_m l
HAS 3 H s_00193436_m l
S M A D 2 H s_00183425_m l
SM A D 3 Hs_00232222_m l
TG F-pl Hs_00171257_m l
TSG6 Hs_00200180_m l
EGF H s_01099999 m 1
EGF-R H s_01076073_m l
Note: Applied Biosystems do not supply sequences of their Q-PCR primers.
2.8 Generation o f HAS2 and EGF-R Over-expressing Clone
A  H A S2 and E G F -R  expression  vecto r w as constructed  by  clon ing  the appropriate 
cod ing  reg ion  into the m ultip le  cloning  site (M C S ) o f  the pC R3.1 vecto r (Invitrogen; 
figure 2 .2). H A S2 open  read ing  fram e (O R F) w as a g ift from  Dr. A ndrew  Spicer (Texas 
A & M  U niversity , C o llege S tation, TX ). E G F -R  O R F w as a gift from  Prof. A lan  W ells 
(U niversity  o f  P ittsburgh , P ennsylvania). S tandard  P C R  w as am plified  to  generate the 
O R F using  Pfic50 D N A  po lym erase (Inv itrogen) to  increase the fidelity  o f  the PC R  
product. T he p rim ers u sed  in  the reaction, include sites for the  restric tion  enzym es K pnl 
and  N o tl (for H A S 2) and X b a l &  H in d lll (for E G F-R ). T he O R F w as inserted  into the 
v ec to r (pC R 3.1) using  a standard  ligation  reaction  w ith  P rom ega T4 D N A  Ligase. 
A m plifica tion  o f  the c loned  vec to r w as perfo rm ed  via bacterial transfo rm ation  (JM 109 
com peten t E scheria  coli, P rom ega). T he in tegrity  and o rien ta tion  o f  the H A S2 O R F w as 
confirm ed  by restric tion  enzym e d igestion  (see F igure 2.1).
A B
5U>
2U>
16U>
l i b
HAS2 ORF 
-1 .6 5  Kb
1KB Ladder Plus
Kpul and N otl digested
Lane A: empty vector 
LaneB: HAS2-pCR3.1
10 kb
3kb
6kb
Skb
4kb
C D
W
X bal andHindmdigested
LaneC: EGF-R-pCR3.1 
LaneD: empty vector
EGF-R ORF 
—4Kb
H yperLadder 1
Figure 2.1 Confirmation of HAS2 and EGF-R cloning into pCR3.1 vector. Purified 
DNA that was extracted from transform ed Escherichia coli and subjected to restriction-enzym e 
double-digestion and w as then resolved using 2%  (w t/vol) agarose gel electrophoresis. Lane A 
and D show  the em pty vector that was treated sim ilarly w ith the restriction enzym es. Land B 
and C show s a sam ple that w as cloned successfully w ith HAS2 open reading fram e (~1.65K b) 
and EGF-R open reading fram e (~4K b), respectively.
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638
T7 promctei^rimhB ate i.
TAATACGACT CACTATAGGG 
ATTATGCTGA GTGATATCCC
Nho I Pim  I H i n d  I I I  Kpn I B a m H I
I  I I I I
AGACCCAAGC TGGCTAGCGT TTAAACTTAA GCTTGGTACC GAGCTCGGAT
TCTGGGTTCG ACCGATCGCA AAT7TGAATT OGAACCATGG CTCGAGCCTA
7t8
BsKI EcoRI
CCACTAGTCC AGTGTGGTGG AATTCGGCTT 
GGTGATCAGG TCACACCACC TTAAGCC
SsOCI
EcoRI Pafl EccRV
Iagccg1 a a t t c t g c a g  a ta t c c a g g a
TTCGGC TTAAGACGTC TATAGGTCGT 
BGH reverse priming
CAGTGGCGGC CGCTCGAGTC TAGAGGGCCC GTTTAAACCC GCTGATCAGC CTCGACTGTG CCTTCTA 
GTCACCGCCG GCGAGCTCAG ATCTCCCGGG CAAATTTGGG CGACTAGTCG GAGCTGACAC GGAAGAT
pCR
Commonts for pCR®3.1
5060 nucleotides
CMV promoter: t>ases 1-596
Putative transcriptional start: bases 620-625
T7 promoter/priming site: bases 638-657
Multiple cloning site: bases 670-801
TA Cloning* site: 737-738
BGH reverse priming site: bases 813-831
BGH polyadenylation site: bases 812-1026
pUC origin: bases 1116-1789
SV40 promoter and origin: bases 3194-3532 (complement) 
Neomycin/kanamycin resistance gene (ORF): bases 2371-3159 (complement) 
Thymidine kinase polyadenylation site: bases 1926-2196 (complement) 
Ampicillin resistance gene (ORF): bases 3611-4471 (complement) 
f1 origin: bases 4602-5058
Figure 2.2 Restriction map and multiple cloning site of the pCR3.1 vector.
2.9 Transient Transfection
Transient transfection was performed with the aid of Nucleofector technology (Amaxa 
Biosystems) in accordance with the manufacturer’s protocol for transfection o f primary 
mammalian fibroblasts. Fibroblasts were grown to 70% confluence in T75 flasks. The 
medium was then removed and the cells harvested by trypsinisation (solution containing 
0.05% trypsin and 0.53 mM EDTA. Once the cells detached, the resulting cell 
suspension was treated with an equal volume o f FCS to neutralise the protease activity. 
Cell counting was performed using a haemocytometer and cell numbers adjusted to a 
final concentration o f 0.5 x 106 cells/ml. The cells were then centrifuged (lOOxg for 
lOmins) and the resulting pellet resuspended in Basic Nucleofector solution (BNS) 
(Amaxa Biosciences). The cells were transfected either with HAS2-pCR3.1 and/or 
EGF-R-pCR3.1 or pCR3.1 alone (control-transfection). The utilised concentrations 
were 100pl of BNS to lpg  o f DNA. The solution was then transferred to an amaxa 
certified cuvette and placed in the nucleofector. Nucleofection was carried out for 5 
seconds according to the pre-specified program designed for mammalian fibroblasts and 
the cells were subsequently transferred to either 35mm dishes or 8 well permanox 
chamber slides containing pre-warmed medium supplemented with 10% FCS. pCR3.1 
alone (empty vector) or pmaxGFP (Green Fluorescent Protein, provided by Amaxa 
Biosciences) vector was used as a control (control transfections). Co-transfection with 
pmaxGFP was also performed in parallel, and expression was determined by 
fluorescence microscopy after 48 hours to access efficiency (see figure 2.3). 
Transfection efficiency was calculated according to the formula:
Transfection efficiency = [Number of GFP-transfected cells (assessed by 
fluorescent microscopy) / Number of total cells (assessed by light microscopy)] x
100
Two negative controls were performed: 1) 0.5x106 cells in lOOpl of BNS containing 
lpg  DNA but without application of the program and 2) 0.5x106 cells in lOOpl o f BNS 
without DNA but with application o f the program. The cells were incubated in medium 
supplemented with 10% FCS for 24 hours followed by a 24 hour incubation in serum- 
free medium prior to experimentation. GFP positivity in pmaxGFP-HAS2 co­
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transfected or pmaxGFP-mock cotransfected cells was also used to visualise individual 
cells for HA coat analysis.
HAS2-pCR3.1 EGF-R-pCR3.1 HAS 2/EGF-R-pCR3 . 1
fU r J r -  /■ r  - ’’o B  • X  l ) ,  \  ,
/  , x
Figure 2.3 Transfection with pmaxGFP vector. Cells were transiently co-transfected 
with pmaxGFP DNA as described in section 2.9 and incubated in the presence o f serum for 24 
hours. The medium was then replaced with serum-free medium and the incubations continued 
for a further 24 hours. The cells were imaged using light (A,C and E) and fluorescent 
microscopy (B, D and F) at 48 hours post-transfection to assesses transfection efficiency. Panels 
A, C and E illustrate overall number o f  cells present in the culture and panels B, D and F are 
images o f the same cells, illustrating the percentage which have co-transfected with pmaxGFP 
and either HAS2-pCR3.1 (B), EGF-R-pCR3.1 (D) or HAS2-pCR3.1 and EGF-R-pCR3.1 (F). 
Transfection efficiency was found to be 41.5%, 44.1 % and 37.8% respectively.
2.10 Small Interfering RNA Transfection
Transient transfection of dermal fibroblasts was performed with specific siRNA 
nucleotides (Ambion) targeting either Smad2 (115717) Smad3 (107875) HAS2 (16704) 
TSG-6 (139706) or CD44 (114068). Transfection was performed using Lipofectamine 
2000 transfection reagent (Invitrogen) in accordance with the manufacturer’s protocol. 
Briefly, cells were grown to 50% confluence in antibiotic free medium in either 12 well 
culture plates or 8 well permanox chamber slides. 2pl of transfection agent was diluted
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in 98pl Opti- MEM reduced growth medium (Gibco) and left to incubate at room 
temperature for 5 minutes. The specific siRNA oligonucleotides were diluted in Opti- 
MEM reduced growth medium to give a final concentration o f 20pM in a total volume 
o f lOOpl. The transfection agent mix and siRNA mix were then combined and incubated 
at room temperature for a further 10 minutes. The newly formed transfection complexes 
(200pl) were then added to cells and incubated at 37°C with 5% C 02 for 24 hours in 
medium supplemented with 10% FCS followed by a 24 hour incubation in serum-free 
medium prior to experimentation. As a control, cells were transfected with negative 
control siRNA (a scrambled sequence that bears no homology to the human genome).
2.11 Visualisation o f  pericellular HA by particle exclusion assay
The exclusion o f horse erythrocytes was used to visualise the HA pericellular coat. 
Formalized horse erythrocytes were washed in PBS and centrifuged at l,000xg for 7 
min at 4°C. The pellet was resuspended in serum-free medium at an approximate 
density lx l0 8 erythrocytes/ml. One millilitre of this suspension was added to each 
35mm dish containing sub-confluent cells and swirled gently for even distribution. The 
dishes were incubated at 37°C for 15 min to allow the erythrocytes to settle around the 
cells. Control cells were incubated with 200pg/ml bovine testicular hyaluronidase in 
serum-free medium for 30 min prior to the addition of formalized horse erythrocytes. 
On settling, the erythrocytes are excluded from zones around the cells with HA 
pericellular coats. This is viewed under the microscope as an area of erythrocyte 
exclusion. Zones o f exclusion were visualised on a Zeiss Axiovert 135 inverted 
microscope. Due to the elongated shape o f the cells, the exclusion zone at some areas of 
the cell was not visible. Therefore, the width o f the exclusion zone was calculated at the 
widest point o f the cell (usually the nucleus).
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2.12 Analysis o f  3H-Radiolabeled HA
Cells were grown to full confluence in T75 flasks and growth-arrested for 48 h in 
serum-free medium. The medium was then replaced with either serum-free medium 
alone or serum-free medium containing lOng/ml TGF-pi and the incubations continued 
for 72 hours. Metabolic labelling was then performed by incubation with 20pCi/ml D- 
[ H]-glucosamine hydrochloride for 24 hours. The culture medium was then removed 
and the cells washed with PBS. The wash and medium were combined to form the 
conditioned medium extract. This was then treated with an equal volume o f 200pg/ml 
Pronase in lOOmM Tris-HCL, pH 8.0, 0.05% sodium azide for 24 hours. Samples were 
passed over DEAE-Sephacel ion exchange columns equilibrated with 8M urea in 20mM 
BisTris buffer, pH6, containing 0.2% Triton X I00. This removed any low molecular 
weight peptides and unincorporated radiolabel. HA was eluted in 8M urea buffer 
containing 0.3M NaCl. Each sample was split into two, and the HA was precipitated 
with 3 volumes o f 1% potassium acetate in 95% ethanol in the presence o f 50pg/ml o f 
each HA, heparin and chondroitin sulphate as co-precipitants. The first half o f each 
sample was resuspended in 500pl of 4M guanidine buffer and analysed on a Sephacryl 
S-500 column equilibrated with 4M guanidine buffer. To confirm that the 
chromatography profile generated was the result o f radiolabeled HA, the second half of 
each sample was digested at 37°C overnight with 1 unit o f Streptomyces hyalurolyticus 
hyaluronidase (ICN pharmaceuticals Ltd.) in 200pl of 20mM sodium acetate, pH6, 
containing 0.05% sodium azide and 0.15M sodium chloride. The sample was then 
mixed with an equal volume o f 4M guanidine buffer and analysed on the same 
Sephacryl S-500 column equilibrated with 4M guanidine buffer. To produce the 
chromatography profile the 3H activity for each half o f the sample was normalised, 
corrected for dilution, and then the Hyal-resistant counts were subtracted. The column
o 'IC
was calibrated with [ H]-glucosamine hydrochloride, Mr 215; [ S]-chondroitin sulphate 
glycosaminoglycans, Mr 25x103; decorin, Mr lOxlO4; and [35S]versican, Mr 1.3xl06. 
The radioactivity was determined by P-counting on a Packard Tri-Carb 1900 liquid 
scintillation analyser and the results represented as disintegrations per minute (dpm).
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2.13 Determination o f  HA concentration
Cells were grown to confluence in 35mm dishes and the HA concentration in the cell 
culture supernatant was determined using a commercially available enzyme-linked HA 
binding protein assay (HA "Chugai" quantitative test kit; Congenix, Petersborough, 
UK). The assay used micro wells coated with a highly specific HA binding protein 
(HABP) from bovine cartilage to capture HA and an enzyme-conjugated version of 
HABP to detect and measure HA in the samples. Briefly, diluted samples and HA 
reference solutions were incubated in HABP-coated microwells allowing binding o f the 
HA in the samples to the immobilised HABP. The wells were then washed and HABP 
conjugated with HRP was added to the wells forming complexes with bound HA. 
Following a second washing step, a chromogenic substrate (TMB/H2O2) was added to 
develop a coloured reaction. Stopping solution was added to the wells, and the intensity 
o f the resulting colour measured in optical density units using a spectrophotometer at 
450nm. HA concentrations were calculated by comparing the absorbance o f the sample 
against a reference curve prepared from the reagent blank and five HA reference 
solutions (50, 100, 200, 500 and 800 ng/ml) included in the kit. The assay is sensitive to 
10 ng/ml, with no cross-reactivity with other glycosaminoglycan compounds.
2.14 Western Blot Analysis
Western Blot analysis to assess changes in protein expression was performed according 
to previously established techniques in our laboratory [210]. Briefly, cells were grown 
to confluence in 35 mm dishes and rinsed with cold PBS. Cells were then lysed using 
1% protease inhibitor, 1% phenymethylsulphonyl flouride and 1% sodium orthanadate 
in RIP A lysis buffer (Santa Cruz biotechnology inc, Germany). The samples were 
scraped, collected and centrifuged at 2500 g for 10 minutes. The supernatant was 
collected, protein concentrations were determined by Bradford assay and the samples 
were stored at -70°C until use. Equal amounts of protein were mixed with equal 
volumes o f reducing SDS sample buffer and boiled for 5 minutes at 95°C before loading 
onto 10% SDS PAGE gels. Electrophoresis was carried out under reducing conditions at 
150 volts for 1 hour and the separated proteins were then transferred at 150 volts over 
90 minutes to a nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK). The
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membrane was blocked with Tris-buffered saline (TBS) containing 5% non-fat 
powdered milk for 1 hour and incubated with the appropriate primary antibody at 4°C 
overnight (See Table 2.7 for antibody dilutions). The blots were subsequently washed 
with TBS containing 1% Tween prior to incubation with the appropriate HRP- 
conjugated secondary antibody for 1 hour at room temperature (See Table 2.8 for 
antibody dilutions). Proteins were visualized using enhanced chemiluminescence (GE 
Healthcare) according to the manufacturer’s instructions.
Table 2.7: Primary Antibodies and Dilutions used in Western Blot Analysis
Antibody Cat. no Host Type Dilution
Anti-Hum an GAPDH 
(Abeam pic, Cambridge, UK)
ab9485 Rabbit Polyclonal 1:7500
Anti-Hum an Phospho-Smad2
Ser245/250/255
(Cell Signaling Technology)
#3104 Rabbit Polyclonal 1:1000
Anti-Hum an Phospho-Smad3 
(Ser423/425) (C25A9)
(Cell Signaling Technology)
#9520 Rabbit M onoclonal
IgG!
1:1000
Anti-Hum an Phospho-p44/42-M APK 
(ERK1 and ERK2) (Cell Signaling)
#9106 M ouse M onoclonal 1:1000
Anti-Hum an EGF-R (Santa Cruz 
Biotechnolgy)
1005:sc-03 Rabbit Polyclonal
IgG
1:200
Anti-Hum an p-EG FR (Santa Cruz 
Biotechnolgy)
sc-12351-R Rabbit polyclonal
IgG
1:500
58
Table 2.8: Secondary Antibodies and Dilutions used in Western Blot Analysis
Antibody Cat. no Host Type Dilution
HRP-Conjugated Anti-M ouse IgG 
(Santa Cruz Biotechnology Inc)
sc-2005 Goat Polyclonal 1:5000
HRP-Conjugated Anti-Rabbit IgG 
(Santa Cruz Biotechnology Inc)
sc-2004 Goat Polyclonal 1:10000
2.15 Immunoprecipitation
Cells were grown washed and lysed as for Western analysis above. Cell protein samples 
(200pg) were pre-cleared with 25pi packed protein A cross-linked 4% beaded agarose 
(Sigma) at 4°C over-night. The beads were removed by centrifugation (13.000 rpm, 10 
min) and the supernatant collected. Samples were subjected to immunoprecipitation 
using rat anti-CD44 antibody (A020 Calbiochem) (2pg/ml) and incubated at 4°C with 
constant mixing over-night. The immune complex was captured by the addition of 
packed agarose protein A beads (50pl) over-night at 4°C. Beads were washed with 
RIPA buffer (50mM Tris, 150mM NaCl, 0.5% sodium deoxycholate, lOmM MgC12, 
0.1% SDS, 1% Triton X-100); 30pl o f sample buffer was then added prior to boiling for 
lOmins. Separation o f the beads was achieved by centrifugation (13,000xg for lOmins) 
and the supernatant removed. Samples were subjected to SDS PAGE and subsequently 
transferred to nitrocellulous membranes and processed as described for Western blot 
analysis using rabbit anti-EGF-R antibody (Santa Cruz Biotechnolgy) as the primary 
antibody. The blots were subsequently washed in Trisbuffered saline-Tween and 
incubated with the appropriate HRP-conjugated secondary antibody (Sigma) in TBS- 
Tween. Proteins were visualised using enhanced chemiluminescence (Amersham) 
according to the manufacturers instructions. Specificity o f immunoprecipitation was 
confirmed by negative control reactions performed with IgG control.
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2.16 Statistical Analysis
All experiments were performed at least in triplicate for individual patient donors. All 
values are provided as means ± standard error. An unpaired Student’s t-test was used to 
assess differences between young and aged cell populations. A paired Student’s Mest 
was used for comparisons of treatments within the same cell population, i.e young or 
aged cells. For multiple variables one-way analysis of variance was used for global 
comparison followed by Tukey’s honestly significant difference method for pairwise 
comparison. Probability values o f P < 0.05 were considered to indicate a significant 
difference.
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Chapter 3
Characterisation of Fibroblast Phenotype and HA 
Regulation with in-vitro Aging
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3.1 Introduction
Wound healing is a complex process involving interaction between resident and 
migratory cells, the ECM and cytokines/growth factors. In normal wound healing, the 
regeneration o f the epithelial and mesenchymal tissues o f the skin is effected by 
fibroblasts and is co-ordinated via complex cell/cell and cell/matrix interactions [6], 
which in the adult skin results in healing with scar formation. These responses are, 
however, altered in chronic/delayed wounds in the aged with prolonged inflammation, a 
defective wound matrix and a failure o f re-epithelialisation. [255].
It has been long established that there is marked alteration in fibroblast function with 
increasing age. Fibroblast proliferation may also be modulated by age resulting in 
decreased cell number at the wound site [25]. Aging in an in-vitro model o f wounding 
has also demonstrated a delay in the ability of human dermal fibroblasts to re-establish a 
confluent monolayer with increasing age [44]. Beyond the effects o f aging on cellular 
migration and proliferation, a loss o f responsiveness to a variety o f cytokines has been 
reported following in-vitro and in-vivo aging in human fibroblasts [256, 257].
The accumulation o f senescent fibroblasts within tissues has been suggested to play an 
important role in mediating impaired dermal wound healing in the elderly. As 
fibroblasts near senescence their responsiveness to extracellular signals diminish [258] 
and they exhibit a decreased ability to divide in response to damage or cell loss [49, 51]. 
Such alterations in fibroblastic phenotype are thought to be responsible for the 
physiological deterioration and limited tissue regeneration observed in aging 
individuals, however, the cellular mechanisms underlying this phenomenon are not 
known.
The regulation of cellular phenotype and differentiation, during tissue repair, is an 
important determinant of wound healing outcomes (including the development of 
abnormal pathology). When activated, fibroblasts undergo a number of phenotypic 
transitions and eventually acquire a contractile “myofibroblastic” phenotype, 
characterised by the expression of a-SM A [259]. These myofibroblasts are responsible
62
for tissue contraction and wound closure and which ultimately gives rise to the 
formation o f a collagen rich scar.
The cytokine TGF-pi is recognised as a mediator of wound healing and its aberrant 
expression has also been widely implicated in progressive tissue fibrosis [260-262]. It is 
a constitute o f serum alongside a multitude o f other growth factors and in addition to its 
direct effect on ECM turnover, it is known to drive fibroblast-myofibroblast 
differentiation and is capable o f up-regulating a-SM A in fibroblasts both in-vitro and 
in-vivo [263, 264]. Deficits in the signal transduction responsiveness to TGF-pi have 
been postulated to explain the age-related defects in wound healing seen in the elderly 
[265]. Therefore the majority o f this thesis has specifically focused on fibroblast 
behaviour in the presence and absence of this cytokine. Previous studies in this 
laboratory [159-162, 266] have established the optimal conditions for induction of 
stable myofibroblastic differentiation in human dermal fibroblasts in-vitro and have 
demonstrated a causal link with HA production.
HA is a ubiquitous carbohydrate component o f the ECM found in almost all connective 
tissues [267]. It influences cellular proliferation and migration [156] following injury 
and plays an important biological role in wound healing and mediating cellular response 
to cytokines such as TGF-pl [268-270]. Although HA production is acutely upregulated 
following injury o f most tissues [267, 271], the function o f this in the course o f repair 
has remained elusive [157]. Indeed it has not been clear whether the accumulation of 
HA is indicative o f tissues undergoing re-organisation and repair or whether it 
contributes directly to wound healing and the scarring process [159, 160, 266].
Previously, work from this laboratory has demonstrated that phenotypic conversion of 
fibroblasts to myofibroblasts, is associated with major changes in the production and 
metabolism of HA [266]. Specifically, myofibroblasts were shown to accumulate 
several-fold more intra and extracellular HA, due to a reduction in their capacity to 
degrade HA. This disease promoting alteration in cell function was also associated with 
the development of extensive pericellular HA coats, which have been shown to be 
associated with cell proliferation and migration [272]. As the formation o f the HA
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pericellular matrix accompanies myofibroblastic differentiation, it is possible it may be 
involved in modulating this process. Therefore, the formation of a HA pericellular 
matrix, during myofibroblastic differentiation, could be a key target for controlling the 
wound healing response. These observations led to interest in HA as a possible 
regulator o f the wound healing process. The functional significance of the alterations in 
HA turnover and assembly associated with the myofibroblastic phenotype, however, 
remain unclear. Despite extensive previous research on HA, there has been limited work 
focusing on both the role o f HA in cellular differentiation and the impact o f aging on 
HA mechanisms and certainly none that has attempted to marry the two. Further insight 
into how HA can influence behaviour and impact on wound healing processes and how 
this alters with age remains necessary.
Because o f their pivotal role in the control o f wound healing, fibroblasts are important 
therapeutic targets in attempts to improve skin wound healing in elderly patients. Work 
by Stephens et al have previously demonstrated that site- and disease-specific 
differences exist in the phenotype o f human fibroblasts [49, 273], differences which are 
not simply related to replicative senescence within the wounds [49]. Fibroblasts have 
distinct phenotypes depending on the site from which they are isolated. Previously, 
using a library o f patient-matched oral and dermal fibroblasts at low passage number 
(i.e. “non-aged”) Meran et al demonstrated the relationship between generation of HA 
and site-specific phenotypic variation [242, 243]. TGF-pl mediated phenotypic 
differentiation in dermal fibroblasts was associated with an induction o f HAS1 and 
HAS2 expression and Hyal2 up-regulation. In contrast, resistance to TGF-pi mediated 
phenotypic differentiation in the non-scarring oral mucosal fibroblast population, was 
associated with a unique failure o f induction o f HAS 1 expression and a down-regulation 
o f HAS2 expression, while HAS3, H yall, Hyal2 and Hyal3 remained unchanged. 
Combined with no change in the induction o f HA-synthetic and degradative enzymes 
and the lack of HAS1 expression, this suggested that these non-scarring, motile 
fibroblasts do not respond to factors that normally switch on genes characteristic o f the 
healing phenotype. The aim of this chapter was to identify whether this is also true of 
“aged” fibroblasts and that as dermal fibroblasts approach senescence, do they exhibit
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differences in a) HA metabolism and b) cellular phenotype, associated with TGF-pi- 
mediated wound healing.
An in-vitro aging model based on cell senescence has previously been described and 
validated as a model o f age related alterations in human aortic smooth muscle cell 
function [274, 275]. Similarly, alterations in fibroblast function in an in-vitro model of 
aging have demonstrated the validity o f this model in terms o f in-vivo age related 
alterations in fibroblast motility and mitogenesis. These are associated with age 
dependent impaired wound healing [276, 277]. The work outlined in this chapter aimed 
to utilize this in-vitro aging model to test the general hypothesis that age-related 
alterations in human wound healing responses are associated with intrinsic differences 
in HA generation. Specifically the aim of this chapter was to extend on previous 
observations [159, 160, 266] and characterise differences in patient matched young and 
aged dermal fibroblasts in relation to:
i Morphology
ii Fibroblast-myofibroblast differentiation
iii HA generation,
iv HAS expression
v HA-dependent pericellular coat formation
vi TSG-6 expression
The results from this chapter will help establish the effect of cellular aging on 
fibroblastic phenotype and characterise the relationship with HA homeostasis.
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3.2 Results
3.2.1 Characterisation ofphenotypic conversion in young and aged fibroblasts
Patient matched young and aged dermal fibroblasts were grown to confluence and 
serum deprived for 48 hours prior to addition o f recombinant TGF-Pi (lOng/ml) for 
times up to and including 72 h. To assess the ability of the fibroblasts to undergo 
differentiation, expression o f the myofibroblastic marker a-SMA was assessed by 
quantitative PCR. As demonstrated previously, using cells at low passage [159], the 
increase in a-SMA mRNA expression was shown to be time-dependent with maximal 
induction o f a-SMA seen at 72 h for patient matched young (Figure 3.1 A) and aged 
(Figure 3.IB) fibroblasts.
A direct comparison o f a-SMA expression between young and aged cells after 72 hours 
was used to assess their potential for phenotypic activation (Figure 3.1C). Q-PCR 
revealed that under un-stimulated conditions, young fibroblasts had significantly higher 
(~5 fold) a-SMA mRNA expression, compared to patient matched aged fibroblasts. 
Following TGF-Pi stimulation, both young and aged dermal fibroblasts up-regulated a- 
SMA expression. Young dermal fibroblasts, however, showed a median 10-fold 
increase in a-SMA expression compared to a median o f only 6-fold increase in aged 
dermal fibroblasts, in response to the same concentration and duration of TGF-pi 
stimulation. Moreover, a direct comparison between cell populations demonstrated that 
TGF-Pi induced a-SMA expression was down-regulated by 8.5-fold in aged fibroblasts 
when compared to patient matched young fibroblasts.
Microscopic analysis o f monolayer cultures of young and aged fibroblasts revealed 
characteristic changes in their cellular morphology (Figure 3.2). Under basal conditions, 
young fibroblasts demonstrated an elongated, spindle-like appearance with no evidence 
o f prominent stress fibres (Figure 3.2A), whereas following TGF-pl stimulation the 
cells appear larger in size with a polygonal shape and prominent stress fibres (Figure 
3.2C). With in-vitro aging the cells become wider, larger and irregular in shape under
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basal conditions with marginally more stress fibres (Figure 3.2B). Following TGF-pl 
stimulation aged cells retain their enlarged morphology but appear more ‘dentritic’ in 
appearance. Stress fibres are still visible but less prominent than stimulated young cells 
(Figure 3.2D).
Both resting and TGF-Pi-stimulated fibroblasts were negative for expression of the 
epithelial cell marker cytokeratin (Figure 3.3E-H) and positive for expression o f the 
mesenchymal cell marker vimentin (Figure 3.3A-D) in young and aged fibroblasts. 
Immunohistochemical analysis of a-SMA was performed to further assess the ability of 
young and aged fibroblasts to undergo differentiation. In support of Q-PCR data, under 
basal conditions,, both young and aged fibroblasts were negative for a-SMA (Figure 3.4 
E and G). Stimulation of young cells with TGF-pi resulted in positive staining of a- 
SMA (Figure 3.4F), whilst in contrast, aged cells stimulated with TGF-pi did not induce 
the expression of a-SMA (Figure 3.4H).
In addition, FITC-phalloidin staining, a fluorescent probe that binds F-actin, was used to 
assess the cytoskeletal re-organisation of fibroblasts in response to TGF-Pi stimulation. 
Young fibroblasts became larger and polygonal in shape. In addition, they demonstrated 
prominent cytoskeletal re-organisation with the actin filaments coalescing to form large, 
thick bundles throughout the cell body (Figure 3.4B). In aged fibroblasts cytoskeletal 
re-organisation was less prominent following TGF-Pi stimulation (Figure 3.3D), with 
less pronounced actin filaments and poorly developed stress fibres not too dissimilar 
from resting aged cells. Notably in aged cells, individual bundles of actin fibres were 
more sparse and restricted to the periphery of the cells.
3.2.2 Analysis o f  HA generation and molecular weight profile in young and aged 
fibroblasts
Labelling o f fibroblasts with [3H]-glucosamine for 24 hours under serum-free 
conditions demonstrated that aged fibroblasts have reduced baseline synthesis o f HA, 
compared to patient-matched young fibroblasts (Figure 3.5A). Analysis of HA by size 
exclusion chromatography indicated that there was at least 2.5-fold more HA present in
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the conditioned medium of young fibroblasts compared to aged fibroblasts. 
Furthermore, aged fibroblasts generated around 4-times less HA in the conditioned 
medium compared to young fibroblasts following TGF-pi stimulation (Figure 3.5B). 
Further analysis on the effect o f TGF-Pi on HA synthesis was then assessed using both 
[3H]-glucosamine labelling and enzyme-linked immuno-sorbent assay. The 
chromatography profiles from the conditioned medium of these cells demonstrated that 
young fibroblasts up-regulated HA generation in response to TGF-pi stimulation (Figure 
3.5C), whereas aged fibroblasts were resistant to up-regulation o f HA in response to 
same dose and duration of TGF-Pi stimulation (Figure 3.5D). The majority o f HA 
produced in each of these three compartments consisted of high molecular weight HA 
polysaccharides o f greater than 1.5 x 106 Da in size. These findings were similar in both 
young and aged cells. These results were further confirmed by measurement of 
extracellular HA concentration in the conditioned medium using ELISA. In this assay, 
there was a significant decrease in extracellular HA concentration as fibroblasts were 
aged in-vitro. Furthermore, although addition of TGF-Pi led to an increase in HA 
concentration at every PD, the magnitude o f this effect decreased significantly as 
fibroblasts were aged in-vitro (Figure 3.6).
3.2.3 The expression o f  hyaluronan synthase enzymes in young and aged fibroblasts
Following growth arrest, young and aged dermal fibroblasts were stimulated with TGF- 
pi. HA was quantified by ELISA and in the same cells, HAS2 mRNA quantified by Q- 
PCR. As previously demonstrated, there was an age dependent decrease in basal HA 
concentration in the culture supernatant and also a decrease in TGF-pi dependent 
stimulation o f HA (Figure 3.7A). In the same cells there was a marked attenuation of 
TGF-pi dependent stimulation o f HAS2 mRNA in aged fibroblasts (Figure 3.7B).
Q-PCR was used to assess expression of all three HAS isoforms. HAS1 expression was 
almost undetectable in both unstimulated young and aged dermal fibroblasts using Q- 
PCR up to 40 cycles. In young fibroblasts, stimulation with TGF-Pi led to a significant 
induction o f HAS 1 expression whilst levels remained almost undetectable in aged cells 
(Figure 3.8A). HAS2 was detected in both unstimulated young and aged dermal
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fibroblasts but baseline expression was showed not to be statistically significant. The 
results demonstrated that whilst TGF-pi stimulation was associated with a significant 
up-regulation in HAS2 mRNA expression in young cells, aged cells demonstrated no 
such induction (Figure 3.8B). A similar pattern was observed for HAS3 expression; 
young and aged fibroblasts demonstrated comparable levels at baseline but whilst young 
cells exhibited a significant up-regulation in HAS3 mRNA expression following TGF- 
Pi stimulation, aged cells demonstrated no significant change (Figure 3.8C). Figure 
3.8D provides the Q-PCR amplification plot for all three HAS genes. Assuming 
comparable sensitivity throughout all three assays, the approximate Ct values indicate 
the relative expression level of HAS isoform in the order : HAS2>HAS3>HAS1.
3.2.4 Accumulation o f hyaluronan-dependent pericellular coats in young and aged 
fibroblasts
HA accumulation can be assessed using the exclusion of formalized erythrocytes. In this 
assay erythrocytes are excluded from the cell membrane o f the fibroblasts by the large 
size and negative charge of any pericellular HA present. This is observed under 
microscopy as a zone of erythrocyte exclusion surrounding the cells. Previously we 
have demonstrated that fibroblast to myofibroblast phenotypic conversion is associated 
with the formation of a HA pericellular coat. Consistent with this, unstimulated young 
or aged fibroblasts did not assemble a significant HA pericellular coat (Figure 
3.9A&B). Whilst stimulation of young fibroblasts with TGF-Pi resulted in the formation 
o f a significant coat (Figure 3.9C), aged fibroblasts failed to assemble a HA pericellular 
coat following stimulation with TGF-Pi (Figure 3.9D). Taking measurements o f the coat 
thickness at the widest point of 30 randomly chosen cells o f each phenotype and “age” 
gave a mean thickness for the young fibroblast coat of 2.99 ± 0.18 pm at baseline and 
7.95 ± 0.39 pm following TGF-pi stimulation (P < 0.001, paired t-test). For aged 
fibroblasts the mean coat thickness at baseline was 2.27 ± 0.16 pm and following TGF- 
Pi stimulation was 2.35 ± 0.21 pm (P = 0.78, paired t-test).
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3.2.5 The expression o f TSG-6 in young and aged fibroblasts
The hyaladherin TSG-6 has been demonstrated to be an important mediator of HA 
pericellular coat assembly [193, 194, 213]. Following growth arrest, young and aged 
dermal fibroblasts were stimulated with TGF-pi, and TSG-6 mRNA quantified by Q- 
PCR. In young fibroblasts stimulation by TGF-Pi resulted in a significant induction of 
TSG-6 mRNA from basal levels, whilst in contrast, aged fibroblasts demonstrated no 
significant induction o f TSG-6 mRNA. Furthermore, there was an age dependent 
decrease in TSG-6 expression both at baseline and following TGF-pi stimulation 
(Figure 3.10).
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Effect o f in-vitro aging on phenotypic activation
(A)
a-SMA mRNA Expression 
in young fibroblasts
□ Control 
■TGF-pl
6 12 24 48 72
Time (hours)
(B) a-SMA mRNA Expression 
in aged fibroblasts
□ Control 
■TGF-pl
Time (hours)
(C) a-SMA mRNA Expression
P=0.02
P=0.01
□ Control 
■ TGF-pl
Young Aged
Figure 3.1 Effect o f in-vitro aging on a-SMA expression. A-B, confluent monolayers of 
patient matched young (A) and aged (B) dermal fibroblasts were growth-arrested in serum-free 
medium for 48 hours, prior to addition of either serum-free medium alone {clear bars) or serum-free 
medium containing lOng/ml TGF-P! {black bars) for the indicated time (hours). C, confluent 
monolayers of patient matched young and aged dermal fibroblasts were growth-arrested in serum-free 
medium for 48 hours, prior to addition of either serum-free medium alone {clear bars) or serum-free 
medium containing lOng/ml TGF-P! {black bars) for 72 hours. Total mRNA was extracted and a-SMA 
expression assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control and 
gene expression was assessed relative to suitable control (Time Oh control for A&B) or (aged-control 
for C) fibroblasts. The comparative CT method was used for relative quantification of gene expression 
and the results are represented as the mean± S.E. of dermal fibroblasts from nine individual 
experiments with cells isolated from three patient donors. Statistical analysis was performed by the 
Student’s / test: *, p <0.05, **, p<0.01 as compared to aged cells.
Effect o f  aging on cellular morphology
Young
Figure 3.2 E ffect o f  in-vitro aging on cellu lar m orphology. 50% confluent 
monolayers o f patient matched young (A&C) and aged (B&D) dermal fibroblasts were 
growth-arrested in serum-free medium for 72 h. The medium was then replaced with serum 
free medium alone (A&B) or containing lOng/ml TGFPi (C&D) and the incubations 
continued for a further 72h. The cells were visualised by phase contrast microscopy on a 
zeiss Axiovert inverted microscopy. Representative o f dermal fibroblasts from four patient 
donors. Original magnification x 200. Under basal conditions young fibroblasts demonstrate 
an elongated, spindle-like appearance with little evidence of prominent stress fibres (A), 
whereas following TGF-P 1 stimulation young cells appear larger in size with a polygonal 
shape and prominent stress fibres (B). With in-vitro aging cells become wider, larger and 
irregular in shape and demonstrate increased stress fibres under basal conditions (C). 
Following TGF-Pi stimulation aged cells show little change in appearance form basal 
conditions (D) and stress fibres are less pronounced than stimulated young cells.
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F igure 3 .3  Im m unohistochem ical analysis o f  vim entin an d  cytokeratin  expression in yo u n g  an d  aged  fibroblasts. Monolayers 
of patient matched young (A,B,E,F,) and aged (C,D,G,H) dermal fibroblasts were growth-arrested in serum-free medium for 48 h. The medium 
was then replaced with either serum-free medium alone (A,E,C,G) or serum-free medium containing lOng/ml TGF-P! (B,F,D,H) for 72h. The 
cells were then fixed and antibodies used for the detection of vimentin (A-D), and cytokeratin (E-H) as described under section 2.14. The cells 
were then mounted in Vectashield fluorescent mountant, and viewed under UV light. All results shown are representative o f dermal fibroblasts 
from three patient donors. Original magnification x 100.
Young Aged
-TGFpl +TGFpl -TGFpl +TGFpl
F igure 3 .4  Im m unohistochem ical analysis o f  F-actin a n d  a-SM A  expression in yo u n g  a n d  aged  fibroblasts. Monolayers of
patient matched young (A,B,E,F,) and aged (C,D,G,H) dermal fibroblasts were growth-arrested in serum-free medium for 48 h. The medium 
was then replaced with either serum-free medium alone (A,E,C,G) or serum-free medium containing lOng/ml TGF-P! (B,F,D,H) for 72h. The 
cells were then fixed and filamentous actin was visualised by staining with fluorescein-conjugated phalloidin (A-D) or antibodies for the 
detection o f a-SMA were added as described under section 2.14. The cells were then mounted in Vectashield fluorescent mountant, and 
viewed under UV light. All results shown are representative of dermal fibroblasts from three patient donors. Original magnification x 100
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Figure 3.5 Age dependent effect on HA generation assessed by size exclusion chromatography.
A,B, confluent monolayers o f patient matched young (black circle) and aged (white circle) dermal 
fibroblasts were growth arrested in serum-free medium for 48 hours. The medium was removed and 
replaced with either serum-free medium alone (A) or with serum-free medium containing lOng/ml o f TGF- 
Pi (B) for 72 hours. Cells were subsequently labelled for 24 hours with 20 pCi/ml [3H]-glucosamine. The 
radio-labelled HA was isolated from the conditioned medium and subjected to size exclusion 
chromatography on a Sephacryl S500 column as describe under section 2.12. C,D, confluent monolayers o f 
patient matched young (C), aged (D) dermal fibroblasts were growth arrested in serum-free medium for 48 
hours. The medium was removed and cells were metabolically labelled with 20 pCi/ml [3H]-glucosamine in 
either serum-free medium alone (black circle) or with serum-free medium containing lOng/ml of TGF-P! 
(white circle) for 72 hours. The radio-labelled HA was isolated from the conditioned medium and subjected 
to size exclusion chromatography on a Sephacryl S500 column as describe under section 2.12. All results 
shown are representative o f dermal fibroblasts isolated from at least two separate donors. Three arbitrary 
sizes o f HA are indicated, high molecular weight (HMW) >1.5 x 106, medium molecular weight (MMW) 
0.4-1.5 x 106 and low molecular weight (LMW) < 40 xlO4 Da.
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F igu re  3 .6  E ffec t o f  in-vitro  ag in g  on ex tracellu lar H A  generation . At the indicated 
PDL, confluent monolayers o f dermal fibroblasts were growth arrested in serum-free medium 
for 48 hours. The medium was then replaced with either serum-free medium alone {clear bars) 
or serum-free medium containing lOng/ml TGF-Pi {black bars) for 72 h. HA concentration in 
the culture medium was quantified by ELISA as describe under section 2.13. The data represent 
mean ± S.E. from six separate experiments using cells isolated from one donor. Statistical 
analysis was performed using ANOVA to show global differences between PDLs for basal 
(p<0.001) and TGF-Pi (p<0.001) conditions, followed by Turkey’s HSD Post-hoc Test 
analysis: *, p<0.01 as compared to PDL 13.
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Age-related changes in HA generation
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F igu re  3 .7  H A S 2  m R N A  expression  in y o u n g  a n d  a g ed  d erm al fib ro b la s ts . Confluent 
monolayers o f patient matched young and aged dermal fibroblasts were growth-arrested in serum- 
free medium for 48 hours. The medium was then replaced with either serum-free medium alone 
(clear bars) or serum-free medium containing lOng/ml TGF-Pi {black bars) and the incubations 
were continued for 72 h. HA secreted into the culture medium was quantified by ELISA as 
describe under section 2.13. Following removal o f the culture medium, total mRNA was extracted 
and cDNA prepared describe under section 2.7. HAS2 expression was assessed by RT-QPCR. 
Ribosomal RNA expression was used as an endogenous control and gene expression was assessed 
relative to control aged fibroblasts. The comparative C t method was used for relative 
quantification o f gene expression. The data are represented as the mean ± S.E. o f six individual 
experiments using cells from two patient donors. Statistical analysis was performed by Student’s t 
test.#, Not significant, *, p <0.01, as compared to aged cells. N/S (not significant).
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Age-related changes in HAS isoform Expression
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F igure 3 .8  E ffect o f  in-vitro aging on H A S  m RN A expression. A-C, confluent monolayers of 
patient matched young and aged dermal fibroblasts were growth-arrested in serum-free medium for 48 
hours. The medium was then replaced with either serum-free medium alone (clear bars) or serum-free 
medium containing lOng/ml TGF-P! (black bars) and the incubations were continued for 72 h. Following 
removal of the culture medium, total mRNA was extracted and cDNA prepared as describe under section 
2.7. HASl (A), HAS2 (B) and HAS3 (C) expression was assessed by RT-QPCR. Ribosomal RNA 
expression was used as an endogenous control and gene expression was assessed relative to control aged 
fibroblasts. The comparative CT method was used for relative quantification of gene expression. The data 
are represented as the mean ± S.E. of six individual experiments using cells from two patient donors. 
Statistical analysis was performed by Student’s t test. #, Not significant, *, p <0.01, **, p <0.001 as 
compared to aged cells. N/S Not Significant. B, Q-PCR amplification plot displaying relative CT values for 
individual genes.
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Hyaluronan-dependent
Yoiuig Aged
Figure 3.9 E ffect o f  aging on H A pericellu lar coat assembly. Subconfluent layers 
of patient matched young (A & C) and aged (B & D) dermal fibroblasts were growth- 
arrested in serum-free medium for 48 h. The medium was then replaced with either serum- 
free medium alone (A & B) or with lOng/ml TGF-P] (C & D) for 72 h. Formalised horse 
erythrocytes were then added as describe under section 2.11 to visualise the HA 
pericellular coat. Zones of exclusion were visualised using Zeiss Axiovert 135 inverted 
microscope. Arrowheads indicate the cell body; Arrows show the extent of the pericellular 
matrix. Representative of dermal fibroblasts from three patient donors. Original 
magnification x 200.
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Age-related changes in TSG-6 expression
TSG-6 mRNA Expression
P=0.05
N/S
Young Aged
F igu re  3 .10  E ffec t o f  ag in g  on  T G F -pi m ed ia ted  TSG -6 induction . Confluent 
monolayers o f  patient matched young and aged dermal fibroblasts were growth-arrested in 
serum-free medium for 48 hours. The medium was then replaced with either serum-free medium 
alone (open bars) or serum-free medium containing lOng/ml TGF-Pi (black bars) and the 
incubations were continued for 72 h. mRNA was extracted and cDNA prepared as describe 
under section 2.7. TSG-6 expression was assessed by RT-QPCR. Ribosomal RNA expression 
was used as an endogenous control and gene expression was assessed relative to control aged 
fibroblasts. The comparative CT method was used for relative quantification o f gene expression 
and the results are represented as the mean± S.E. o f dermal fibroblasts from three patient 
donors. Statistical analysis was performed by the Student’s t test: *,p<0.05 as compared to aged 
cells. N/S, not significant.
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3.3 Discussion
Whilst the disruptive effects o f aging on the proliferative and migrative capacity of 
fibroblasts have been well documented [1, 35], the effects of aging on cellular 
differentiation have not been extensively reviewed. This chapter specifically examines 
the potential for TGF-Pi-mediated fibroblast-myofibroblast differentiation associated 
with in-vitro aging and characterises the differences in synthetic enzyme transcription, 
generation and packaging of HA.
The Results presented in this chapter demonstrate for the first time a failure of dermal 
fibroblast-myofibroblast differentiation associated with in-vitro aging, which may be of 
relevance to the impaired wound healing associated with aging. In accordance with 
previous work [159, 160], young dermal fibroblasts readily differentiated into 
myofibroblasts in response to TGF-P i and this was associated with a significant 
induction in expression and incorporation of a-SMA into their stress fibres. In-vitro 
aged cells demonstrated attenuated a-SMA mRNA expression under both basal and 
TGF-P i stimulated conditions and failed to incorporate a-SMA into their stress fibres, 
indicating resistance to TGF-Pi-mediated phenotypic activation. This chapter extends 
on previous findings and demonstrates in addition to being site specific [159, 160], 
fibroblastic phenotype is age specific.
Further comparison by young and aged dermal fibroblasts revealed characteristic 
changes in cellular morphology in addition to the age-dependent changes in phenotypic 
activation. Under basal conditions young fibroblasts demonstrated an elongated, 
spindle-like appearance with little evidence o f prominent stress fibres. Following TGF- 
Pi stimulation, young cells appeared more polygonal in shape, increased in size and 
demonstrated prominent cytoskeletal re-organisation of filamentous actin stress fibres. 
Aged cells at rest, appeared larger and more irregular in shape and possessed more 
stress fibres than their younger counterparts. Furthermore, cytoskeletal re-organisation 
was less prominent following TGF-pi stimulation when compared to young cells and 
actin fibres appeared more sparse and restricted to the cell periphery.
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HA expression is tightly associated with, and is thought to regulate cellular 
differentiation. In human skin organ cultures, factors like all-trans-retinoic acid, which 
increase HA synthesis, have been shown to delay differentiation [278]. Likewise, 
organotypic epidermal cultures show that keratinocyte differentiation is stimulated and 
inhibited by factors that decrease and increase HA synthesis, respectively [279]. In 
contrast, enhancing turnover of cell surface HA by Hyaluronidase promotes terminal 
differentiation o f keratinocytes [213] and previously work in the Institute o f Nephrology 
(ION) demonstrated that HA upregulation is associated with TGF-pi-driven dermal 
fibroblast-myofibroblast transition [159, 160, 266]. I subsequently sought to relate age 
related changes in HA generation to failure of phenotypic activation in the aged 
phenotype.
The HA profile o f young dermal fibroblasts resembled that previously characterised 
[159, 160]. Under basal conditions, dermal fibroblasts generated large amounts o f high 
molecular weight extracellular HA. Following stimulation by TGF-pi, young cells 
generation o f extracellular HA was augmented and cells were characterised by the 
formation of prominent HA-dependent coats which surrounded the cell. The data 
presented in this chapter clearly demonstrated a decrease in HA generation both in 
unstimulated cells and also following addition of TGF-pi associated with in vitro aging 
but it should be added that the molecular weight did not vary. Young cells demonstrated 
at rest, 2.5-fold more HA in the conditioned medium when compared to aged cells and 
over 4-fold more HA in the conditioned medium following TGF-pi stimulation. Further 
analysis revealed that young and aged cells differentially regulated their HA 
accumulation by TGF-Pi. Whilst young fibroblasts demonstrated sizeable gains in HA 
generation in response to TGF-P i, patient matched aged fibroblasts were resistant to HA 
up-regulation in response to the same dose and duration of TGF-Pi stimulation. 
Associated with this was an age-related failure to generate a HA pericellular coat.
These data are consistent with our previous observations suggesting that increased HA 
generation were causally related to TGF-pi mediated fibroblast-myofibroblast 
conversion [159]. Previously, studies demonstrated a significant difference in HA
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generation under basal conditions with cells capable of myofibroblastic change, i.e. 
young dermal fibroblasts, generating significantly more HA than those resistant to 
phenotypic change i.e. oral mucosal fibroblasts [159]. Furthermore it was previously 
demonstrated that the different basal patterns o f HA generation were associated with the 
regulation of differing proliferative responses to TGF-pl by the two fibroblast 
populations [160]. Similarly, data presented in this chapter demonstrated that resistance 
to TGF-pl-mediated phenotypic activation in aged cells is associated with attenuation 
o f HA synthesis.
Upregulation of HASs has been found in the context of tissue injury [179]. Previous 
work has suggested that specific HA synthase isoform activity plays an essential role in 
instigating cell differentiation [280]. Recently, direct evidence on the role o f HA in 
epidermal keratinocytes emerged by the finding that HAS2 regulated HA synthesis 
controls migration rate o f keratinocytes in scratch-wounded monolayer cultures [281]. 
Sugiyama et al [282] found that TGF-Pi upregulates HASl and HAS2 expression 
independently in cultured human skin fibroblasts, whilst HAS3 gene expression was 
downregulated upon TGF-Pi-mediated myofibroblastic differentiation and cellular 
senescence [283]. In addition to HA accumulation, the results from this chapter 
examined the differential expression of HAS isoforms associated with the aging 
fibroblast.
Accumulation o f extracellular HA in response to TGF-Pi was consistent with the 
findings that TGF-Pi induced the expression o f H ASl, HAS2 and HAS3 isoforms in 
young dermal fibroblasts. Accordingly, the data presented in this chapter demonstrated 
in- vitro aging and resistance to phenotypic conversion was accompanied by a failure of 
H A Sl, HAS2 and HAS3 induction by TGF-pi. The observed age-related attenuation in 
HA generation under resting conditions could not be so easily explained by differences 
in HAS expression. Baseline expression of HASl and HAS3 enzymes did not 
significantly differ between young and aged cells. Despite not being statistically 
significant, however, blunted expression of basal HAS2 may play an important role in 
dictating attenuated HA levels in the aged phenotype. A unique deficiency of the HASl 
isoform was observed in the non-scarring non-differentiating oral fibroblasts. Neither
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HASl over-expression in oral fibroblasts nor HASl down-regulation in dermal 
fibroblasts influenced TGF-pi-mediated phenotypic activation in previous studies [159], 
suggesting that HASl isoform expression is not critical for acquisition of the 
myofibroblast phenotype. Data from this chapter further support a redundant role of 
HASl in regulating cellular phenotype. Assuming comparable sensitivity o f assays for 
HAS 1-3 by QPCR, evaluation o f the amplification plot revealed relative expression 
levels o f HASl were almost undetectable in quiescent cells, and despite a large 130-fold 
induction of HASl by TGF-pi in young fibroblasts, it should be recognised that this is 
130-fold induction o f negligible levels. Comparison of relative HAS transcription 
revealed, regardless o f age, HAS2 mRNA was more abundant, suggesting it may be 
important for regulating myofibroblastic differentiation.
Vigetti et al showed that the accumulation of HA during aging is likely to be a result of 
increased expression of synthetic enzymes, rather than a down-regulation of degrading 
enzymes [284]. Consistent with this, work from this laboratory demonstrated that no 
significant differences in Hyal expression was detected between dermal and oral 
fibroblasts, suggesting that increased HA related to dermal fibroblasts was a result of 
increased HA generation rather than reduced turnover [285]. In contrast to these studies, 
Jenkins et al [266] propose that HA accumulation associated with myofibroblastic 
differentiation in lung fibroblasts was a consequence of a decrease in HA degradation as 
opposed to an increase in HA synthesis. The authors’ specifically showed that cell 
associated Hyal activity is redistributed and shed from myofibroblasts when they have 
differentiated, thus reducing their capacity for HA degradation.
A comparison o f Hyal expression was not assessed between young and aged dermal 
fibroblasts in this study and so it cannot be ruled out that in-vitro aging may result in 
upregulation in Hyal activity and increased HA degradation. It is, however, more likely 
that age-related attenuation in HA generation was attributed solely to reduced HA 
synthase transcription, based on the notion that augmented Hyal activity in aged cells 
would have resulted in generation of smaller HA fragments and clearly the molecular 
weight o f HA generated did not decrease with in-vitro aging. Therefore, I propose that
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age-related attenuation in HA generation was attributed solely to reduced HA synthase 
transcription.
Recent data suggested that the functional effects o f HA depend on the context in which 
HA is assembled and packaged. This has been aided by a recent report that in proximal 
tubular epithelial cells HA can be either disease promoting or disease limiting, 
depending on organisation of HA into coat or cable like structures, respectively [194]. 
HA-rich matrices are essential for the proliferative and migratory phenotype [212, 213], 
during embryonic development and organogenesis and are involved in tumour cell 
invasion [286]. Increased cell-associated HA and increased thickness of the cell coat has 
also been associated with myofibroblast differentiation [266, 287].
The other striking disparity between young and aged dermal fibroblasts from this 
chapter was their ability to generate pericellular HA coats. In young cells, phenotypic 
activation was associated with assembly o f pericellular coats, whereas resistance to 
differentiation in in-vitro aged cells was associated with failure of HA coat assembly. 
The functional consequence of these differences, in terms of potential for phenotypic 
maturation, will be investigated in the following chapter.
Many studies have demonstrated the importance of HA-binding proteins, termed 
hyaladherins, in the organisation o f HA matrices. One hyaladherin, which has a 
particular role in the formation o f pericellular HA coats, is tumour necrosis factor-a- 
stimulated gene 6 (TSG-6). It is implicated in the stabilization o f ECM structure, 
particularly by supporting the formation of cross-linked HA networks [288]. Fiilop et al 
have shown that TSG-6 -/- mice are infertile due to their inability to form a HA-rich 
extracellular matrix [289]. In addition, work in the ION has shown the importance of 
TSG-6 in the formation of a pericellular HA in epithelial cells of renal origin [290]. 
Furthermore, the ability of TSG-6 to modulate the interaction of HA with CD44 has 
important implications for CD44-mediated cell activity at sites o f inflammation [190]. 
In the current study I have demonstrated an age dependent impairment in HA 
pericellular coat assembly. Consistent with this, in-vitro aged fibroblasts demonstrated a 
decrease in TSG-6 expression, both in unstimulated cells and in response to TGF-pi.
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Data from this chapter presents evidence that in-vitro aging is associated with 
attenuation o f numerous TGF-pi-dependent responses, including a-SMA induction, HA 
synthesis, induction of HAS and TSG-6 transcription and assembly of HA-dependent 
pericellular coats. In fact, all the responses mediated by TGF-Pi investigated throughout 
this chapter have displayed impairment with in-vitro aging. This strongly suggests that 
the results observed may be simply a product o f an age-dependent global deficit in 
TGF-Pi signalling. Several studies have provided a link between dysregulation of TGF- 
pi signalling and disease promotion whether it be through loss of receptor expression 
[291] [292], increased receptor internalisation [209, 293], or modulation of SMAD and 
non-SMAD signal transduction pathways [106, 160, 210, 294]. The impact of in-vitro 
aging on TGF-Pi signalling will be further investigated in the subsequent chapter.
The data presented herein suggest a model o f dermal fibroblast aging in which both 
basal and TGF-pi-stimulated cell activities decline with increasing PDs. Loss of 
TGFpi-mediated responsiveness in aged cells is linked to decreased levels in HA 
generation and failed acquisition o f a HA pericellular coat. The decrease in basal cell 
activities is likely due to a second, possibly independent cell change that does not 
involve TGF-Pi signalling. It remains to be determined whether these two events have a 
common casual basis at the gene regulation level.
Differential regulation o f HAS2 expression by dermal and oral fibroblasts was assumed 
to be the mechanism responsible for differences in TGF-pi-directed HA generation 
[159]. The data from this chapter support a role for HAS2 over HAS1 and HAS3 by 
virtue o f its increased transcription. In addition it serves as the only HAS candidate that 
could account for differences in basal HA and generation of both high molecular weight 
and pericellular HA. In light o f these results and in light of previous research relating to 
the HAS2 isoform in cellular differentiation [159, 162], examining the role o f this 
isoform in regulating fibroblast behaviour will be further examined in the next chapter.
The salient findings of this chapter are summarised in figure 3.11. In summary, 
the data presented demonstrates an age related alteration in fibroblast behaviour which
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results in an inability to undergo phenotypic transformation to become a myofibroblast. 
TGF-Pi addition to young cells, induced their differentiation to a-SM A positive 
myofibroblasts. In-vitro aging of dermal fibroblasts confers resistance to TGF-pi-driven 
fibroblast-myofibroblast conversion and is associated with age-dependent attenuation in 
HAS transcription, synthesis of HA and its assembly into a pericellular coat. Since it is 
the myofibroblast that orchestrates the successful formation of granulation tissue and 
matrix remodelling, this is an important finding that may be central to the delayed 
healing seen in the elderly. This data adds credence to the hypothesis that the matrix 
polysaccharide HA is an important component o f the regulation of fibroblast phenotype 
and that its dysregulation may be casually related to failure of a fibroblast to acquire a 
myofibroblastic phenotype.
The data presented in this chapter demonstrated distinct age-related heterogeneity in HA 
biosynthesis and packaging by patient matched young and aged cells which may yield 
important insights into impaired wound healing processes characterised in the elderly
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F igure 3.11 Com parison o f  yo u n g  an d  in-vitro aged  f ib ro b la st phenotype. A comparison of 
cell morphology, HA generation and phenotype of patient matched young (A&C) and aged (B&D) 
dermal fibroblasts at rest (A&B) and following TGF-pi stimulation (C&D), based on the analysis 
compacted from this results chapter. Under basal conditions, vimentin positive young dermal 
fibroblasts are elongated, spindle-like with no evidence of prominent stress fibres (A). In response to 
TGF-pi, fibroblasts readily differentiate into myofibroblastic cells which are lager, polygonal in shape 
and incorporate prominent stress fibres and a-SMA (C). This is associated with upregulated HAS 
expression, increased HA synthesis, TSG-6 induction and assembly o f a HA pericellular coat. With in- 
vitro aging, vimentin positive fibroblasts become wider, larger and more irregular in shape and exhibit 
more stress fibres (B). Following TGF-pi stimulation the cells appear more dentritic but fail to 
incorporate a-SMA or assemble prominent stress fibres in contrast to their younger counterparts (D). 
Resistance to TGF-pi mediated myofibroblastic differentiation is associated with attenuated HAS 
induction, reduced HA synthesis, TSG-6 induction and failure to synthesise a HA pericellular coat.
Chapter 4 
Differential Effects of Aging on TGF-pi 
Signalling and Organisation of Pericellular
Hyaluronan
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4.1 Introduction
In the previous chapter failure of TGF-pi-induced cellular differentiation and HA coat 
formation in aged cells was associated with the inability to induce HAS2. Several 
studies have confirmed a specific role for HAS2 in both of these processes. Previously it 
was demonstrated that resistance o f oral mucosal fibroblasts to TGF-pl mediated 
myofibroblastic change is associated with failure of induction of HAS2 [159]. HA 
synthesis regulated by HAS2 is an important component in epidermal proliferative and 
differentiation processes [279]. This is in accordance with previous work demonstrating 
that HAS2 inactivation in mice embryo is lethal because of failure o f cardiac endothelial 
cells to undergo epithelial to mesenchymal transition [295].
Induction of HAS2 in human vascular smooth muscle cells using the prostacyclin 
analogue, iloprost markedly increased pericellular formation of HA coats [286]. HA 
secreted by HAS2 binds to CD44, and functions in pericellular coat formation and 
hydration in the extracellular space, thus offering an advantageous environment for 
osteosarcoma cells [296], whilst inhibition of HAS2 activity with HAS2 antisense 
oligonucleotides has been demonstrated to disable pericellular matrix assembly in 
human articular chondrocytes [297].
Manipulation of the HAS genes has enabled the over-expression or inhibition of the 
different HA synthase isoforms, which has provided a preliminary insight into the role 
o f HA synthesis in biological processes. Whilst HA synthesis, induced by HAS1 
overexpression led to increased HA cable formation [298], HAS2 overexpression led to 
the formation o f pronounced pericellular coats. This was shown to enhance cell 
motility, a key early stage in epithelial to mesenchymal transition [194]. HAS2 
adenoviral transfection in Madin-Darby canine kidney epithelial cells has been 
associated with the development of mesenchymal and malignant characteristics [280].
These studies together with the work outlined in the previous chapter lead me to 
postulate that resistance to phenotypic conversion observed in aged fibroblasts was 
related to an age-dependent failure in HAS2 induction by TGF-pl. Furthermore, that the
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increase in HA synthase that is driven by the inducible form HAS2, is responsible for 
pericellular formation of HA coats. For examination of this hypothesis, this chapter 
utilises siRNA technology and over-expression techniques to characterise the 
participation of HAS2-driven HA synthesis and its pericellular assembly in regulating 
fibroblast phenotype.
The results from the previous chapter have demonstrated that young and aged dermal 
fibroblasts exhibit intrinsic differences in their ability to respond to TGF-pl, associated 
with resistance to phenotypic conversion and alterations in HA generation, distribution 
and HAS isoform expression. Mogford et al [299] demonstrated that aged fibroblasts 
have an impaired migratory capacity that is a result of decreased TGFPRI levels. The 
authors propose that such deficits in the migratory and signal transduction 
responsiveness to TGF-pl may partly explain diminished healing capabilities often 
observed in aged patients. It is therefore interesting to speculate that the diminished 
response to TGF-pi exhibited in my aged cells may be a consequence of either reduced 
autocrine secretion of, impaired binding of, or dysfunctional receptors for TGF-pi.
Although it is now appreciated that TGF-Pi plays a central role in mediating the 
response to injury, very little is known of the signalling pathways in-vivo that regulate 
fibroblasts-myofibroblast differentiation. The classical signalling pathway for TGF-P 
involves the Smad family of transcriptional activators [300, 301]. The receptor 
associated R-Smad, Smad2 and Smad3 are phosphorylated directly by the TGF-P type 1 
receptor kinase, after which they hetero-oligomerize with Smad4, translocate to the 
nucleus, and together with their binding partners activate or repress their target genes. 
In-vitro studies have shown that manipulation of Smad2 and Smad3 levels differentially 
influences cellular responses such as ECM production, chemotaxis, proliferation and 
stress fibre organisation [302]. Targeted deletion o f Smad2 or Smad3 genes in mice and 
in embryonic fibroblasts, revealed distinct non-redundant roles for each of these 
transcription factors [303] and TGFPi-Smad-dependent events may be mediated by 
either or both Smad2 and Smad3. Transcription of a-SMA in lung myofibroblasts-like 
cells was reported to be predominantly mediated by the binding of Smad3 [133], 
whereas nuclear translocation of Smad2 was shown to be directly responsible for
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myofibroblast differentiation [294]. In this chapter the role of Smad2 and Smad3 in 
TGF-P 1 mediated fibroblasts-myofibroblast differentiation is assessed.
It is interesting to postulate that the differential response to TGF-pl in my 
phenotypically distinct populations of young and aged fibroblasts are due to differences 
in Smad2 and Smad3 signalling. Therefore in addition, potential age-related alterations 
in Smad signalling which could account for diminished responsiveness to TGF-pl are 
investigated.
The role of R-Smads have been previously demonstrated in the regulation o f TGF-P 1 
dependent fibroblast proliferation. Furthermore this effect may be modified by HA 
[270, 304, 305]. Previous work from this laboratory, using epithelial cells, has 
demonstrated that HA may modify TGF-P 1 signalling by altering the turnover of TGF-P 
receptors at the cell surface, resulting in alteration in the pattern of activation and 
phosphorylation of the signalling intermediates Smad2 and Smad3 [209, 210]. 
Bourgignon et al demonstrated that in metastatic breast cancer cells, CD44 is physically 
linked to the TGF-P receptor and that binding of HA to CD44 promotes TGF-P 1 
mediated cell migration through augmentation o f Smad2/3 signalling [203]. In addition 
to assessing the role o f HA in myofibroblast differentiation this chapter will investigate 
the relationship between HA and TGF-P 1 signalling.
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The aim of this chapter is:
i To characterise TGF-pl signalling in young and aged dermal fibroblasts,
specifically:
- the significance of Smad2 and Smad3 in phenotypic activation
- the significance of age-related alterations in Smad2 and Smad3
ii To determine a functional role for HA in myofibroblastic differentiation
specifically:
- the significance of age-related changes in HAS2 expression
- the significance of age-related changes in HA pericellular coat 
formation
iii To examine whether modulating HA levels can influence the aged phenotype
iv To investigate a relationship between TGF-pl signalling and pericellular HA
organisation
The results from this chapter will help address the hypotheses that age-related resistance 
to myofibroblastic differentiation results from defective pericellular HA organization 
and/or defective TGF-P 1 signalling. Furthermore this chapter addresses whether 
modulation of HA levels alters cellular wound healing responses and the aging 
phenotype
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4.2 Results
4.2.1 The effect o f ALK-5 inhibition on phenotypic activation
The importance of TGF-P 1 signalling for phenotypic activation was investigated using 
SB431542, an inhibitor o f activin receptor-like kinase (ALK)5 (the TGF-p type I 
receptor). It also inhibits the activin type I receptor ALK4 and the nodal type I receptor 
ALK7, which are very highly related to ALK5 in their kinase domains. Growth-arrested 
fibroblasts were incubated for 72 h in serum-free medium alone or containing 
SB431542 (10 pM) in the absence or presence o f TGF-pi (10 ng/ml). Incubation of 
young fibroblasts with SB431542 resulted in abrogation o f TGF-P 1 dependent induction 
o f a-SMA mRNA expression compared to control treatments as assessed by Q-PCR 
(Figure 4.1 A) and immunohistochemistry (Figure 4.1D-G). In contrast, incubation with 
the p38MAPK inhibitor SB203580 had no effect on a-SMA expression (Figure 4.1 A). 
In parallel experiments, the importance of TGF-P 1 signalling in the induction o f HAS2 
(Figure 4 .IB) and TSG-6 expression (Figure 4.1C) was investigated by Q-PCR analysis. 
Whilst basal and TGF-pl-mediated HAS2 induction was significantly reduced in cells 
incubated with SB431542, there was no significant variation in levels of TSG-6 
expression. The P38MAPK inhibitor SB203580 demonstrated no effect on both HAS2 
and TSG-6 expression.
4.2.2 The expression o f endogenous TGF-pl in young and agedfibroblasts
It has been previously demonstrated that autocrine TGF-P 1 signalling is necessary for 
maintenance o f myofibroblast phenotype [162]. To determine whether impaired 
autoinduction of TGF-P 1 could account for diminished TGF-P 1 responsiveness 
associated with in-vitro aging, generation of TGF-pl was examined at the level of 
transcription by Q-PCR in young and aged fibroblasts in the absence and presence of 
exogenous TGF-pl (Figure 4.2). Under basal conditions, aged cells demonstrated 
increased expression of TGF-P 1 mRNA but more significantly neither young nor aged 
cells demonstrated significant variation in autocrine levels. This result suggests
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autocrine TGF-P 1 signalling is competent in aged fibroblasts and cannot explain the age 
dependent loss of TGF-P 1 dependent phenotypic activation.
4.2.3 The effect o f Smad2 and Smad3 knock-down in TGF-pl mediated responses in 
young fibroblasts
Given the importance of TGF-P 1 in the phenotypic conversion of fibroblasts, the role of 
the TGF-pi signalling intermediates Smad2 and Smad3 in TGF-pi dependent 
phenotypic activation was examined by gene silencing using siRNA. Suppression of 
Smad2 expression (Figure 4.3A) and Smad3 expression (Figure 4.4A), following 
transfection with siRNA was confirmed by Q-PCR.
Inhibition of Smad2 expression was associated with a failure of TGF-P 1 to increase a- 
SMA in young fibroblasts (Figure 4.3B), confirming previous work suggesting the 
involvement of this signalling intermediate in fibroblast phenotypic activation [112]. In 
contrast, successful knockdown of Smad3 using siRNA failed to have an effect on TGF- 
pl-mediated phenotypic differentiation (Figure 4.4B). Suppression of Smad2 or Smad3 
displayed no significant changes in the expression of HAS2 (Figure 4.3C & 4.4C) or 
TSG-6 (Figure 4.3D & 4.4D).
4.2.4 The effect o f in-vitro aging on Smad 2 and Smad 3 signalling
Given the age dependent failure of TGF-P 1 directed phenotypic activation demonstrated 
in the previous chapter, I sought to examine the effects of in-vitro aging on Smad2 and 
Smad3 signalling by Western blot analysis of TGF-pl dependent phosphorylation. 
Work in ION has previously shown that young dermal fibroblasts strongly 
phosphorylate Smad 2 and Smad3 in response to TGF-pl [160]. In these experiments, 
Smad2 and Smad3 activation by TGF-P 1 and the effect of in-vitro aging were assessed. 
Smad2 was rapidly phosphorylated (within 15 minutes) after addition of TGF-P 1 to 
quiescent cells and peak activation was observed after lhr. This kinetic profile did not 
change across the range of in-vitro ages investigated, extending from young (PDL 15), 
through to near-senescent cells (PDL 39) (Figure 4.5A). Peak Smad2 phosphorylation
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(lh r with TGF-P 1) was directly compared across the range of in-vitro ages 
demonstrating that the extent o f phosphorylation also did not vary with aging (Figure 
4.5B).
Smad3 was also phosphorylated in response to TGF-pi stimulation (Figure 4.6A). The 
phosphorylation pattern observed was not as consistent across the range of in-vitro ages 
investigated as for Smad2 but despite this, peak activation (3h with TGF-pl) was 
chosen for a direct comparison of phosphorylation events. As with Smad2, Smad3 
phosphorylation did not change with increasing PDL’s (Figure 4.6B). These results 
collectively suggest that age dependent loss o f TGF-P 1 dependent phenotypic activation 
was not the result o f altered Smad2/3 signalling.
4.2,5 The effect o f inhibition o f HA synthesis on fibroblast phenotypic conversion
The results from the previous chapter demonstrate that age-related resistance to TGF- 
pi-mediated phenotypic activation was associated with age-related attenuation in HA 
generation, down-regulation in HAS2 expression and inability to assemble HA 
pericellular coats. In light o f these results, 4-methylumbelliferone (4MU) was used to 
inhibit HA synthesis, to investigate what consequence this has on phenotypic activation. 
4MU depletes the UDP-glucuronic acid pool that is essential for HA chain elongation 
[306], leading to inhibition of HA synthesis and HAS enzyme function. A concentration 
of 0.5mM 4MU was previously determined as the optimal concentration to yield 
effective inhibition of HA synthesis with minimal cytotoxicity in dermal fibroblasts 
[285]. Expression of a-SMA was assessed to investigate the role of HA in 
myofibroblastic differentiation following incubation with 4MU. Q-PCR assessment 
revealed that induction of a-SMA by TGF-P 1 was significantly down-regulated in the 
presence of 4MU (Figure 4.7A). Further analysis by Q-PCR demonstrated 4MU 
significantly attenuated induction of both HAS2 (Figure 4.7B) and TSG-6 (Figure 4.7C) 
expression by T G Fpi.
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4.2.6 The relationship between HAS2 andfibroblast phenotype
In the previous chapter it was demonstrated that reduced HA generation is associated 
with a blunted HAS2 response. The importance o f the HAS2 isoform of HA synthase 
was further examined by gene silencing of HAS2 in young cells. Validation of several 
new HAS2 Silencer Select siRNA’s (Invitrogen) were investigated (Figure 4.8) and 
subsequently HAS2 siRNA#2 (ID s6458) at a concentration o f lOnM, was chosen to be 
used for further investigation. HAS2 siRNA transfection resulted in significant 
inhibition of HAS2 mRNA expression (Figure 4.9A), and abrogation o f TGF-pl 
dependent induction of a-SMA (Figure 4.9B).
Furthermore, the ability of a young fibroblast to assemble a HA pericellular coat was 
lost following HAS2 suppression. Particle exclusion clearly illustrates that cells 
transfected with a scrambled control exhibit notable HA coats after TGF-pl stimulation 
(Figure 4.9E) compared to unstimulated cells (Figure 4.9C). In contrast, cells 
transfected with HAS2 siRNA do not assemble notable coats under basal (Figure 4.9D) 
or TGF-P 1 stimulated (Figure 4.9F) conditions. Measurements of the coat thickness 
were taken at the widest point of 30 randomly chosen cells from three separate 
experiments (three different patients). The mean thickness for the scramble -TGF-P 1 
(Figure 4.9C) was 3.13 ± 0.42pm and 7.50 ± 0.31 pm in scramble + TGF-pi (Figure 
4.9E) (P <0.01, paired t-test). In contrast cells that had received the HAS2 siRNA failed 
to assemble a HA pericellular coat after stimulation with TGF-P 1. The mean thickness 
for the HAS2 siRNA - TGF-pl (Figure 4.9D) was 4.63 ± 0.41pm and 4.44 ± 0.32 pm in 
HAS2 siRNA + TGF-P 1 (Figure 4.9F) (P = 0.63, paired t-test).
As age-dependent loss of TGF-pl induced pericellular coat assembly and myofibroblast 
phenotype was associated with reduced HAS2 expression, I sought to examine the 
effect o f over-expression of HAS2 on the phenotype of aged fibroblasts. Although over­
expression of HAS2 in the aged fibroblast led to the expected increase in HA 
concentration in the culture supernatant as assessed by ELISA (Figure 4.10A), there 
was no significant change in a-SMA expression as assessed by Q-PCR (Figure 4.10B)
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and immunohistochemistry (Figure 4.10 C&D). Further analysis by particle exclusion 
revealed no distinguishable change in pericellular HA accumulation following 
restoration of HAS2 in resting aged fibroblasts (Figure 4.10 E&F). Taking 
measurements o f the coat thickness at the widest point of 30 randomly chosen cells, 
gave a mean thickness for the aged mock transfected fibroblast coat of 4.82 ± 0.31pm 
(Figure 4.10E) and 4.41 ± 0.42 pm in the aged fibroblast transfected to over-express 
HAS2 (Figure 4.1 OF) (P = 0.42, paired t-test).
4.2.7 The role o f TSG-6 in myofibroblastic differentiation
The hyaladherin TSG-6 has been demonstrated to be an important mediator of HA 
pericellular coat assembly [193, 289, 307]. In the previous chapter, age-dependent 
resistance to phenotypic activation was associated with an age-dependent decrease in 
TSG-6 expression both at baseline and following TGF-pl stimulation. The functional 
importance o f age-dependent reduction in TSG-6 expression was subsequently 
examined by TSG-6 gene silencing using siRNA. Following transfection with TSG-6 
siRNA there was a marked inhibition in the effect of TGF-P 1 on TSG-6 mRNA 
expression, as assessed by Q-PCR (Figure 4.11 A). Abrogation of TGF-pl dependent 
induction of TSG-6 mRNA expression was also associated with a failure of TGF-P 1 to 
increase a-SMA in the young fibroblast (Figure 4.1 IB). In light o f these results it was 
hypothesised that assembly of the pericellular coat was dependent on both stimulation 
o f HA via HAS2 and also the induction of TSG-6.
4.2.8 The effect o f HAS2 restoration and TGF-p i stimulation on phenotype in aged 
fibroblasts
In order to explore this, aged fibroblasts were transfected with HAS2 and subsequently 
stimulated with TGF-pl. In these experiments the combination of HAS2 over­
expression and TGF-pl stimulation, restored the ability o f aged fibroblasts to form a 
pericellular HA coat, as assessed by the exclusion of formalized erythrocytes (Figure 
4.12A-C). Taking measurements o f the coat thickness at the widest point of 30 
randomly chosen cells of each phenotype, gave a mean thickness for the aged mock 
transfected fibroblast coat o f 3.19 ± 0.27 pm and 6.59 ± 0.41 pm in the aged fibroblast
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transfected to over-express HAS2, following TGF-P 1 stimulation (P < 0.001, paired t- 
test). Transfection with HAS2 did not, however, restore TGF-P 1 responsiveness in 
terms o f the induction o f a-SMA, as assessed by immunocytochemistry (Figure 4.12D- 
F), and QPCR (Figure 4.13A). This suggested a dissociation of pericellular coat 
formation and regulation of phenotype. In contrast, and consistent with the formation of 
the pericellular coat, over-expression of HAS2 and increased HA generation, was 
associated with partial restoration o f the induction of TSG-6 following stimulation with 
TGF-P 1 in the aged fibroblasts (Figure 4.13B).
4.2.9 The effect o f IL-lp on phenotype o f young and aged fibroblasts
Age dependent regulation of HAS2 was further examined by stimulation with IL-lp. In 
contrast to TGF-pl responsiveness, which diminished with age, stimulation of aged 
cells with IL-ip led to a significant induction of HAS2 gene expression (Figure 4.14A) 
and was also associated with an increase in HA, as assessed by ELISA (Figure 4.14B). 
TSG-6 induction was also significant following addition of IL-lp, compared to the 
blunted effect o f TGF-P 1 in aged cells (Figure 4.14C). In contrast stimulation with IL- 
ip , despite the alterations in HA associated gene regulation, did not lead to any change 
in expression of a-SMA (Figure 4.14D). The increase in HAS2, associated with 
induction of the hyaladherin TSG-6, would suggest that IL-lp stimulation may induce 
the formation o f a pericellular HA coat and this was confirmed by visualisation of the 
pericellular HA coat in young and aged cells (Figure 4.15). Taking measurements of the 
coat thickness at the widest point of 30 randomly chosen cells of each phenotype and 
“age” gave a mean, thickness for the young fibroblast coat o f 3.04 ± 0.19pm at baseline 
and 8.25 ± 0 .1 8  pm following IL-ip stimulation (P < 0.001, paired test). For aged 
fibroblasts the mean coat thickness at baseline was 3.15 ± 0.35 pm and following IL-lp 
stimulation was 7.95 ± 0.42 pm (P = 0.001, paired t-test). These data suggests that 
following IL-lp stimulation there is a dissociation of pericellular HA coat assembly and 
regulation of phenotype.
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4.2.10 The relationship between hyaluronan-dependent pericellular coat assembly 
and myofibroblastic differentiation
Data presented above suggest that TSG-6 dependent regulation o f the HA pericellular 
coat is required for TGF-pl phenotypic conversion. However, TGF-pl stimulation of 
HAS2 overexpressing cells and IL-lp stimulation in the aged phenotype, suggest that 
the formation of the pericellular coat in itself does not lead to acquisition of a 
myofibroblastic phenotype. The role o f the pericellular coat in TGF-pl dependent 
regulation of phenotype was further examined following its digestion with Hyal 
(confirmed by particle exclusion) (Figure 4.16A&C). There was no effect on TGF-P 1 
dependent induction of HAS2 (Figure 4.17A). In contrast Hyal digestion led to 
inhibition of TGF-pl dependent phenotypic activation as determined by expression of 
a-SMA by Q-PCR (Figure 4.17B) and immunohistochemistry (Figure 4.16B&D). 
Furthermore, treatment with Hyal demonstrated significant knock-down of TSG-6 
induction by TGFpi (Figure 4.17C).
Collectively these data suggests that the pericellular HA coat is therefore necessary but 
not sufficient to drive fibroblast to myofibroblast activation.
4.2.11 The effects o f Smad siRNA on hyaluronan-dependent pericellular coat 
accumulation
As TGF-pl signalling through the Smad-dependent pathway is required for 
myofibroblastic differentiation, the effect of 4MU and Hyal on phosphorylation of 
Smad2 was analysed by Western blot. To analyse Smad2 phosphorylation, young 
fibroblasts were incubated for 0, 30 and 60 min with either 4MU (0.5mM), Hyal 
(200pg/ml) or serum-free medium (control treatment) in the presence or absence of 
TGF-P 1 and protein extracts collected. Consistent with previous results, 
phosphorylation of Smad2 followed TGF-pl stimulation and peaked at 30min and lh  
for all conditions (Figure 4.18A). Direct comparison of the extent o f pSmad2 for all 
treatments at these time points, demonstrated incubation with 4MU or Hyal had no 
significant effect on the activation of Smad2 (Figure 4.18B), suggesting a dissociation
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of HA regulation (in particular its assembly into a pericellular coat) and Smad 
signalling.
4.2.12 The effect o f HA coat removal on Smad signalling
To support this, young fibroblasts were transfected with siRNA for Smad2 and Smad3 
prior to incubation with or without TGF-pl and their ability to assemble a HA 
pericellular coat assessed by particle exclusion (Figure 4.19). Cells were transfected 
with a scrambled oligonucleotide (scrambled) as a control. Measurements of the coat 
thickness were taken at the widest point of 30 randomly chosen cells from three separate 
experiments (two different patients) for each treatment: The mean thickness for the 
scramble -TGF-pl was 4.02 ± 0.28pm and 8.02 ± 0.46 pm in scramble + TGF-pi (P 
<0.01, paired t-test). Cells that had received the Smad2 siRNA generated significant HA 
coats following TGF-pl stimulation. The mean thickness for the Smad2 siRNA -TGF- 
pi was 4.82 ± 0.40pm and 7.55 ± 0.39 pm in Smad2 siRNA + TGF-pi (P <0.01, paired 
t-test). Cells that had received the Smad3 siRNA generated significant HA coats 
following TGF-pl stimulation. The mean thickness for the Smad2 siRNA -  TGF-P 1 
was 3.98± 0.46pm and 7.24 ± 0.56 pm in Smad2 siRNA + TGF-pi (P = <0.01, paired t- 
test). Collectively these results demonstrated, that for all treatments, stimulation with 
TGF-pl resulted in formation of a HA pericellular coat, indicating that TGFpl- 
dependent HA pericellular coat synthesis was not dependent on Smad signalling.
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Figure 4.1 E ffect o f  A L K  5 inhibition on a-SM A , H A S2 an d  TSG-6 expression  Confluent 
monolayers o f young dermal fibroblasts were growth-arrested in serum-free medium for 48 hours, prior to 
addition of either serum-free medium alone (clear bars) or serum-free medium containing lOng/ml TGF- 
31 {black bars) in the absence (control treatment) or presence of the ALK-4/5/7 inhibitor SB431542 or p38 
inhibitor SB203580 for 72 hours. Total mRNA was extracted and a-SMA (A) HAS2 (B) and TSG-6 (C) 
expression was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control 
and gene expression was assessed relative to control-control cells. The comparative CT method was used 
for relative quantification o f gene expression and the results are represented as the mean± S.E. o f nine 
individual experiments using cells isolated from three different donors. Statistical analysis was performed 
by the Student’s t test.#, Not significant, *, p <0.05, as compared to control treatment. N/S, not significant. 
In parallel experiments monolayers of young dermal fibroblasts were growth-arrested in serum-free 
medium for 48 h. The medium was then replaced with either serum-free medium alone (D,E) or serum-free 
medium containing lOng/ml TGF-P! (F,G) then fixed and stained for a-SMA, as describe under section 
2.4.The cells were then mounted in Vectashield fluorescent mountant, and viewed under UV light. All 
results shown are representative of dermal fibroblasts from three patient donors. Original magnification x 
100 .
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Figure 4.2 Effect of in-vitro aging on endogenous generation of TGF-pl.
Confluent monolayers o f patient matched young and aged dermal fibroblasts were growth- 
arrested in serum-free medium for 48 hours, prior to addition o f either serum-free medium 
alone {clear bars) or serum-free medium containing lOng/ml TGF-P 1 {black bars) for 72 
hours. Total mRNA was extracted and TGF-P 1 expression was assessed by RT-QPCR. 
Ribosomal RNA expression was used as an endogenous control and gene expression was 
assessed relative to control-control cells. The comparative CT method was used for relative 
quantification o f gene expression and the results are represented as the mean± S.E. o f six 
individual experiments using cells isolated from two different donors. Statistical analysis was 
performed by the Student’s t test. #, Not significant, as compared to aged cells. N/S, not 
significant.
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F igu re  4 .3  E ffec t o f  S m ad2  siR N A  on a -S M A , H A S 2  a n d  T SG -6 expression . Confluent monolayers o f  young dermal fibroblasts were transfected with Smad2 
siRNA, a scrambled oligonecleotide (scramble) or serum free medium (non-transfected) as describe under section 2.10 and incubated in medium supplemented with 10% FCS 
for 24 hours,. The medium was then replaced with serum-free medium for 24 hours. The cells were then incubated in either serum-free medium alone {clear bars) or serum- 
free medium containing lOng/ml TGF-B1 {black bars) for a further 72 hours and smad2 (A), a-SM A  (B), HAS2 (C) and TSG-6 (D) expression assessed by RT-QPCR. 
Ribosomal RNA expression was used as an endogenous control and gene expression was assessed relative to control scramble cells. The comparative CT method was used for 
relative quantification o f gene expression and the results are represented as the m ean t S.E. o f nine individual experiments using cells isolated from three different donors. 
Statistical analysis was performed by the Student’s t te s t.#, Not significant, *, p <0.05, as compared to scramble.
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Figure 4.4 Effect o f Smad3 siRNA on a-SMA, HAS2 and TSG-6 expression. Confluent monolayers o f young dermal fibroblasts were transfected with Smad3 
siRNA, a scrambled oligonecleotide (scramble) or serum free medium (non-transfected) as describe under section 2.10 and incubated in medium supplemented with 10% FCS 
for 24 hours. The medium was then replaced with serum-free medium for 24 hours. The cells were then incubated in either serum-free medium alone (clear bars) or serum- 
free medium containing lOng/ml TGF-B1 (black bars) for a further 72 hours and Smad2 (A), a-SM A  (B), HAS2 (C) and TSG-6 (D) expression assessed by RT-QPCR. 
Ribosomal RNA expression was used as an endogenous control and gene expression was assessed relative to control scramble cells. The comparative CT method was used for 
relative quantification o f gene expression and the results are represented as the mean± S.E. o f nine individual experiments using cells isolated from three different donors. 
Statistical analysis was performed by the Student’s t t e s t . N o t  significant, *, p <0.05, as compared to scramble.
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Figure 4.5 E ffect o f  in-vitro ageing on Sm ad2 signalling. A, confluent monolayers of dermal 
fibroblasts at the indicated PDL’s were growth arrested in serum-free medium for 48 hours. The 
medium was replaced with either serum-free medium alone or serum-free medium containing lOng/ml 
TGF-P 1 for the indicated times. B, direct comparison o f TGF-P 1 stimulated cells at lhr across indicated 
PDL’s. Cell lysates were subsequently subjected to Western blot analysis utilising antibodies against 
the phosphorylation form of Smad2. Expression of GAP-DH was analysed as a control to ensure equal 
loading. The results shown are representative of five independent experiments from the same patient 
donor.
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F igure 4.6 E ffect o f  in-vitro ageing on Sm adS signalling. A, confluent monolayers of dermal 
fibroblasts at the indicated PDL’s were growth arrested in serum-free medium for 48 hours. The 
medium was replaced with either serum-free medium alone or serum-free medium containing 
lOng/ml TGF-pi for the indicated times. B, direct comparison of TGF-(31 stimulated cells at 3 hr 
across indicated PDL’s. Cell lysates were subsequently subjected to Western blot analysis utilising 
antibodies against the phosphorylation form of Smad3. Expression of GAP-DH was analysed as a 
control to ensure equal loading. The results shown are representative of five independent experiments 
from the same patient donor
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Figure 4.7 a-SMA, HAS2 and TSG-6 mRNA expression following inhibition of HA chain 
elongation. Confluent monolayers of young dermal fibroblasts were growth arrested in serum-free 
medium for 48 hours. The medium was then replaced with either serum-free medium alone {Control), 
serum-free medium containing 0.5 mM 4MU, serum-free medium containing lOng/ml TGF-Pi or serum- 
free medium containing both 0.5 mM 4MU and lOng/ml TGF-P! for 72 h. mRNA was extracted as 
describe under section 2.6 and a-SMA (A) HAS2 (B) and TSG-6 expression was assessed by RT-QPCR. 
Ribosomal RNA expression was used as an endogenous control and gene expression was assessed relative 
to control cells. The comparative CT method was used for relative quantification o f gene expression and 
the results are represented as the mean± S.E. o f six individual experiments using cells isolated from two 
different donors. Statistical analysis was performed by Student’s t test and statistical significance was 
taken as p < 0.05. N/S, not Significant.
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F igu re  4 .8  V alidation o f  H A S 2  S ilen cer S e lec t siR N A . Young dermal fibroblasts were transfected with three different HAS2 silencer select siRNA’s (from 
Ambion: ID s645(7)(8)(9) donated HAS2 siRNA #(1)(2)(3)) or silencer select scrambled oligoneucleotide control (#1) (scramble) at either lOnM or 30nM. HAS2 siRNA 
#0 denotes previously used HAS2 siRNA (non-silencer select, 16704). Following transfection cells were incubated in medium supplemented with 10% FBS for 24 h. The 
medium was then replaced with serum-free medium for a further 24 h, prior to addition o f serum-free medium alone {clear bars) or serum-free medium containing lOng/ml 
TGF-P! {black bars) for 72 h. Total mRNA was extracted and HAS2 expression was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous 
control and gene expression was assessed relative to untransfected samples. The comparative CT method was used for relative quantification o f gene expression and the 
results are represented as the mean± S.E. o f six individual experiments using cells isolated from two different donors.
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Figure 4.9 E ffect o f  H A S2 siRNA on a-SM A expression an d  HA pericellu lar coat form ation.
Young dermal fibroblasts were transfected with HAS2 siRNA or a scrambled oligoneucleotide control 
(scramble) as describe under section 2.14 and incubated in medium supplemented with 10% FBS for 24 h. 
The medium was then replaced with serum-free medium for a further 24 h, prior to addition o f  serum-free 
medium alone (clear bars) (C&D) or serum-free medium containing lOng/ml TGF-Pi (black bars) (E&F) 
for 72 h before analysis by either Q-PCR or particle exclusion. A-B, total mRNA was extracted and 
HAS2 (A) and a-SM A (B) expression was assessed by RT-QPCR. Ribosomal RNA expression was used 
as an endogenous control and gene expression was assessed relative to control-scramble samples. The 
comparative CT method was used for relative quantification o f gene expression and the results are 
represented as the mean± S.E. o f nine individual experiments using cells isolated from three different 
donors. Statistical analysis was performed by the Student’s t test. *, p <0.05, as compared to scramble. 
Visualisation o f  the pericellular HA coat (C-F) was performed by addition o f  formalised horse 
erythrocytes as describe under section 2.11. Arrowheads indicate the cell body; Arrows show the extent o f  
the pericellular matrix. Representative o f  dermal fibroblasts from three patient donors. Original 
magnification x 200.
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Figure 4.10 O ver-expression o f  H A S2 in aged  derm al fibroblasts. Aged dermal fibroblasts were 
transfected with either HAS2-pCR3.1 (HAS2 transfected) or pCR3.1 (Mock transfected). HA secreted into the 
culture medium 48 h after transfection was quantified by ELISA (A). Following removal of the culture medium, 
total mRNA was extracted. a-SMA expression was subsequently assessed by RT-QPCR (B). Ribosomal RNA 
expression was used as an endogenous control and gene expression was assessed relative to mock transfected. The 
comparative CT method was used for relative quantification of gene expression and the results are represented as 
the mean± S.E. of dermal fibroblasts from nine separate experiments using cells isolated from three patient donors. 
Statistical analysis was performed by the Student’s t test. N/S, not significant. Immunohistochemical analysis was 
performed to examine a-SMA protein expression on mock transfected (C) and HAS2-overexpressing (D) aged 
dermal fibroblasts 48 h after transfection. The cells were then fixed and stained for a-SMA, mounted in 
Vectashield fluorescent mountant, and viewed under UV light. Original magnification x 100. In parallel 
experiments, the HA pericellular coat was visualised. 48 h after transfection formalised horse erythrocytes were 
added to mock-transfected (E) or HAS2-overexpressing (F) aged dermal fibroblasts as described under section 
2.11 to visualise the HA pericellular coat. Arrows indicate the cell body; arrowheads show the extent o f the 
pericellular matrix. Representative o f dermal fibroblasts from two patient donors. Original magnification was x 
200 .
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F igu re 4.11 E ffec t o f  TSG -6 siR N A  on a-S M A  expression . To further examine the role o f TSG-6, 
young dermal fibroblasts were transfected with TSG-6 siRNA or scrambled oligoneucleotide control 
(scramble) as describe under section 2.14 and incubated in medium supplemented with 10% FBS for 24 h. 
The medium was then replaced with serum-free medium for a further 24 h, prior to addition o f serum-free 
medium alone (clear bars) or serum-free medium containing lOng/ml TGF-0! {black bars) for 72 h, Total 
mRNA was extracted and TSG-6 (B) and a-SM A (C) expression was assessed by RT-QPCR. Ribosomal 
RNA expression was used as an endogenous control and gene expression was assessed relative to control- 
scramble samples. The comparative CT method was used for relative quantification o f gene expression and 
the results are represented as the mean± S.E. o f nine individual experiments using cells isolated from three 
different donors. Statistical analysis was performed by the Student’s t test and statistical significance was 
taken as p < 0.05. N/S (Not Significant)
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F igure 4.12 E ffect o f  H A S2 restoration on pericellu lar HA coat assem bly an d  a-SM A  expression fo llo w in g  TGF~Pj in aged  derm al fibroblasts.
Patient matched young (A & D) and aged (B,C,E & F) dermal fibroblasts were transfected either with pCR3.1 alone (mock) (A,B,D & E) or HAS2-pCR3.1 (HAS2) (C & 
F). 48 h after transfection, cells were incubated in serum-free medium containing lOng/ml TGF-P, for 72 h. Visualisation of pericellular HA coat (A-C) was performed by 
addition of formalised horse erythrocytes as describe under section 2.12. Arrows indicate the cell body; arrowheads show the extent o f the pericellular matrix. Images are 
representative of dermal fibroblasts from three patient donors. Original magnification was x 200. D-F, following stimulation cells were fixed and a-SM A  visualised by 
immunohistochemistry as describe under section 2.4. Slides were mounted in Vectashield fluorescent mountant, and viewed under UV light. Original magnification x 100.
HAS2 restoration in aged fibroblasts
(A)
a-SMA mRNA
P=0.0001
P=0.001
g 60
3? 40
3 30
& 20
Mock Mock HAS2
Transfected Transfected Transfected
Young Aged
(B) TSG-6 mRNA
P=0.0001
P=0.0001
& 12
Mock Mock HAS 2
Transfected Transfected Transfected
Young Aged
Figure 4.13 Effect of HAS2 over-expression on TGF-fij dependent responses in aged dermal 
fibroblasts. Aged dermal fibroblasts were transfected either with HAS2-pCR3.1 or pCR3.1 alone (mock 
transfected). Parallel mock transfections were performed on patient matched young dermal fibroblasts. 48 
h after transfection, cells were incubated in either serum-free medium alone (clear bars) or serum-free 
medium containing lOng/ml TGF-(3i (black bars) for 72 h. a-SM A (A) and TSG-6 (B) mRNA expression 
was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control and gene 
expression was assessed relative to control mock-transfected aged cells. The comparative CT method was 
used for relative quantification o f gene expression and the results are represented as the mean± S.E. o f nine 
individual experiments using cells isolated from three different donors. Statistical analysis was performed 
by the Student’s t test and statistical significance was taken as p < 0.05. N/S, not Significant.
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Figure 4.14 H A S2 responsiveness is retained in aged  cells fo llow in g  addition o f  IL-1 p. Confluent 
monolayers of patient matched young and aged dermal fibroblasts were growth arrested in serum-free medium 
for 48 hours. The medium was then replaced with either serum-free medium alone (clear bars), serum-free 
medium containing lOng/ml TGF-Pi (grey bars) or serum-free medium containing lng/ml IL-1 P (black bars) 
for a further 72 h. mRNA was extracted and cDNA prepared as describe under section 2.6. HAS2 (A), TSG-6
(C) and a-SMA (D) expression was assessed by RT-QPCR. Ribosomal RNA expression was used as an 
endogenous control and gene expression was assessed relative to control aged cells. The comparative CT method 
was used for relative quantification of gene expression and the results are represented as the mean± S.E. o f six 
individual experiments using cells isolated from two different donors. Statistical analysis was performed by 
Student’s t test and statistical significance was taken as p < 0.05. N/S, not Significant. HA secreted into the 
culture medium o f aged cells was quantified by ELISA (B). The data are the mean ± S.E. six individual 
experiments using cells isolated from two different donors. Statistical analysis was performed by Student’s t 
test: *, p <0.05, **, p<0.01 as compared to control cells.
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Accumulation o f HA dependent 
pericellular coats by IL-lfi
Young Aged
Figure 4.15 E ffect o f  I L - lp  on HA pericellu lar coat assembly. Subconfluent 
layers o f patient matched young (A & C) and aged (B & D) dermal fibroblasts were 
growth-arrested in serum-free medium for 48 h. The medium was then replaced with 
either serum-free medium alone (A & B) or lng/ml IL-lp (C & D) for 72 h. Formalised 
horse erythrocytes were then added as describe under section 2.11 to visualise the HA 
pericellular coat. Zones of exclusion were visualized using Zeiss Axiovert 135 inverted 
microscope, arrowheads indicate the cell body; Arrows show the extent o f the 
pericellular matrix. Representative of dermal fibroblasts from two patient donors. 
Original magnification was x 200.
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Relationship between HA pericellular coat and
phenotypic activation
(B)
(D)
Figure 4.16 E ffect o f  hyaluronidase on H A pericellu lar coat form ation  an d  a- 
SM A expression. Serum free medium alone (A) or bovine testicular hyaluronidase (200 
|j.g/ml) (C) were added to growth arrested cells for lh prior to the addition of lOng/ml 
TGF-p! and the incubations continued for 72 h. Formalised horse erythrocytes were then 
added to visualise the HA pericellular coat as describe under section 2.11. Zones of 
exclusion were visualized using Zeiss Axiovert 135 inverted microscope. Arrows indicate 
the cell body; arrowheads show the extent o f the pericellular matrix. Representative of 
dermal fibroblasts from two patient donors. Original magnification was x 200. 
Immunohistochemical analysis was also performed to assess dermal fibroblast phenotype 
following treatment with hyaluronidase. Serum free medium alone (B) or bovine testicular 
hyaluronidase (200 jig/ml) (D) were added to growth arrested cells for lh prior to the 
addition of lOng/ml TGF-P] and the incubations continued for 72 h. The cells were fixed 
and stained for a-SMA, as describe under section 2.4, mounted in Vectashield fluorescent 
mountant, and viewed under UV light. Original magnification x 100.
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Effect o f HA coat removal on fibroblast phenotype
(A)
HAS2 Expression
Control Hyaluronadase
Treatment Treated
(B)
a-SMA Expression
P<0.05
*  20
Control Hyaluronadase
Treatment Treated
(C)
TSG-6 Expression
□ Control 
■ TGF-pi
Control Hyaluronadase
Treatment Treated
F igure 4 .1 7  C onsequence o f  inh ibiting H A  coa t assem bly on TG F-fij dependent 
ph en o typ ic  activation  o f  fib rob lasts . Confluent monolayers o f young dermal fibroblasts were 
growth-arrested in serum-free medium for 48 h. Bovine testicular hyaluronidase (200 pg/ml) was 
then added in serum free medium at 37 °C for 1 h, prior to the addition (to the hylauronidase) of 
either serum free medium alone (clear bars) or lOng/ml TGF-Pj (black bars) for a further 72h. In 
control experiments hyaluronidase treatment was replaced by adding serum free medium alone. 
HAS2 (A), a-SM A (B) and TSG-6 (C) mRNA expression was assessed by RT-QPCR. Ribosomal 
RNA expression was used as an endogenous control and gene expression was assessed relative to 
the control treatment in non-stimulated cells. The comparative CT method was used for relative 
quantification o f gene expression and the results are represented as the mean± S.E. six individual 
experiments using cells isolated from two different donors. Statistical analysis was performed by the 
Student’s t test: Not Significant, *,p<0.05 as compared to control treatment. N/S, not Significant.
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Effect o f HA coat removal
(A )
Control
treatm ent
Hyal
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Figure 4.18 E ffect o f  HA disruption on Sm ad2 signalling. A, confluent monolayers of 
young dermal fibroblasts were growth arrested in serum-free medium for 48 hours. The 
medium was replaced with either serum-free medium alone or serum-free medium containing 
lOng/ml TGF-pi in the absence of (control treatment) or presence of either Hyal (200pg/ml) or 
4MU (0.05mM) for the indicated times. B, direct comparison of cell lysates at 30min and lhr 
for all treatments. Cell lysates were subsequently subjected to Western blot analysis as describe 
under section 2.14 utilising antibodies against the phosphorylation form of Smad2. Expression 
of GAP-DH was analysed as a control to ensure equal loading. The results shown are 
representative o f five independent experiments from the same patient donor.
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Scrambled Smad2 siRNA Smad3 siRNA
F igure 4.19 E ffect o f  Sm ad2/3 siRN A on HA pericellu lar coat form ation . Confluent monolayers of young dermal fibroblasts were transfected with either a 
scrambled oligonecleotide control (A&D), Smad2 siRNA (B&E) or Smad3 siRNA (C&F) as describe under section 2.14, for 48 hours . The medium was then replaced 
with either serum-free medium alone (A-C) or with serum-free medium containing lOng/ml TGF-Pi (D-F) for 72 h. Formalised horse erythrocytes were then added as 
describe under section 2.11 to visualise the HA pericellular coat. Arrowheads indicate the cell body; Arrows show the extent of the pericellular matrix. Representative of 
dermal fibroblasts from three patient donors. Original magnification x 200
4.3 Discussion
The aim of this chapter was to increase my understanding of the mechanisms which 
drive the phenotypic and functional changes associated with the differentiation process, 
particularly those associated with TGF-pl signalling and HA regulation. The work from 
this chapter then addresses how age-related alterations by these two components may 
explain the differentiation impairment observed with in-vitro aging.
Selective ALK5 inhibition in young fibroblasts antagonised induction of a-SMA 
mRNA and protein expression confirming the involvement of classical TGF-P 1 receptor 
activation during phenotypic conversion. Interestingly, whilst HAS2 induction was 
inhibited by the ALK5 inhibitor, TSG-6 induction was not, suggesting that they may be 
regulated by different signalling pathways. TGF-pi-mobolizes both Smad-dependent 
and non-Smad dependent signalling [140]. p38 MAPK has been implicated in the 
participation of non-Smad TGF-pl signalling [129] but showed no involvement in any 
of the responses to TGF-pi examined in this study.
Given the age-dependent failure of TGF-pi-directed phenotypic activation that was 
demonstrated in the previous chapter, I sought to examine the effects of aging on Smad 
signalling. In response to TGF-pl stimulation, Smad2 and Smad3 appear to be 
phosphorylated synchronously, indicating a functional Smad-dependent TGF-pi 
signalling pathway. Furthermore, the extent of phosphorylation did not change across 
the range of in-vitro ages tested, extending from young through to near-senescent cells. 
This indicates that the differential responses to TGF-pi of aged cells was not due to an 
inability of these cells to respond to TGF-pi stimulation. Consistent with this, young 
and aged cells generated almost identical levels of TGF-pl mRNA through 
autoinduction. Thus, the original hypothesis that aging may be associated with 
differences in TGF-P receptor expression and functionality appear to be invalid. Despite 
recent reports that over-expression of Smads were used for treatment o f chronic 
cutaneous wounds that become unresponsive to TGF-P 1 [308], restoration of TGF-P 1 
responsiveness and myofibroblastic conversion in my aged cells by this approach would
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presumably prove ineffective. In support of my data, Colwell et al demonstrated that 
Smad signalling does not change in fetal and adult mouse fibroblasts despite their 
differential healing responses [309].
Smad 2 and Smad3 are known to activate unique transcriptional targets, based in part on 
their differential DNA binding activity. Thus, Smad3 binds cognitive GTCT motifs 
directly, while an insertion in the N-terminal MH1 domain of Smad2 precludes its direct 
DNA binding, permitting only indirect regulation of gene transcription via binding of 
transcription factors [310]. The different roles of Smad2 and Smad3 are further 
highlighted in this chapter by their differential requirement for phenotypic activation as 
assessed by their knockdown. Consistent with previous observations [285], Smad2 but 
not Smad3 activation was demonstrated to be essential for TGF-P 1-mediated cellular 
activation. This data is also supported by others; Evans et al demonstrated that 
transfection with Smad2 but not Smad3 resulted in TGF-P 1-independent alteration in 
fibroblast cell phenotype, upregulation of a-SMA and reorganisation of the actin 
cytoskeleton [112]. Furthermore, Petridou et al demonstrated nuclear translocation of 
Smad2 is directly responsible for myofibroblast differentiation [294], a phenomenon 
which was reported for fetal and adult human fibroblasts in response to TGF-pl 
stimulation [311].
Collectively, these data demonstrate that Smad2 signalling (over Smad3) mediates 
TGF-P 1 driven phenotypic conversion. Defective TGF-pl signalling however cannot 
explain why in-vitro aged cells resist fibroblast-myofibroblast conversion.
It was also interesting to discover that in young cells, whilst TGF-P 1 mediated 
myofibroblastic differentiation was associated with an upregulation of Smad2 
expression, Smad3 expression actually declined following TGF-P 1 stimulation, despite 
demonstrating a similar degree of phosphorylation as Smad2. Tissue formation during 
regeneration after injury demands highly coordinated cell migration and proliferation, 
followed by cellular differentiation and matrix synthesis and assembly and all o f these 
are biological responses to TGF-P 1. In their study, Grotendorst et al [312] present 
evidence that fibroblast proliferation and differentiation represent two distinct biological
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response pathways that are mutually exclusive for cells that have been activated by 
TGF-P 1, that is, cells which are proliferating cannot differentiate and vice versa. It is, 
therefore, interesting to speculate that reduction in Smad3 in the myofibroblast serves to 
suppress other TGF-pl-mediated cellular processes such as proliferation. Consistent 
with this concept, Meran et al showed that whilst Smad3 does not appear to be involved 
in fibroblast myofibroblast transition, it plays a key role in the regulation of TGF-P 1- 
dependent fibroblast proliferation [160]. In conclusion, from this chapter and the work 
of others [160, 285] Smad2 and Smad3 are implicated in dermal fibroblast 
differentiation and proliferation respectively. This would also help explain reports that 
loss of Smad3 results in a more rapid closure of wounds [136, 137] due to preference 
over a contractile phenotype.
In the previous chapter, resistance to TGF-P 1 directed myofibroblastic differentiation 
by in-vitro aged fibroblasts was shown to be associated with attenuation in HA 
generation. It has been speculated that regulating HA pericellular coat assembly, rather 
than HA synthase isoform activity, is critical for phenotypic conversion [159], whilst 
others have described the acquisition of a HA coat to be a product rather than a cause of 
differentiation [266]. To investigate the importance of HA synthesis, the effect of 4MU 
on TGF-P 1 mediated myofibroblastic differentiation of young dermal fibroblasts was 
studied. Depletion of the UDP-glucuronic acid pool by 4MU has been shown to inhibit 
HA synthesis and pericellular HA coat formation in a number of cell types including 
fibroblasts [159, 161, 162, 306, 313]. In one study, 4MU was found to inhibit HA 
synthesis in cultured human skin fibroblasts but to have no effect on synthesis of any 
other GAGs [314]. The results from this chapter demonstrate that in the presence of 
4MU, induction of a-SMA mRNA was significantly reduced. This was associated with 
suppression of HAS2 and TSG-6 induction. The resulting response to TGF-pl 
stimulation was essentially comparable to the response seen in aged fibroblasts. 
Collectively this suggests that increased synthesis of HA associated with the young 
phenotype facilitates fibroblast-myofibroblast transition conferring a role for HA in 
wound closure.
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In the previous chapter in-vitro aging and resistance to phenotypic conversion were 
accompanied by a failure of induction of HAS2 after addition of TGF-P 1. Resistance of 
oral mucosal fibroblasts to TGF-P 1-mediated myofibroblastic change has also been 
associated with failure of induction of HAS2 [159]. In light o f these findings, the 
hypothesis that HAS2 isoform activity is critical in driving myofibroblast differentiation 
was subsequently tested in young cells. Silencing HAS2 gene expression using siRNA 
led to a significant inhibition of TGF-p i dependent induction of a-SMA. These 
observations led me to determine if isoform specific over-expression o f HAS2 was 
sufficient to restore TGF-Pi responsiveness and phenotypic alteration by in-vitro aged 
fibroblasts. Although over-expression of HAS2 was associated with increased HA 
generation, there was no alteration in a-SMA expression, suggesting that restoration of 
the age dependent decrease in HAS2 expression was not the sole factor leading to the 
loss of TGF-pi dependent phenotypic sensitivity. This is consistent with the 
observation that the aged cells retained the ability to induce HAS2 in response to IL-lp 
suggesting that aging specifically affects TGF-Pi responses rather than causing a global 
defect in HAS2 regulation.
Previous studies have demonstrated that the ability of the fibroblast to transform under 
the influence of TGF-pl to myofibroblasts may be related to the capacity o f the cell to 
incorporate HA into a pericellular coat [159] but this has only been speculation. In 
support of this, in the previous chapter phenotypic conversion and coat formation were 
intrinsically linked, in that young cells capable of differentiation exhibited HA coats 
whereas aged cells unable to differentiate failed to exhibit coats. Consistent with this, 
attenuation of a-SMA induction following HAS2 silencing was associated with 
impaired HA pericellular coat assembly.
Webber et al showed that inhibition of autocrine TGF-P 1 signalling and loss of the 
myofibroblast phenotype was associated with suppression of the expression of the 
hyaladherin TSG-6 [162]. In the previous chapter I demonstrated an age-dependent 
decrease in TSG-6 expression both in unstimulated and in response to TGF-P 1. In this 
chapter I confirm a role for TSG-6 in facilitating fibroblast-myofibroblast differentiation 
by demonstrating that silencing of TSG-6 gene expression using siRNA led to an
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inhibition of TGF-P 1-dependent induction of a-SMA. These results suggests that 
coordinated induction o f HAS2 and TSG-6 facilitation of HA pericellular coat assembly 
are necessary to allow TGF-P 1-dependent phenotypic activation of fibroblasts, and both 
components of this response are impaired with in-vitro aging.
The importance of the pericellular HA coat in regulating the fibroblast -  myofibroblast 
activation process is further highlighted by the data demonstrating that inhibition of coat 
formation by Hyal, also prevented TGF-P i mediated phenotypic conversion. This result 
confirmed that the formation of a pericellular HA coat was necessary to drive 
myofibroblastic differentiation in dermal fibroblasts. This was consistent with recent 
reports that extracellular HA matrices are an essential mediator in the persistence of the 
myofibroblast phenotype in lung fibroblasts [162].
This chapter has confirmed that a HA coat is a pre-requisite for fibroblast-myofibroblast 
differentiation but the functional significance o f the pericellular matrix in facilitating 
this process remains unclear. Recent data from Kultti et al [313] has demonstrated that 
in several cell types, the HA coat can induce and maintain prominent microvilli in cell 
plasma membranes that rest on filamentous actin, these microvilli were degraded when 
the pericellular coat was destroyed and were dependent on an intact cytoskeleton. It is 
interesting to speculate that the pericellular coat may influence cellular differentiation 
processes through direct interaction with the actin cytoskeleton.
Formation of a pericellular coat following stimulation with IL-lp did not facilitate 
phenotypic activation. Similarly, stimulation o f HAS2 over-expressing cells although 
restoring the cell’s ability to form a pericellular coat, was not associated with 
phenotypic activation. Restoration of high basal level of HA synthesis in the aged 
dermal fibroblast, however, as a result o f HAS2 over-expression, did result in
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restoration of TGF-p i dependent induction of TSG-6, further emphasising its role in 
mediating HA coat formation. These data therefore suggest that although formation of 
the pericellular coat is necessary for TGF-pi dependent phenotypic activation, the 
formation of the coat in itself is not the sole driving force and is not sufficient to drive
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the myofibroblastic phenotype. Dissociation of coat formation and phenotypic 
activation points to the involvement of other mechanisms.
This chapter has demonstrated that TGF-P 1 signalling through Smad2-dependent 
pathway is required for myofibroblastic differentiation. Webber et al demonstrated that 
assembly of the HA coat in lung myofibroblasts facilitates Smad-dependent responses 
that maintain the myofibroblast phenotype in lung fibroblasts [162]. In this chapter I 
addressed the hypothesis that the HA coat may be involved in regulation o f Smad 
signalling. Having shown the HA coat to be a prerequisite for TGF-P 1-mediated 
phenotypic conversion it was surprising to discover that disruption of HA synthesis and 
pericellular coat formation using either 4MU or Hyal did not influence TGF-P 1- 
mediated phosphorylation of Smad2. Likewise, transfection of young cells with Smad2 
or Smad3 siRNA’s did not impair assembly of HA pericellular coats. Collectively these 
results demonstrate that TGF-pl mediated dependent HA pericellular coat synthesis 
does not utilise Smad-dependent signalling pathways. Furthermore, induction of TSG-6 
and HAS2 by TGF-P 1 was not suppressed by Smad2 or Smad3 silencing further 
supporting their involvement in pericellular coat assembly in a manner independent 
from Smad signalling. Taken together, the data suggest that whilst cytoskeletal 
remodelling and HA pericellular matrix assembly are both induced by TGF-P 1 they are 
mediated by independent pathways.
Cross-talk between Smad and non-Smad signalling pathways may enhance TGF-p 1- 
dependent responses in other cell systems [315, 316]. For example, cooperative action 
of MAP kinase and Smad pathways have been implicated in mediating effects o f TGF- 
pi on gene targets [124]. Co-localisation of CD44 and TGF-P receptors have been 
shown to facilitate modulation of both Smad and non-Smad-dependent TGF-P 1- 
mediated events by HA [210]. The data from this chapter suggests that HA may 
facilitate TGF-P 1 dependent differentiation through recruitment of alternative signalling 
pathways to the classical Smad pathway. Another plausible explanation is that HA 
influences targets at either the level of the TGF-P receptor or by a separate mechanism 
downstream of Smad2 signalling.
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The salient findings of this chapter are summarised in figure 4.19. In summary the 
data suggests that resistance to myofibroblastic conversion by aged cells cannot be 
explained by a global deficit in TGF-pl signalling. Rather, the data presented 
demonstrates that coordinated induction of HAS2 and TSG-6 facilitation of HA 
pericellular coat assembly is necessary for TGF-P 1-dependent activation of fibroblasts, 
and both components of this response are impaired with in-vitro aging. This chapter 
presents further evidence that highlights the intimate involvement of HA in the 
modulation of fibroblast-myofibroblast differentiation. In conclusion, whilst the 
synthesis and organisation of HA into a pericellular coat is integral for differentiation to 
occur, it is not sufficient to correct for the age-dependent defect in phenotypic 
conversion. It would appear therefore and perhaps not surprisingly, that in addition to 
pericellular HA coat assembly other mechanisms must become disrupted during in-vitro 
aging leading to impaired cellular differentiation. Ascertaining these other mechanisms 
forms the drive of the next chapter.
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F igure 4.19 Com parison o f  you n g  an d  in-vitro aged  fib ro b la st phenotpye. A comparison of 
cell morphology, HA generation and phenotype of patient matched young (A&C) and aged (B&D&E) 
based on the analysis compacted from this results chapter. In response to TGF-P 1 young fibroblasts 
(A) readily differentiate into myofibroblastic cells (C) which incorporate prominent stress fibres and 
a-SMA. This is mediated via activation o f Alk-5 and Smad2. Accordingly, phenotypic differentiation 
is attenuated by the Alk-5 inihibitor SB431542, and Smad2 siRNA. In addition, myofibroblastic 
differentiation is dependent on HAS2 induction of HA and its assembly into a pericellular coat. 
Disruption of the coat and HA synthesis with either TSG-6 siRNA, HAS2siRNA, 4MU of Hyal 
inhibits phenotypic activation. In aged fibroblasts TGF-P 1 stimulation alone failed to mediate 
myofibroblastic differentiation associated with inability to form a HA coat and upregulate a-SMA
(D). Restoration of HA levels by HAS2 over-expression in aged cells restored TGF-31-mediated coat 
formation and TSG-6 induction but did not lead to acquisition of a myofibroblast phenotype (E). IL-1 P 
failed to promote a-SMA expressing myofibroblasts but did mediate coat assembly through induction 
of HAS2-dependent HA synthesis and TSG-6. Furthermore the IL-13 response was independent of in- 
vitro aging unlike the age-dependent attenuation in TGFpi responsiveness observed. Finally Smad 
signalling did not change between the young and aged phenotype. Dysregulation of Smad signalling 
did not impair HA coat formation and vice versa indicating these events are independent from each 
other {red).
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Chapter 5 
The Role of Hyaluronan-Dependent 
CD44/EGF Receptor Signalling
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5.7 Introduction
Failure of TGF-Pi-induced differentiation to the myofibroblast phenotype as a 
consequence of aging is associated with the inability to induce HAS2, a decrease in HA 
synthesis and a lack of pericellular coat formation. HA synthesis and coat assembly 
could be restored by forced overexpression of HAS2 followed by TGF-P 1 stimulation. 
This did not, however, restore the myofibroblast phenotype. Furthermore, despite 
demonstrating that in-vitro aging is associated with attenuation of numerous TGF-P 1 
dependent responses, the previous chapter revealed that intrinsic differences in young 
and aged cells could not be accounted for by variation in their TGF-P signalling 
machinery. Collectively, this suggests that other factors (in addition to TGF-pl and 
HAS2) must be operative in young cells but have been lost during the aging process.
TGF-P signalling involves a diverse group of cellular elements in addition to the Smad 
family of proteins. TGF-P-stimulated activation of ERK, p38MAPK and c-Jun NH2- 
terminal kinase (JNK) has been demonstrated previously in different cell types [317] 
and furthermore there is evidence for cooperativity of Smad and non-Smad pathways 
[316]. In the previous chapter the organisation of HA into a pericellular coat by TGF-P 1 
was shown to be Smad-independent. Since this process is integral for myofibroblastic 
conversion it was deduced that Smad-independent TGF-pl signalling plays an 
important role in myofibroblastic differentiation. A further layer of complexity can be 
added to the understanding of TGF-P signalling by the realisation that it may influence 
or be influenced by physical and functional interactions with other receptors (cytokine 
and matrix). For example, in metastatic breast tumour cells [203] and renal proximal 
tubular epithelial cells [210], CD44 has been shown to be physically linked to the TGF- 
P receptor I allowing for modulation of both Smad and non-Smad-TGF-pi mediated 
events by HA.
Key stimuli for human dermal fibroblasts are ligands for the epidermal growth factor 
receptor (EGF-R) [1]. Epidermal growth factor (EGF) is a member o f the EGF super­
family of cytokines [318, 319]. They function as pleiotropic effector molecules during
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foetal development and pathological processes, such as wound healing and cancer 
progression [318, 319]. Synergistic effects between TGF-pl and EGF have been 
demonstrated to regulate cell phenotype and function in several systems [320-326]. He 
et al demonstrated that EGF contributes to the differentiation and migration of 
myofibroblasts induced by TGF-pl through transactivation of EGF-R [327]. Earlier 
studies have shown that TGF-P 1 induces the expression of high-affinity EGF-R in 
stromal fibroblasts [328] and in the A431 epidermal cell line, TGF-pl caused increased 
tyrosine phosphorylation of the EGF-R that was not dependent on protein synthesis 
[329]. Other studies have shown that TGF-P amplifies the content of EGF-R in 
granulose cells from rat ovaries and increases EGF-R transcription in kidney fibroblasts 
[330, 331]. The involvement of EGF-R transactivation in TGF-P-induced fibronectin 
mRNA expression in mesangial cells was recently reported [317]. Interestingly, in their 
study the authors showed that TGF-p-mediated Smad2 phosphorylation was 
independent of TGF-P-mediated EGF-R signalling. Equally, in the previous chapter I 
demonstrated that the TGF-P 1/Smad2 signalling cascade and regulation of HA 
pericellular matrix assembly represented crucial yet independent events for TGF-p 1- 
mediated myofibroblastic differentiation. This could be conceivably explained with the 
addition o f an EGF-R component.
Furthermore, studies have revealed that fibroblasts aged in-vitro demonstrate a 
reduction in their ability to respond to the mitogenic effects of EGF as compared to cells 
at an earlier population doubling level [35, 256]. It was determined that the decreased 
responsiveness of aged cells to EGF was due to preferential loss in EGF-R levels. In 
fact EGF-R expression decreases by about half in near senescent fibroblasts [35]. 
Decreased numbers of high and low affinity EGF-R during serial cultivation in-vitro 
have been reported in human endothelial cells [332], and the diminished responsiveness 
to EGF to chondrocytes derived from aged animals also seems to be due to a reduction 
in the number of EGF receptors [333]. I therefore postulate that a TGF-P 1-dependent 
and an EGF-R-dependent pathway are both necessary for full myofibroblastic 
differentiation.
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HA is known to influence the differentiation o f other cells in a manner dependent on 
EGF-R and ErbB receptor signalling [295, 326]. Rapid HA accumulation after 
epidermal wounding occurs through a mechanism requiring cleavage of HB-EGF and 
activation of EGF-R signalling [222]. Pienimaki et al showed that EGF increased HA 
synthesis and induced a coat of HA in epidermal keratinocytes through activation of 
HAS2 mRNA but not HAS1 or HAS3 [318]. In view of my data demonstrating the 
importance of HAS2 mediated coat formation in phenotypic activation and maintenance 
[162], I also postulate that HA is a key factor in regulating the coordinated action of the 
TGF-P 1 and EGF signalling pathways, required for acquisition of myofibroblast 
phenotype, such that defects in both HA synthesis and EGF signalling both contribute 
to age dependent impaired wound healing.
I have demonstrated in the previous chapters an age-related defect in myofibroblast 
differentiation, associated with impaired synthesis o f HAS2 mediated pericellular coat 
but have failed to prescribe its role in a mechanistic sense. It has previously been 
demonstrated that maintenance of the chondrocyte phenotype, as well as initial cartilage 
differentiation, may depend on the close association of the cell with its matrix as well as 
on cell shape as modulated by the actin cytoskeleton [334]. CD44 is the main receptor 
associated with the formation of the HA pericellular matrix [219], internalisation of HA 
[335] and mediation of HA-induced signals. Several studies indicate that the 
intracellular domain of CD44 selectively interacts with the intracellular actin 
cytoskeleton [211] via cytoskeletal proteins such as ankyrin [203], filamin [206] and 
cortactin [336]. It is interesting to speculate that interaction between the HA pericellular 
matrix and CD44 provides a direct link to the cytoskeleton allowing changes in HA 
synthesis, organisation and assembly, to modulate cellular phenotype and orchestrate 
cell function. Furthermore, there is evidence suggesting a relationship between HA 
production and CD44 expression [337], which led me to hypothesise that age related 
attenuation in HA synthesis is associated with reduced CD44 expression. Therefore age- 
related disruption in HA-CD44 and its interaction with the cytoskeleton may provide an 
explanation for resistance to phenotypic conversion observed in aged cells.
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Although it is well established that fibroblasts bind HA to their surface via the 
expression o f CD44, the cellular responses following ligand-receptor interaction still 
remain to be clearly established. The capacity of CD44 to form stable complexes with 
the EGF-R has been previously reported in numerous studies [206, 326, 338]. This 
chapter further aims to investigate whether CD44/EGF-R interaction plays a role in 
mediating dermal fibroblast-myofibroblast differentiation.
The aim of this chapter is :
i To characterise EGF-R signalling in dermal fibroblasts, specifically:
-the significance of EGF-R signalling in phenotypic activation 
-the significance of age-related alterations in EGF-R signalling
ii To characterise the relationship between EGF-R signalling and HA regulation
iii To examine whether modulating EGF-R levels can influence the aged
phenotype
iv To characterise the role of CD44, specifically
-the significance of CD44 signalling in phenotypic activation 
-the significance of age-related alterations in CD44 signalling
v To investigate the relationship between CD44, EGF-R and HA
The results from this chapter will help address the hypothesis that synergy between 
TGF-j31-dependent pathways and a competent EGF signalling pathway are required for 
myofibroblastic differentiation and that central to this process is the induction of HAS2 
and synthesis of HA. Furthermore I differentiate what contribution that these pathways 
(Smad and non-Smad) make towards age related impairment in phenotypic activation.
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5.2 Results
5.2.1 The role o f the EGF-R in TGF-fil-mediated myofibroblastic differentiation
The relative contribution of TGF-P 1 receptor and EGF receptor signalling in TGF-pl 
dependent fibroblast to myofibroblast phenotypic activation was examined by addition 
of TGF-pl to growth arrested young fibroblasts for 72 hours in the presence of either 
AG1478, an inhibitor of EGF-R signalling or, the TGF-p-R/Alk5 inhibitor SB431542. 
Addition of either inhibitor attenuated TGF-P 1 induced expression of a-SMA (Figure 
5.1), suggesting that in the absence of exogenous EGF, that TGF-pi utilises both its 
own and the EGF-R to facilitate phenotypic activation. These data also highlighted that 
EGF is not sufficient to induce myofibroblastic differentiation. As previously 
demonstrated, TGF-P 1 induces significant upregulation of a-SMA mRNA, however 
combined addition of TGF-pl and EGF demonstrated marginally increased expression 
than with TGF-P 1 alone. The results using chemical inhibition showed that synergism 
between TGF-pi and EGF involves the activation of EGF-R and ALK-5 signalling.
5.2.2 Effect o f aging on EGF-R expression.
Given the age dependent failure o f TGF-P 1 directed phenotypic activation that was 
previously demonstrated in chapter 3 and 4 , 1 sought to examine the effects of aging on 
EGF-R expression. Cell protein was extracted from growth arrested patient matched 
fibroblasts over a range of different in-vitro ages ranging from young (PDL 15) through 
to near-senescence (PDL 39). Western blot analysis o f EGF-R demonstrated that in- 
vitro aging was associated with an age dependent decrease in EGF-R protein 
expression, with barely detectable levels in near-senescent cells (PDL 33-39) (Figure 
5.2A). This was confirmed by densitometry analysis (Figure 5.2B). These results 
demonstrated that with in-vitro aging fibroblasts displayed attenuated levels of 
endogenous EGF-R. Consistent with these results, Q-PCR analysis revealed an age- 
dependent attenuation in EGF-R transcription (Figure 5.2C). Young fibroblasts had
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significantly higher (~3 fold) EGF-R mRNA expression compared to patient matched 
aged fibroblasts.
Collectively these results suggest that age dependent loss o f TGF-pi dependent 
phenotypic activation is associated with loss of EGF-R.
5.2.3 The effect o f EGF-R restoration on TGF-pl-mediated myofibroblastic 
differentiation in aged fibroblasts
I hypothesised that loss of EGF-R may be responsible for loss o f TGF-pi 
responsiveness in aged fibroblast. Previous studies have demonstrated restoration of age 
dependent EGF responsiveness by forced over-expression of EGF-R cDNA [35]. To 
examine the role of age dependent decrease in EGF-R expression in TGF-pl 
responsiveness, aged fibroblasts were transfected with cDNA encoding either EGF-R or 
GFP (as a control). Confirmation of EGF-R over-expression was demonstrated by Q- 
PCR (Figure 5.3A). TGF-pl responsiveness of EGF-R over-expressing cells was 
examined by stimulation with TGF-pi for 72hours after transfection. There was no 
difference in a-SMA expression between EGF-R over-expressing cells and GFP 
transfected cells following additions of TGF-pl (Figure 5.3B), suggesting that 
restoration of EGF-R expression in aged cells did not restore TGF-pi responsiveness. 
The functional nature of the transfected EGF-R was explored by examining the EGF 
dependent proliferative response of EGF-R over-expressing aged fibroblasts. These 
experiments demonstrated significantly increased proliferation, as assessed by [3H]- 
thymidine incorporation, following addition o f exogenous EGF to EGF-R over­
expressing cells compared to control GFP transfected cells, thus confirming the 
functionality of the transfected receptor (Figure 5.3C).
5.2.4 The role o f EGF in TGF-ftl-mediated myofibroblastic differentiation
Synergy between TGF-pl and EGF in regulating cell phenotype is well recognised, in 
other cell systems [339, 340]. The effect of in-vitro aging on the expression of EGF was 
examined under basal conditions and following stimulation with TGF-pi (Figure 5.4A).
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Fibroblasts were grown to confluence and serum deprived for 48 hours prior to addition 
o f either recombinant TGF-pl or serum free medium alone (control treatment) for a 
further 72 hours. Q-PCR analysis revealed that under basal conditions aged cells 
exhibited a small but significant attenuation in EGF mRNA. Moreover, following 
addition of TGF-pi, whilst young cells responded with a significant induction (~7 fold) 
in EGF mRNA, in contrast aged cells demonstrated no change in EGF mRNA 
expression. These data demonstrate that in addition to the loss of expression of EGF-R, 
in-vitro aging is associated with a loss of TGF-pl dependent induction o f EGF. This 
raises the possibility, that loss of autocrine EGF activity may also be involved in age 
dependent loss of TGF-pl phenotypic activation. To examine this, aged fibroblasts 
over-expressing EGF-R were co-stimulated with exogenous EGF and TGF-pl. In 
contrast to stimulation with TGF-pl in isolation, co-stimulation led to augmented 
phenotypic activation as assessed by expression of a-SMA (Figure 5.4B). It was 
implicated in the previous chapter that both HAS2 dependent HA synthesis and its 
assembly into a pericellular matrix by TSG-6 were required for TGF-pi dependent 
phenotypic activation of fibroblasts. In addition to a-SMA, co-stimulation led to a 
restoration of induction of HAS2 (Figure 5.4C) and the hyaladherin TSG-6 (Figure 
5.4D), which did not occur following addition of TGF-pi in isolation.
TGF-Pi activation o f EGF-R has been reported in several studies to be through direct 
synthesis of EGF [341]. To investigate the participation of EGF in TGF-pl-dependent 
phenotypic activation young cells were treated with TGF-pi in the presence of either an 
anti-EGF antibody or the EGF-R inhibitor AG1478 and the expression of a-SMA 
assayed by Q-PCR (Figure 5.5). Addition of neutralising anti-EGF antibody inhibited 
TGF-pi-mediated a-SMA accumulation by -50%  whilst complete inhibition was 
achieved using the chemical inhibitor AG1478, as expected from Figure 5.1.
5.2,5 The relationship between the EGF-R andHAS2
The induction of HAS2 in aged cells following restoration of EGF signalling together 
with the reported up-regulation of HAS2 and HA synthesis mediated by EGF-R 
signalling in epidermal keratinocytes [342] and human ovarian tumour cells [343] led
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me to investigate the role of EGF signalling in regulation of HAS2 in my cell system. 
TGF-pi mediated induction of HAS2 in young fibroblasts was significantly attenuated 
by treatment with the EGF-R inhibitor AG1478 (Figure 5.6A). These data suggested 
that TGF-pl induced HAS2 dependent HA synthesis is mediated through EGF-R 
signalling pathways and further validated EGF as an intermediate signalling molecule.
Previous work has demonstrated that HA through CD44 may directly activate EGF-R in 
the context of oncogenic signalling [338, 344]. To examine the potential of endogenous 
HA to activate EGF-R in the absence of exogenous EGF, aged fibroblasts over­
expressing both EGF-R and HAS2 were stimulated with TGF-pi and cell phenotype 
monitored by quantitation of a-SMA. Under these experimental conditions, TGF-pl 
dependent phenotypic activation was restored in the absence of exogenous EGF (Figure 
5.7C). This suggests that in aged cells, forced over-expression of HAS2-dependent HA 
synthesis, removes the need for exogenous EGF in phenotypic activation of EGF-R 
overexpressing cells. Collectively these data indicate HAS2 participates in phenotypic 
activation and is downstream of TGF-pl-mediated EGF synthesis
5.2.6 TGF-ftl activates ERK through EGF-R signalling
EGF-R is required for TGF-pi-initiated fibroblast-myofibroblast conversion. Activation 
of the EGF-R following addition of EGF and TGF-pi, in young cells was investigated 
by western analysis of EGF-R phosphorylation. Phosphorylation of EGF-R was 
observed 30 min after exposure to EGF (Figure 5.8A), and such activation was inhibited 
by pre-treatment with the EGF-R inhibitor AG1478 but not the ALK-5 inhibitor. 
(Figure 5.8B). TGF-pi did not alter p-EGF-R levels at 30min in isolation or in 
combination with EGF (Figure 5.8B). TGF-pl-induced EGF-R activation compared to 
EGF stimulation was both modest and relatively delayed; a significant increase in the 
phosphorylation of the EGF-R was not evident until 3 hours after addition of TGF-pi 
(Figure 5.8C). These data confirm that TGF-pl stimulation leads to phosphorylation of 
the EGF-R.
137
Several effector pathways for the EGF-R have been described [345] among them, the 
MAP Kinase cascades are important as well as being been reported as one of the 
downstream cascades of TGF-pi [345]. In particular, a role for EGF-R-mediated 
activation of ERK and p38MAPK has been reported [317]. I examined whether these 
MAPKs are involved in myofibroblastic differentiation by TGF-pi. ERK inactivation by 
the inhibitor PD98059 but not the p38MAPK inhibitor SB203580 significantly inhibited 
TGF-pi mediated a-SMA induction in young dermal fibroblast suggesting involvement 
of ERK but not p38MAPK signalling during phenotypic activation (Figure 5.9A).
Western analysis was used to investigate the kinetic profile of ERK activation upon 
stimulation by TGF-pl using phospho-specific ERK1/2 antibody. Young cells exhibited 
significant basal ERK 1/2 phosphorylation and although both ERK1 and ERK2 were 
phosphorylated preferential phosphorylation of ERK2 was observed. My studies have 
shown that ERK1/2 is activated rapidly (10 mins) following administration of TGF-pi 
in young cells and rapidly returned to below basal levels after 30 mins (Figure 5.9B). 
Significantly TGF-pl mediated ERK activation was markedly attenuated in aged cells 
(Figure 5.9C), consistent with the age dependent reduction in EGF-R expression, 
however, basal ERK phosphorylation remained unchanged.
It was hypothesised that EGF-R signalling converge at the ERK signalling pathway to 
mediate cellular responses. In support of this, activated ERK levels coincided with 
EGF-R phosphorylation (Figure 5.10A). Furthermore, TGF-pl mediated activation of 
ERK was abolished by the EGF-R inhibitor, AG 1487, suggesting that kinase activity of 
EGF-R is thus required for further downstream signalling o f p42/p44 MAP kinases 
(ERK1/2). Age-related resistance to ERK1/2 activation was thus consistent with the 
age-related deficit in EGF-R levels.
Furthermore, a combinational effect of EGF and TGF-pl on ERK activation was 
demonstrated to be greater than administration of either in isolation (Figure 5.10A). 
Inhibition of EGF-R pathway using AG 1478 abolished the synergistic action of EGF on 
TGF-pi induced ERK signalling whilst the ALK-5 inhibitor had no effect. This data
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shows that EGF contributes to ERK activation induced by TGF-pi through EGF-R 
activation.
There was a major discrepancy with this data. It was unclear how TGF-pl induced 
ERK 1/2 could be activated within 10 minutes and still be downstream of EGF-R 
phosphorylation, which was not evident until 3 hours after TGF-pi stimulation. In an 
effort to explain this, a longer time course for TGF-pl mediated ERK1/2 
phosphorylation was carried out. Interestingly, the results demonstrated a biphasic 
activation profile. ERK activation was induced at 10 minutes (consistent with the 
previous data) and in accordance with the proposed model at 3 hours (Figure 5.1 OB). 
An explanation for rapid ERK1/2 by TGF-pi is discussed later.
5.2.7 The differential requirement of EGF and HA signalling in TGF-pl mediated 
activation o f ERK and Smad2
The relationship between Smad2 and ERK signalling was investigated. As expected 
from chapter 4, Smad2 phosphorylation was rapidly induced following TGF-pl 
stimulation at 10 min. Pre-treatment with the EGF-R inhibitor, AG1487 and anti-EGF 
antibody significantly suppressed ERK phosphorylation providing further evidence that 
EGF contributes to ERK activation induced by TGF-pi through EGF-R activation. In 
contrast, Smad2 phosphorylation was unaffected (Figure 5.11), suggesting a 
dissociation of Smad and EGF signalling events by TGF-pi. Furthermore this 
corroborated with the earlier observation that whilst the former was not altered with in- 
vitro aging, the latter was.
Activation of EGF-R by HA associated with cytoskeletal reorganisation in head and 
neck squamous cell carcinoma cells, has been associated with downstream activation of 
MAP kinase (in particular ERK1 and ERK2) [206] and data presented above suggests 
that HA is intrinsically linked to EGF-R signalling. The role of HA in TGF-pi 
mediated ERK activation was examined by either inhibition of HA synthesis by the 
depletion of the UDP-glucuronic acid pool using 4MU, or digestion of HA using Hyal. 
Both inhibition of HA synthesis and degradation of HA inhibited TGF-pl mediated
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activation of ERK1 and ERK2 (Figure 5.11). The requirement of HA for TGF-pl 
directed Smad2 phosphorylation was also investigated in the same way. As expected 
from chapter 4 neither inhibition of HA synthesis nor degradation of HA had an effect 
on Smad2 activation providing further evidence that the TGF-P-specific Smad pathway 
is HA independent (Figure 5.9C).
Collectively these data demonstrate that TGF-pi-mediated Smad signalling is 
independent from TGF-P-mediated EGF-EGF-R-ERK signalling. Whilst both pathways 
were required to mediate TGF-pl-directed cellular differentiation, significantly, age- 
related resistance to phenotypic activation was associated with age-related impaired 
ERK 1/2 signalling, a consequence of defective EGF-R and HA signalling.
5.2.8 The expression o f CD44 in young and agedfibroblasts and its role in 
myofibroblastic differentiation through ERK signalling
Acharya et al reported decreased levels of a-SMA in CD44KO fibroblasts compared 
with CD44WT fibroblasts [201] and the use o f CD44 siRNA’s have demonstrated 
inhibition of HA-mediated keratinocyte differentiation [284].
Having demonstrated the importance of HA in phenotypic activation by TGF-pl 
dependent phosphorylation of ERK1/2, I sought to examine the role of the principal 
receptor for HA, CD44 in phenotypic activation, and its relationship to age associated 
resistance to the effects o f TGF-pl.
Young fibroblasts were transfected with a specific siRNA for CD44 to determine its 
functional requirement for myofibroblast conversion. Efficacy of this approach was 
confirmed by QPCR assessment of CD44 mRNA suppression (Figure 5.12A). 
Suppression of CD44 expression was associated with abrogation of TGF-pi dependent 
induction of a-SMA as assessed by QPCR (Figure 5.12B) and immunohistochemistry 
(Figure 5.13F).
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In contrast, suppression of CD44 expression did not affect TGF-pl mediated up- 
regulation of HAS2 (Figure 5.12C). In addition suppression of CD44 had a disruptive 
effect on the accumulation of pericellular HA. Whilst accumulation of HA outside the 
cell could be visualised it was assembled in an irregular coat, compared to untransfected 
and scrambled cells which demonstrate an organised HA coat linearly localised around 
the cell in a linear fashion (5.12G-I)
It was recently reported by Toole et al that ‘clusterization’ of CD44 is required for 
effective functionality [214]. Expression and localisation of CD44 and its relationship to 
phenotypic activation as assessed by expression of a-SMA, was examined by 
immunohistochemistry (Figure 5.14). In young cells, as expected, TGF-pl increased 
expression of a-SMA (Figure 5.14F), when compared to unstimulated conditions. 
(Figure 5.13E). This was also associated with a re-localisation of CD44; under basal 
conditions CD44 was seen predominantly in a linear distribution around the cell 
periphery (Figure 5.141). In contrast following TGF-pl dependent phenotypic 
activation, CD44 appeared in a diffuse pattern throughout the cell (Figure 5.14J). Aged 
cells are resistant to TGF-pl dependent phenotypic activation (Figure 5.14G-H), and 
this was associated with failure of CD44 re-localisation which remains predominantly in 
a linear distribution at the cell periphery (Figure 5.14K-L). Although these data 
demonstrate a defect in CD44 re-localisation associated with age, there was no 
alteration in CD44 mRNA expression when comparing young and in-vitro aged cells 
(Figure 5.15). Notably, in both cell types re-localisation of CD44 was associated with a 
TGF-pi dependent decrease in CD44 mRNA.
5,2.9 The interaction o f CD44 and the EGF-R in phenotypic activation o f young and 
agedfibroblasts.
It was recently reported that CD44 can co-immunoprecipitate with EGF-R in head and 
neck squamous carcinoma cells [338] and glioblastoma cells [326] and that this 
functional coupling may mediate cellular responses. Given the dependence of CD44 
and EGF-R in TGF-pl induced phenotypic activation I sought to examine their potential 
for interaction. Anti-CD44 immunoprecipitation followed by anti EGF-R immunoblot 
analysis in young cells indicated that a low level o f EGF-R is present in the anti-CD44
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immunoprecipitated materials (Figure 5.16). TGF-J31 dependent phenotypic activation 
in young cells was associated with recruitment of a significant amount of EGF-R to the 
CD44-EGF-R complex. Inhibition of HA synthesis using 4MU, or digestion of HA 
using Hyal resulted in a reduction of EGF-R accumulation in the CD44 
immunoprecipitant. These results demonstrate that in young cells TGF-pi facilitates a 
physical association o f CD44 and EGF-R through a HA-dependent manner.
To determine whether this physical linkage changes with age the distribution of CD44 
and EGF-R was subsequently assessed in patient matched young and aged fibroblasts 
by immunohistochemistry (Figure 5.17-5.21) and confocal microscopy (Figure 5.22- 
5.26). The results clearly demonstrate co-localisation of CD44 and EGF-R following 
TGF-pl dependent phenotypic activation of young cells (Figure 5.18, 5.23 & 5.24) 
when compared to non-stimulated cells (Figure 5.17 & 5.22). In contrast aged co­
localisation of CD44 and EGF-R was not apparent following TGF-pl stimulation 
(Figure 5.20 & 5.25) and consistent with earlier data, both unstimulated aged (Figure 
5.19 & 5.25) and stimulated aged (Figure 5.20 & 5.25) cell populations, stained poorly 
for EGF-R as assessed by confocal analysis. An overview of immunohistochemistry 
(5.21) and confocal (5.26) results are presented. These results suggested that age- 
dependent defect in TGF-pi-mediated phenotypic activation is associated with an age- 
dependent loss of EGF-R and subsequent CD44-EGF-R co-localisation.
The importance of HAS2 dependent HA in loss of phenotypic activation and CD44 re­
localisation, was examined by TGF-pi stimulation of cells transiently transfected with 
HAS2 (Figure 5.27B) or EGF-R (Figure 5.27C) over-expression vectors either alone, or 
in combination (Figure 5.27D). Transfection with GFP was used as a mock control 
(Figure 5.27A). In these experiments the combination of EGF-R and HAS2 over­
expression (but not independently) restored co-localisation of CD44 and EGF-R in aged 
cells.
Collectively these results suggest that TGF-pi promotes CD44 and EGF-R association 
whilst failure to do so in aged cells derives from age-related loss of EGF-R expression 
and HAS2 induction. A recent report indicates ERK 1/2 phosphorylation is triggered by
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CD44 interactions [284]. Previous data from this chapter has demonstrated that ERK 
signalling is EGF-R-dependent (Figure 5.10-11). To identify whether CD44-EGF-R 
interaction plays a role in signalling to ERK, young cells were treated with an anti- 
CD44 blocking antibody and ERK1/2 phosphorylation assessed (Figure 5.27E). Basal 
and TGF-pi mediated ERK1/2 activation was inhibited by the anti-CD44 blocking 
antibody, this together with earlier data implies that ERK 1/2 activation is downstream 
of HA dependent CD44- EGF-R association.
5.2.10 Involvement o f calcium calmodulin-dependent kinase II
CD44 is known to be linked to various transmembrane and intracytoplasmic signalling 
pathways in addition to EGF-R [338]. Involvement of Calcium calmodulin-dependent 
kinase II (CaMKII), a serine/threonine protein kinase that phosphorylates diverse 
substrates including the cytoskeletal protein filamin, has been demonstrated to be a 
downstream target of HA-CD44 mediated signalling in head and neck carcinoma cells 
[206]. In order to examine a potential signalling function for HA-CD44 interactions in 
my cell system, fibroblasts were treated with or without TGF-pi in the presence of 
either KN-93, a CaMKII inhibitor, KN-92 a suitable control or no treatment (control 
treatment). Immunofluorescence analysis of FITC-phalloidin-labelled cells 
demonstrated TGF-pl phenotypic activation by an increase in stress fibres (Figure 
5.28B) and associated with this was up-regulation of a-SMA (Figure 5.28F). KN-93 
prevented phenotypic activation, cells were smaller and retained their spindle cell 
appearance, had less stress fibres (Figure 5.28D), and did not up-regulated a-SMA 
(Figure 5.28H). KN-92 in contrast had no effect on phenotypic activation, stress fibre 
formation and a-SMA expression (Figure 5.8C &G).
5.2.11 Effect o f disrupting the cytoskeleton on pericellular HA organisation
Having shown that interruption of the pathways that modulate cytoskeletal 
reorganisation abrogate phenotypic activation, I determined the direct role of the actin 
cytoskeleton in CD44-mediated pericellular HA assembly. Young dermal fibroblasts 
were treated with cytochalasin B prior to TGF-pl stimulation. Cytochalasin binds to the
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(+) of actin filaments causing destabilization and depolymerisation of the actin network 
[334]. Although disruption of the cytoskeleton did not significantly alter surface CD44 
expression (Figure 5.29B), it did significantly attenuate TGF-pi mediated a-SMA 
induction (Figure 5.29A). Cells were processed for histology and HA pericellular matrix 
assembly (Figure 5.30). Analysis of TRITC-phalloidin-labelled cells demonstrated 
increased disruption of f-actin organisation associated with increasing concentrations of 
cytochalasin B (Figure 5.30 E-H). Destabilization of the actin network resulted in cell 
rounding, consistent with previous findings [334] and changes in pericellular HA 
formation. In control cells the HA coat was uniformly organised around the cell (Figure 
5.30A). Ever increasing concentrations of cytochalasin B did not reduce the amount of 
pericellular HA as observed for 4MU and Hyal treatments in chapter 4, but rather, the 
retention of the HA was reduced and instead of a ‘coat’ a disorganised ‘puddle’ of HA 
was observed (Figure 5.30 B-D), similar to the effect of CD44 siRNA. These data 
indicate that regulation of fibroblast phenotype may depend on the close association of 
CD44 with the cytoskeleton. Disruption of the f-actin components of the cytoskeleton 
reduce the anchorage of pericellular HA indicating that cytoskeletal elements regulate 
CD44-HA binding. These data demonstrate that direct interaction of fibroblasts with 
their HA matrix is vital for maintenance of phenotype.
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TGF-pl is acting through EGF-R 
to induce myofibroblastic differentiation
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Figure 5.1 Involvement o f EGF-R and ALK-5 in phenotypic conversion.
Confluent monolayers of young dermal fibroblasts were growth arrested in serum-free medium 
for 48 hours. Cultures were then incubated in the presence o f serum-free medium alone, serum- 
free medium containing lOng/ml TGF-pi, serum-free medium containing lOng/ml EGF, or 
both, in combination with either the EGF-R inhibitor AG1478 (10pM) and/or the ALK5- 
specific inhibitor SB431542 (lOpM) for a further 72 hours. Total mRNA was extracted and a - 
SMA expression assessed by RT-QPCR. Ribosomal RNA expression was used as an 
endogenous control and gene expression was assessed relative to cells that had received only 
serum-free medium alone. The comparative C t method was used for relative quantification o f 
gene expression and the results are represented as the mean± S.E. o f six individual experiments 
using cells isolated from two different donors. Statistical analysis was performed by the 
Student’s t test: *, p <0.05 as compared to no treatment (lane 1). N/S, not significant.
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Aging dermal fibroblasts exhibit reduced EGF-R
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Figure 5.2 Effect o f  in-vitro aging on EGF-R. A, confluent monolayers o f  
dermal fibroblasts at the indicated PDL’s were growth arrested in serum-free medium 
for 48 hours. Cell protein was extracted, and cell lysates were subjected to Western blot 
analysis using antibodies against EGF-R as described in section 2.14. Expression o f  
GAP-DH was analysed as a control to ensure equal loading. The results shown are 
representative o f  five independent experiments from the same patient donor. B, 
following scanning densitometry, alterations in EGF-R expression were corrected for 
the expression o f GAP-DH. C, confluent monolayers o f patient matched young, and in- 
vitro aged dermal fibroblasts were growth arrested in serum-free medium for 48 hours.
Total mRNA was extracted and EGF-R mRNA expression was assessed by RT-QPCR. 
Ribosomal RNA expression was used as an endogenous control and gene expression 
was assessed relative to control aged cells. The comparative Ct method was used for 
relative quantification o f gene expression and the results are represented as the mean±
S.E. o f six individual experiments using cells isolated from two different donors. 
Statistical analysis was performed by the Student’s t test: *, p <0.05. 146
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Figure 5.3 Over-expression o f EGF-R in aged dermal fibroblasts. Aged dermal 
fibroblasts were transfected with either EGF-R-pCR3.1 (EGF-R transfected) or GFP (Mock 
transfected) using nucleofector technology as described in section 2.9. 48 h after transfection, cells 
were incubated in serum-free medium containing lOng/ml TGF-|31 for 72 hours. Total mRNA was 
extracted and EGF-R (A) and a-SM A (B) mRNA expression was assessed by RT-QPCR. 
Ribosomal RNA expression was used as an endogenous control and gene expression was assessed 
relative to mock transfected. The comparative CT method was used for relative quantification of 
gene expression and the results are represented as the mean± S.E. o f nine individual experiments 
using cells isolated from three different donors. Statistical analysis was performed by the Student’s t 
test: **p<0.01, N/S Not significant. C, EGF induced proliferation was determined by incorporation 
o f [3H] Thymidine. Expression plasmids for EGF-R or GFP (mock) were introduced into aged 
fibroblasts using nucleofector technology prior to metabolic labelling, performed by incubation with 
1 pCi/ml D- [3H]Thymidine following addition o f serum-free medium containing lOng/ml EGF for 
24 hours. Data are the mean ± S.E. from six individual experiments, using cells isolated from two 
different donors. Statistical analysis was performed by the Student’s t test: *, p <0.05.
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EGF expression and combinatory effects o f EGF and 
TGF-pl in EGF-R transfected aged cells
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Figure 5.4 Effect o f  in-vitro aging on EGF expression (A), synergistic effects o f  TGF- 
p i  and EGF in EGF-R over-expressed aged cells (B-D) A, confluent monolayers o f patient 
matched young and aged dermal fibroblasts were growth-arrested in serum-free medium for 48 hours, prior 
to addition o f either serum-free medium alone (clear bars) or serum-free medium containing lOng/ml 
TGF-pi (black bars) for 72 hours. Total mRNA was extracted and EGF expression assessed by RT- 
QPCR. B, aged dermal fibroblasts were transfected either with EGF-R-pCR3.1 (EGF-R transfected) or 
GFP (mock transfected) using nucleofector technology as described in section 2.9. 48 h after transfection, 
cells were incubated in either serum-free medium alone (clear bars) or serum-free medium containing 
lOng/ml TGF-pi in combination with lOng/ml EGF (black bars) for 72 hours and a-SM A expression 
assessed by RT-QPCR. C-D, aged dermal fibroblasts were transfected either with EGF-R-pCR3.1 (EGF-R 
transfected) or GFP (mock transfected) using nucleofector technology. 48 hours after transfection, cells 
were incubated in either serum-free medium alone (clear bars), serum-free medium containing lOng/ml 
TGF-pi(Z>/tfcA: bars) or serum-free medium containing TGF-pi(10ng/ml) in combination with EGF 
(lOng/ml) (grey bars) for 72 hours. TSG-6 (C) and HAS2 (D) mRNA expression was assessed by RT- 
QPCR. In all experiments ribosomal RNA expression was used as an endogenous control and gene 
expression was assessed relative to aged control (A) or mock transfected control (B,C,D). The 
comparative CT method was used for relative quantification of gene expression and the results are 
represented as the mean± S.E. of nine individual experiments using cells isolated from three different 
donors. Statistical analysis was performed by the Student’s / test: #p<0.05, as compared to aged cells, 
*p<0.05, **p<0.01, N/S, not significant.
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Figure 5.5 Effect o f EGF inhibition on phenotypic activation. Confluent 
monolayers o f young dermal fibroblasts were growth arrested in serum-free medium for 48 
hours. The medium was replaced with serum-free medium containing TGF-pi(10ng/ml) 
alone or in combination with either the EGF-R inhibitor AG 1478 (lOpM) or anti-EGF 
antibody (lOpg/ml) for 72 hours and a-SM A expression assessed by RT-QPCR. Ribosomal 
RNA expression was used as an endogenous control and gene expression was assessed 
relative to TGF-pi alone stimulated cells. The comparative CT method was used for relative 
quantification o f gene expression and the results are represented as the mean± S.E. o f  six 
individual experiments using cells isolated from two different donors. Statistical analysis was 
performed by the Student’s t test: *, p <0.05, **, p<0.01.
150
TGF-PI-mediates HAS2 induction through EGF-R 
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Figure 5.6 Involvement o f EGF-R in TGF-pi dependent HAS2 induction.
Confluent monolayers o f young dermal fibroblasts were growth-arrested in serum-free 
medium for 48 hours, prior to addition o f either serum-free medium alone (control), or 
serum-free medium containing either TGF-pi(10ng/ml) or EGF (lOng/ml) in isolation or in 
combination with the EGF-R inhibitor AG 1478 (lOpM) for 72 hours. Total mRNA was 
extracted and HAS2 expression assessed by RT-QPCR. Ribosomal RNA expression was 
used as an endogenous control and gene expression was assessed relative to TGF-pialone 
stimulated cells. The comparative C t method was used for relative quantification o f gene 
expression and the results are represented as the mean± S.E. o f six individual experiments 
using cells isolated from two different donors. Statistical analysis was performed by the 
Student’s t test: *, p <0.05, as compared to control. **, p<0.01.
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EGF-R and HAS2 over-expression in aged cells
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Figure 5.7 Combinatory effects o f EGF-R and HAS2 over-expression in aged 
cells. Aged dermal fibroblasts were transfected either with EGF-R-pCR3.1 alone (EGF-R 
transfected) or in combination with HAS2-pCR3.1 (EGF-R/HAS2 transfected) or GFP (mock 
transfected) using nucleofector technology as described in section 2.9. 48 hours after transfection, 
cells were incubated in either serum-free medium alone (clear bars), or serum-free medium 
containing lOng/ml TGF-01 (black bars) for 72 hours and HAS2 (A), EGF-R (B) and a-SM A  (C) 
mRNA expression assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous 
control and gene expression was assessed relative to control mock transfected cells. The comparative 
CT method was used for relative quantification o f gene expression and the results are represented as 
the mean± S.E. o f six individual experiments using cells isolated from two different donors. 
Statistical analysis was performed by the Student’s t test: *, p <0.05. N/S, not significant.
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Figure 5.8 EGF-R activation. A, growth arrested confluent monolayers of young dermal 
fibroblasts were stimulated with EGF (lOng/ml) for the indicated times and were analysed by 
western blot with antibodies for the phosphorylated form of EGF-R. B, growth arrested confluent 
monolayers of young dermal fibroblasts were stimulated with either serum free medium alone or 
containing EGF (lOng/ml) and TGF-31 (lOng/ml) in isolation or in combination with or without 
either the EGF-R inhibitor AG1478 (lOpM) or the ALK-5 inhibitor SB431542 (lOpM). Stimulations 
lasted 30 minutes after which cell lysates were analysed by western blot with antibodies for the 
phosphorylated form of EGF-R as describe under section 2.14. TGF-pi did not alter pEGF-R levels 
at 30 minutes (B) but did increase EGF-R activation at a later time point (3-4 h) (C). All blots were 
normalised to antibodies for total EGF-R.
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Figure 5.9 The role o f ERK in phenotypic conversion (A), TGF-pi dependent 
activation of ERK signalling (B) and the effects o f in-vitro ageing (C).
A, confluent monolayers o f young dermal fibroblasts were growth-arrested in serum-free medium 
for 48 hours, prior to addition o f either serum-free medium alone or serum-free medium containing 
lOng/ml TGF-piin isolation or in combination with the p38 inhibitor SB203580 (lOpM) or the 
ERK inhibitor PD98059 (lOpM) for 72 hours. Total mRNA was extracted and a-SM A mRNA 
expression assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous 
control and gene expression was assessed relative to untreated cells. The comparative CT method 
was used for relative quantification of gene expression and the results are represented as the mean± 
S.E. o f six individual experiments using cells isolated from two different donors. Statistical 
analysis was performed by the Student’s t test: *, p <0.05, N/S not significant B, growth arrested 
confluent monolayers o f young dermal fibroblasts (Q) were incubated with lOng/ml TGF-pi for up 
to 60 minutes and phosphorylation of ERK 1/2 proteins assessed by western analysis at the time 
points indicated as describe under section 2.14. C, lOng/ml TGF-piin serum free medium, was 
added to confluent growth arrested confluent monolayers of patient matched young, and in-vitro 
aged dermal fibroblasts for 10 minutes. Cell lysates were prepared for western blot with 
antibodies for the phosphorylated form of ERK 1/2. All blots were normalised to antibodies for 
GAP-DH.
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Figure 5.10 Phosphorylation o f  ERK1/2 coincides with phosphorylation o f  EGF-R 
(A), and displays a an early and late response toTGF-pi (B). A, growth arrested confluent 
monolayers o f young dermal fibroblasts were stimulated with either serum free medium alone or 
containing EGF (lOng/ml) and TGFpi (lOng/ml) in isolation or in combination with or without either the 
EGF-R inhibitor AG1478 (lOpM) or ALK-5 inhibitor SB431542 (lOpM). Lysates were analysed by 
western blot with antibodies for the phosphorylated form o f EGF-R and the phosphorylated form o f  
ERK1/2 as describe under section 2.14. Stimulations lasted 30 minutes for p-EGF-R and 10 minutes for 
p-ERKl/2. B, growth arrested confluent monolayers o f  young dermal fibroblasts were incubated with 
lOng/ml TGF-Pj for up to 3hrs and phosphorylation o f  ERK1/2 proteins assessed by western analysis at 
the time points indicated as describe under section 2.14. Blots were normalised to antibodies for total 
EGF-R (A) and GAP-DH (B).
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Figure 5.11 The involvement o f  HA and EG F signalling during ERK activation.
The involvement of EGF and HA in activation of ERK 1/2 phosphorylation and Smad 2 
phosphorylation was analysed by Western blot as describe under section 2.14. Confluent monolayers 
of growth arrested young dermal fibroblasts were pre-treated with either lOpM EGF-R inhibitor 
AG1478 (lane3), lOpg anti-EGF antibody (lane 4), 0.5mM 4MU (lane5) or 200 pg/ml hyaluronidase 
(Hyal) (lane6) for 30 minutes prior to a further 10 min incubation with lOng/ml TGF-(31. Control 
cells received serum-free medium alone (lanel). Blots were normalised to antibodies for GAP-DH.
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CD44 is required for TGF-fil-mediated phenotypic activation
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Figure 5.12 Effect o f CD44 gene silencing on TGF-Pi dependent phenotypic 
activation. Confluent monolayers of young dermal fibroblasts were transfected with CD44 siRNA or 
scramble oligonecleotide control (scramble) for 48 hours prior to addition of serum-free medium alone 
(<clear bars) or serum-free medium containing lOng/ml TGF-pi {black bars) for a further 72 hours, and 
CD44 (A), a-SM A (B) or HAS2 (C) expression assessed by RT-QPCR. Ribosomal RNA expression 
was used as an endogenous control and gene expression was assessed relative to scramble control- 
scrambled samples. The comparative CT method was used for relative quantification of gene expression 
and the results are represented as the mean± S.E. o f six individual experiments using cells isolated from 
two different donors. Statistical analysis was performed by the Student’s t test: *, p <0.05, **, p<0.01as 
compared to scramble. N/S, not significant.
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Figure 5.13 E ffect o f  CD44 silencing on a-SM A incorporation an d  assem bly o f  
pericellu lar HA. Immunohistochemical analysis was performed to assess dermal fibroblast 
phenotype in un-transfected cells (A,D,G) or cells transfected with either scramble 
oligonecleotide control (scramble) (B,E,H) or CD44 siRNA (C.F,I) prior to addition o f serum- 
free medium alone (A-C) or in combination with lOng/ml TGF-pi(D-I) for a further 72 hours. 
A-F, cells were fixed and stained for a-SM A, mounted in Vectashield fluorescent mountant, and 
viewed under UV light as describe under section 2.14. Original magnification was x 100. G-I, 
Formalised horse erythrocytes were added as described under section 2.11 to visualise the HA 
pericellular coat. Arrowheads indicate the cell body; Arrows show the extent o f the pericellular 
matrix. Representative o f  dermal fibroblasts from three patient donors. Original magnification 
x 200.
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Figure 5.14 Overview o f  relationship between CD44 expression and phenotypic activation. 70% confluent monolayers o f patient matched young 
(A,B,E,F,1,J) and aged (C,D,G,H,K,L) dermal fibroblasts were growth-arrested in serum-free medium for 48 hours, prior to addition of either serum-free medium alone 
(A,C,E,G,I,K) or serum-free medium containing lOng/ml TGF-pi(B,D,F,H,J,L). The cells were fixed and stained for vimentin (A-D), a-SMA (E-H) or CD44 (I-L) as 
describe under section 2.4. Cells were mounted in Vectashield fluorescent mountant, and viewed under UV light. Representative images of 3 individual experiments 
using cells isolated from three different donors are shown. Original magnification was x 100.
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Figure 5.15 Effect of age on CD44 mRNA expression. Monolayers of patient 
matched young and in-vitro aged dermal fibroblasts were growth-arrested in serum-free 
medium for 48 hours, prior to addition of either serum-free medium alone {clear bars) or 
serum-free medium containing lOng/ml TGF-B {black bars). Total mRNA was extracted and 
CD44 expression assessed by RT-QPCR. Ribosomal RNA expression was used as an 
endogenous control and gene expression was assessed relative to aged control cells. The 
comparative CT method was used for relative quantification of gene expression and the results 
are represented as the mean± S.E. o f nine individual experiments using cells isolated from 
three different donors. Statistical analysis was performed by the Student’s t test: # not 
significant as compared to aged cells.
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Figure 5.16 Co-localization o f  CD44 and EGF-R and impact o f  HA disruption.
Western blot analysis o f the association of CD44 and EFGR receptors. Cell protein was extracted 
from confluent monolayers of serum deprived young dermal fibroblasts exposed to either serum- 
free medium alone (lanel) serum-free medium containing lOng/ml TGF-piin isolation (lane 4) or 
in combination with hyaluronidase (Hyal) (200 pg/ml) (lane5) or 4MU (0.5mM) (lane 6) for 3 hr. 
Subsequently samples were immunoprecipitated (IP) with anti-CD44 antibody, followed by 
immunoblotting with anti-EGF-R antibody as describe under section 2.15. Specificity of 
immunoprecipitation was confirmed by negative control reactions performed with IgG control 
(lane 5) and lane 2 and lane 3 received Hyal and 4MU alone, respectively.
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F igure 5 .17  Im m unocytochem ical localisation o f  CD44 and E G F -R  in you n g  
resting fibroblasts. 70% confluent monolayers of young dermal fibroblasts were 
growth-arrested in serum-free medium for 48 hours, prior to addition of serum-free 
medium for 24h. Cells were fixed and the expression of CD44 (red) and EGF-R {green) 
were examined by immunocytochemistry and their association examined by merging of 
individual images (yellow). In merged images DAPI was used to visualise the nuclei 
(blue). Representative images of 12 individual experiments using cells isolated from 
four different donors (I-IV) are shown. Original magnification was x 100.
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CD44/EGF-R co-localisation in young fibroblasts after
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Figure 5.18 Im m unocytochem ical localisation o f  CD44 an d  EG F-R in you n g  
fibrob lasts stim ulated  with TG F-fil. 70% confluent monolayers of young dermal 
fibroblasts were growth-arrested in serum-free medium for 48 hours, prior to addition of 
serum-free medium containing lOng/ml TGF-pifor 24h. Cells were fixed and the 
expression of CD44 (red) and EGF-R {green) were examined by immunocytochemistry 
and their association examined by merging of individual images {yellow). In merged 
images DAPI was used to visualise the nuclei {blue). Representative images of 12 
individual experiments using cells isolated from four different donors (I-IV) are shown. 
Original magnification was x 100.
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CD44/EGF-R co-localisation in aged resting fibroblasts
CD44
F ig u re  5 .1 9  Im m u n o c y to c h e m ic a l lo ca lisa tio n  o f  C D 4 4  a n d  E G F -R  in a g e d  
re s tin g  f ib r o b la s ts .  70% confluent monolayers o f aged dermal fibroblasts were growth- 
arrested in serum-free medium for 48 hours, prior to addition o f  serum-free medium for 24h. 
Cells were fixed and the expression o f CD44 (red) and EGF-R (green) were examined by 
immunocytochemistry and their association examined by merging o f individual images 
(yellow). In merged images DAPI was used to visualise the nuclei (blue). Representative 
images o f 12 individual experiments using cells isolated from four different donors (I-IV) are 
shown. Original magnification was x 100.
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Figure 5.20 Im m unocytochem ical localisation o f  CD44 and EG F-R in aged  
fibrob lasts stim ulated  with T G F -pi. 70% confluent monolayers o f aged dermal 
fibroblasts were growth-arrested in serum-free medium for 48 hours, prior to addition o f  
serum-free medium containing lOng/ml TGF-plfor 24h. Cells were fixed and the expression 
o f CD44 (red) and EGF-R (green) were examined by immunocytochemistry and their 
association examined by merging o f  individual images (yellow). In merged images DAPI was 
used to visualise the nuclei (blue). Representative images o f  12 individual experiments using 
cells isolated from four different donors (1-IV) are shown. Original magnification was x 100.
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Figure 5.21 E ffect o f  in-vitro aging on co-localization o f  CD44 and EGF-R. 70%
confluent monolayers o f  patient matched young (A&B) and aged (C&D) dermal fibroblasts 
were growth-arrested in serum-free medium for 48 hours, prior to addition o f  either serum- 
free medium alone (A&C) or serum-free medium containing lOng/ml TGF-pi(B&D). Cells 
were fixed and the expression o f CD44 (red) and EGF-R {green) were examined by 
immunocytochemistry and their association examined by merging o f  individual images 
(yellow). In merged images DAP1 was used to visualise the nuclei (blue). Original 
magnification was x 100.
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F igure 5.22 Im m unocytochem ical localisation o f  CD44 an d  E G F-R in you n g  resting  
fibroblasts. 70% confluent monolayers o f young dermal fibroblasts were growth-arrested in 
serum-free medium for 48 hours, prior to addition o f  serum-free medium for 24h. Cells were fixed 
and the expression o f CD44 (B) and EGF-R (C) was examined by confocal section using the Leica 
TCS SP2 AOBS confocal microscope, and their association was examined by merging o f  individual 
images (D). CD44 label is red, EGF-R label is green, nuclei are counterstained blue with DAPI (A), 
and co-localisation is represented by yellow. A rrow s indicate co-localisation at different 
magnification Representative images o f 6 individual experiments using cells isolated from two 
different donors are shown.
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Figure 5.23 Im m unocytochem ical localisation o f  CD44 an d  E G F-R in you n g  
fibrob lasts  stim ula ted  with TGF-fil. 70% confluent monolayers o f young dermal fibroblasts 
were growth-arrested in serum-free medium for 48 hours, prior to addition o f serum-free medium 
containing lOng/ml TGF-|31for 24h. Cells were fixed and the expression o f CD44 (B) and EGF-R
(C) was examined by confocal section using the Leica TCS SP2 AOBS confocal microscope, and 
their association was examined by merging o f  individual images (D). CD44 label is red, EGF-R 
label is green, nuclei are counterstained blue with DAPI (A), and colocalisation is represented by 
yellow. A rrow s indicate co-localisation at different magnification Representative images o f 6 
individual experiments using cells isolated from two different donors are shown.
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Figure 5.24 Im m u n o c y to c h e m ic a l lo ca lisa tio n  o f  C D 4 4  a n d  EGF-R in y o u n g  
f ib r o b la s ts  s t im u la te d  w ith  TGF-pl. 70% confluent monolayers o f  young dermal 
fibroblasts were growth-arrested in serum-free medium for 48 hours, prior to addition o f serum- 
free medium containing lOng/ml TGF-pifor 24h. Cells were fixed and the expression o f CD44 
(B) and EGF-R (C) was examined by confocal section using the Leica TCS SP2 AOBS confocal 
microscope, and their association was examined by merging o f  individual images (D). CD44 
label is red, EGF-R label is green, nuclei are counterstained blue with DAPI (A), and 
colocalisation is represented by yellow. A rrow s indicate co-localisation at different 
magnification Representative images o f 6 individual experiments using cells isolated from two 
different donors are shown.
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and after TGF-pi stimulation
Figure 5.25 Im m unocytochem ical localisation o f  CD44 an d  E G F -R  in aged fibroblasts  
under resting (A-D) and T G F -pl stim ulated  (E-H) conditions. 70% confluent monolayers of 
aged dermal fibroblasts were growth-arrested in serum-free medium for 48 hours, prior to addition of 
serum-free medium containing alone (A-D) or serum-free medium containing lOng/ml TGF-pi(E-H) 
for 24h. Cells were fixed and the expression o f  EGF-R (B&F) and CD44 (C&G) was examined by 
confocal section using the Leica TCS SP2 AOBS confocal microscope, and their association was 
examined by merging o f  individual images (D&H). CD44 label is red, EGF-R label is green, nuclei 
are counterstained blue with DAPI (A&E), and co-localisation is represented by yellow. A rrow s 
indicate co-localisation at different magnification Representative images o f  6 individual experiments 
using cells isolated from two different donors are shown.
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Figure 5.26 E ffec t o f  in-vitro aging on co-localization o f  CD44 and EGF-R. 70%
confluent monolayers o f  patient matched young (A-H) and aged (I-P) dermal fibroblasts were growth- 
arrested in serum-free medium for 48 hours, prior to addition o f  either serum-free medium alone (A- 
D,I-L) or serum-free medium containing lOng/ml TGF-pi(E-H,M-P). Cells were fixed and the 
expression o f CD44 (B,F,J and N) and EGF-R (C,G,K and O) was examined by confocal section 
using the Leica TCS SP2 AOBS confocal microscope, and their association was examined by 
merging o f individual images (D,H,L and P). CD44 label is red, EGF-R label is green, nuclei are 
counterstained blue with DAP1 (A,E,I and M), and co-localisation is represented by yellow. A rrow s 
indicate co-localisation at different magnification
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Figure 5.27 Effect of HAS2 and EGF-R over-expression in aged cells on co­
localization of CD44 and EGF-R. Aged dermal fibroblasts were transfected either with 
GFP (mock transfected) (A), HAS2-pCR3.1 (HAS2 transfected) (B) EGF-R-pCR3.1 (EGF-R 
transfected) (C) .or the combination o f HAS2-pCR3.1 and EGF-R-pCR3.1 (D) using 
nucleofector technology as described in section 2.9. Cells were growth-arrested in serum-free 
medium for 48 hours, prior to addition of serum-free medium containing lOng/ml TGF-plfor a 
further 72 hours. The cells were fixed and the expression o f CD44 (red) and EGF-R {green) 
were examined by immunocytochemistry and their association examined by merging of 
individual images (yellow). In merged images DAPI was used to visualise the nuclei (blue). 
Original magnification was x 100. E, confluent monolayers of young dermal fibroblasts were 
growth-arrested in serum-free medium for 48 hours, prior to addition o f either serum-free 
medium alone, or serum-free medium containing lOng/ml TGF-pias indicated for 10 min, in the 
presence or absence o f a blocking antibody to CD44 (final concentration 5pg/ml). Cell lysates 
were prepared and subjected to western blot analysis for the phosphorylated form o f ERK1/2. 
Blots were normalised to antibodies for GAP-DH.
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Figure 5.28. Im m unohistochem ical analysis o f  F-actin an d  a-SM A expression in you n g  fib rob lasts  fo llo w in g  KN -93 treatm ent. 50% confluent 
monolayers o f  young dermal fibroblasts were growth-arrested in serum-free medium for 48 hours, prior to addition o f  serum-free medium alone (A&E) or containing 
lOng/ml TGF-pl(B,C,D,F,G,H) in the absence (A,B,E,F) or presence o f  KN-92(5pM) (C&G) or KN-93(5 pM) (D«feH) for 72h. Cells were fixed and filamentous actin 
was visualised with fluorescein-conjugated phalloidin (A-D) or antibodies for the detection o f  a-SMA were added as described under section 2.4. The cells were then 
mounted in Vectashield fluorescent mountant, and viewed under UV light. DAPI was used to visualise the nuclei (blue). Representative images o f  6 individual 
experiments using cells isolated from two different donors are shown. Original magnification x 100.
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Figure 5.29 Consequence of disrupting the cytoskeleton on a-SMA (A) and CD44 
(B) expression. Confluent monolayers o f young dermal fibroblasts were growth-arrested in 
serum-free medium for 48 h. Cytochalasin B (lOpM) was then added in serum free medium 
at 37 °C for 1 h, prior to the addition of either serum free medium alone (clear bars) or 
lOng/ml TGF-Pi {black bars) for a further 72h. In control treatments cytochalasin B was 
replaced by adding serum free medium alone. a-SM A (A) and CD44 (B) mRNA expression 
was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control 
and gene expression was assessed relative to the control treatment in non-stimulated cells. 
The comparative C t method was used for relative quantification of gene expression and the 
results are represented as the mean± S.E. six individual experiments using cells isolated from 
two different donors. Statistical analysis was performed by the Student’s t test: u, not 
Significant, as compared to control treatment. *,P<0.01.
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Figure 5.30 Effect o f  cytochalasin B on HA pericellular coat assembly and organisation o f  actin cytoskeleton. Serum free medium alone (A&E) or 
increasing concentrations o f cytochlasin B (B-D,F-H) were added to growth arrested cells for lh prior to the addition o f lOng/ml TGF-(3! and the incubations continued for 
72 h. A-D, formalised horse erythrocytes were then added to visualise the HA pericellular coat as described in section 2.11. Zones o f exclusion were visualized using Zeiss 
Axiovert 135 inverted microscope. Original magnification was x 200. E-H, cells were fixed and filamentous actin was visualised with fluorescein-conjugated phalloidin as 
describe under section 2.4. The cells were then mounted in Vectashield fluorescent mountant, and viewed under UV light. Original magnification was x 100. All images are 
representative o f six individual experiments using cells isolated from two different donors.
5.3 Discussion
This chapter demonstrates that as well as HAS2, functional EGF-R is required for TGF- 
pl stimulated phenotypic activation of fibroblasts, and both are lost with in-vitro aging. 
Furthermore the results demonstrate the need for a synergistic activation of both TGF-P 
receptor associated signalling with the indirect activation of the EGF-R by TGF-P 1. 
This synergy is supported by suppression of TGF-pl driven phenotypic activation by 
either inhibition of Smad signalling, or inhibition of the activity of the EGF-R using 
AG1478. These data therefore further emphasize the importance of age dependent 
decrease in the expression of EGF-R in age dependent alterations in fibroblast functions 
such as proliferation, as well as regulation of phenotypic activation, two aspects of 
dermal fibroblast behaviour which are fundamentally important to wound healing. The 
data also suggest that activation o f the EGF-R is related to TGF-pl dependent 
stimulation of EGF. EGF administration was insufficient to induce a-SMA, however, 
the combinatory effect o f EGF and TGF-P 1 was greater than that of TGF-P 1 alone. This 
synergistic effect was inhibited by EGF-R blockade, suggesting that EGF contributes to 
the differentiation of myofibroblasts induced by TGF-pl through EGF-R activation. 
Age associated decreased activation of the EGF-R is related to both decreased 
expression of EGF-R, as previously demonstrated [276] and also abrogation of TGF-pl 
stimulated EGF synthesis. In support of this, it was possible to partially restore age 
dependent TGF-pl phenotypic activation by over-expression of the EGF-R, and co­
stimulation with TGF-pl and EGF.
My data with the neutralising EGF antibody affirmed a role for EGF as an intermediate 
signalling molecule for TGF-pl dependent fibroblast differentiation. However, the 
modest inhibition elicited by neutralising EGF antibody compared to the complete 
inhibition by EGF-R inhibitor AG1478, suggests EGF may not be the only signalling 
molecule involved in TGF-pi induced EGF-R activation. In addition to EGF, five other 
ligands are known to bind to EGF-R namely, amphiregulin, epiregulin, betacellulin, 
TGFa and Heparin-binding EGF-like growth factor (HB-EGF). In particular the 
liberation of HB-EGF has been widely implicated as an intermediate signalling
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molecule for EGF-R activation [222, 346], whilst several studies have demonstrated 
direct transactivation o f EGF-R by TGF-pl can occur in a manner independent of EGF- 
R ligands. [327, 342].
With regards to the role o f HAS2 dependent HA regulation in the control of fibroblast 
phenotypic activation, the data presented in this chapter builds upon the previous 
chapters demonstrating loss o f HAS2 induction by TGF-P 1 in aged cells. Blockade of 
the EGF-R signalling pathway was shown to prevent myofibroblastic differentiation of 
young fibroblasts, a process I demonstrated in the previous chapters to be influenced by 
HA. I now report that HAS2-dependent HA synthesis, is regulated by EGF-R signalling 
as pharmacological blockade by AG1478 attenuates its TGF-pl-dependent up- 
regulation. It has previously been reported that EGF can upregulate HA synthesis by 
adult dermal fibroblasts and oral fibroblasts [347] and that this is required for the 
manifestation of their respective motogenic activities [244]. EGF also induces HAS2- 
dependent HA biosynthesis in rat epidermal keratinocytes [318]. Data presented in this 
chapter confirm the stimulatory effect of EGF on HA synthesis, from this we can 
extrapolate that EGF represents an intermediate signalling molecule for TGF-pl 
dependent induction of HAS2. Perhaps in hindsight, confirmation of reduced HAS2 
expression or HA accumulation should have been assessed following addition of the 
neutralising EGF antibody. The involvement of EGF-R pathway has been implicated in 
mediating HA synthesis previously in epidermal keratinocytes [348]. This is consistent 
with a recent publication that demonstrates wounding induced synthesis of HA in 
organotypic epidermal cultures is downstream of EGF-R signalling [222]. Here I 
demonstrate that age associated EGF-R loss may directly disrupt HAS2-dependent HA 
accumulation.
The data presented also suggests that HA itself facilitates subsequent EGF-R signalling 
which may occur in a ligand/EGF independent way. The potential involvement of HA, 
and its principle receptor CD44, in modulation of EGF-dependent responses is well 
recognised in tumour cells. For example, in the absence of exogenous EGF, EGF-R can 
be directly activated by HA through EGF-R interactions with CD44 [349]. In the 
context of wound healing, EGF dependent motogenic responses of dermal fibroblasts
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requires functionality o f the HA receptor, CD44 [150]. The relationship between EGF 
signalling and HAS2 dependent HA synthesis however has not been previously 
explored in the context o f age associated defects in wound healing and fibroblast 
function. The demonstration that the need for exogenous EGF could be overcome by 
over-expression of HAS2 in this study also suggests that the EGF-R could be activated 
by HA, although whether this activation is the result of direct receptor activation, or 
through HA dependent activation of its own receptor remains to be determined. 
Furthermore, restoration of phenotypic activation in the aged cells by over-expression 
of EGF-R together with co-stimulation by TGF-pl and EGF is associated with 
restoration of HAS2 induction. Collectively, this implies EGF synthesis is upstream of 
HAS2-dependent HA accumulation.
CD44 is the main hyaluronan binding receptor and with HA it participates in many vital 
functions such as migration, adhesion proliferation and differentiation. Using a CD44- 
specific siRNAs strategy, I showed that down-regulation of CD44 inhibits HA-mediated 
phenotypic activation o f young cells. Considering the variation in HA biosynthesis, it 
was surprising to find that relative expression of CD44 did not alter between young and 
aged fibroblasts. But rather with age, there is a failure of CD44 re-localisation, which in 
the young cells, is associated with TGF-P 1 stimulation and phenotypic activation. How 
CD44 re-distribution from a discrete punctate to diffuse pattern facilitates differentiation 
in a mechanistic sense in unknown. A further vexing result revealed expression of 
CD44 mRNA was downregulated by TGF-Pl stimulation, a phenomena previously 
reported in keratinocytes [279]. One possible explanation for this downregulation is that 
enhanced cytoskeletal linkage through CD44 re-localisation may lead to stabilization of 
CD44 at the cell surface, thus retarding its internalisation [334]. Previous studies have 
shown that cytokine induced regulation o f HA binding by CD44 may in addition to 
CD44 transcription be dependent on alternate splice variant expression or post 
translational modifications such as glycosylation or sulphation [337] events which 
could, in theory, be effected by in-vitro aging.
HA binding to chondrocytes has been shown to upregulate the phosphorylation of CD44 
[334], which can influence its interaction with cytoskeletal components [350].
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Conversely in this chapter it was demonstrated that cytoskeletal elements may regulate 
CD44-HA binding since cytoskeletal disruption using cytochalasin B proved 
detrimental to the anchorage and structure of pericellular HA around the cell. CD44 
expression itself did not change so it is likely that the capacity for HA to bind to CD44 
was affected. The spatial organization of CD44 at the cell surface, for example, has 
been reportedly controlled via cytoskeletal interactions [334] so it would be easy to 
imagine how the structure of the pericellular HA matrix could be disrupted in this 
manner. In addition to artificial cytoskeletal-disrupting agents such as cytochalasin B, 
natural agents include nitrogen Oxide (NO). It is interesting to consider that NO is 
known to be elevated in degenerative disorders [351].
In the young cells, CD44 re-localisation is associated with co-localisation of CD44 with 
EGF-R as demonstrated by immunoprecipitation and immunohistochemistry studies. 
Consistent with this, Ellis et al demonstrated that fibroblast activation by EGF requires 
the cooperative interaction of EGF-R and the matrix receptor CD44. They present a 
model whereby receptor cooperativity may involve a physical association between 
activated EGF-R and CD44 within membrane “platforms” leading to transactivation 
[150]. They also propose that endogenously produced HA is only required for 
manifestation of EGF motogenicity. In contrast, the data from this chapter demonstrates 
that inhibition of HA synthesis, prevents co-localisation of CD44 and EGF-R 
suggesting that HA binding to CD44 directly regulates this functional coupling. It is 
also interesting to speculate that HA may be involved in regulating its own synthesis 
through feedback interactions between CD44 and EGF-R. Taken together these data 
demonstrate that HA may drive an increase in the association of CD44 and the EGF-R, 
which subsequently facilitates EGF-R signalling. Disruption of this mechanism due to a 
deficit in HAS2 and EGF-R contributes to age related impairment of fibroblast to 
myofibroblast activation since over-expression of both components in aged cells 
restores phenotypic activation with associated restoration of CD44-EGF-R co­
localisation.
Previous studies into the pathogenesis of head and neck squamous cell carcinomas, have 
demonstrated direct activation of EGF-R tyrosine kinase activity by the addition of
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exogenous HA, which in turn stimulates downstream MAPK (in particular ERK1 and 
ERK2) pathways and carcinoma cell growth [349]. Furthermore, TGF-P 1-mediated 
EGF-R transactivation was shown to activate the ERK pathway in mesangial cells [317] 
whilst Tsatas et al [326] demonstrate that the kinase activity of EGF-R is required for 
further downstream signalling o f ERK1 and ERK2 by HA in a glioma cell line.
In this chapter I have demonstrated using the ERK inhibitor PD98059 that TGF-P 1 
mediated- fibroblast differentiation signals through the MAPK/ERK pathway. The data 
suggests that ERK 1/2 activation signals downstream of EGF mediated EGF-R 
activation and its HA-dependent association with CD44, since AG1478, anti-EGF 
antibody, HA disruption, or CD44 inhibition all suppressed ERK1/2 phosphorylation. 
One caveat from this study is that ERK activation was observed with biphasic 
phosphorylation at 10 minutes and 3 hours after TGF-P 1 stimulation. The delayed 
activation corresponded with EGF-R phosphorylation (both occurring at 3 hours) 
however, the initial phase (10 minutes) after TGF-pl stimulation was too rapid to result 
from EGF-R phosphorylation and cannot be explained by the present data alone.
Studies in rat hepatocytes have demonstrated an age-related decline in EGF stimulated 
MAPK activation, and in particular ERK2 associated with age-related decline in 
proliferative capacity [352]. Vigetti et al [284] show convincing evidence that during 
aging, HA can modulate cell migration involving CD44-mediated signalling through 
ERK1/2. I have demonstrated that consistent with age-dependent decrease in EGF-R 
expression and its association with CD44, there was an age-dependent decrease in TGF- 
pi dependent activation of ERK 1 and 2. This signalling pathway is however distinct 
from EGF/ligand activation of EGF-R, since CD44 blockade whilst inhibiting ERK 1/2 
phosphorylation did not influence HAS2 expression which is also EGF-R dependent. 
Collectively, the current data suggests HA dependent CD44-EGF-R co-localisation is a 
pre-requisite for phosphorylation of ERK and subsequent phenotypic activation by 
TGF-pl. I have demonstrated that with in-vitro aging, impaired CD44-EGF-R 
signalling results in impaired ERK 1/2 signalling, leading to resistance to phenotypic 
conversion.
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Clearly a basal state of ERK signalling was evident in quiescent cells and this did not 
alter with aging. This may point to the existence of other mechanisms that utilises EGF- 
R-independent ERK1 and ERK2 or could just indicate that the effects of aging are 
restricted to upstream events i.e. age-related EGF-R deficit. The results using chemical 
inhibition showed that TGF-pl mediated phenotypic activation involves the activation 
of EGF-R and ERK1/2 since EGF-R blockade with AG1478 or ERK inactivation by the 
inhibitor PD98059 resulted in a significant decrease in a-SMA expression in young 
fibroblasts. The effects of ERK inhibition were less impressive indicating that other 
pathways may converge from EGF-R/CD44 activation that are involved in cell 
differentiation, CD44 for example is known to be linked to various transmembrane and 
intracytoplasmic signalling pathways in addition to EGF-R, including those involving 
phospholipase C (PLC)-gamma-l, P I3 kinase, and others [338]. One paper by 
Bourgignon et al propose a model for HA/CD44 interaction with EGF-R in human head 
and neck squamous carcinoma cells [206]. Two pathways are described that converge 
from EGF-R/CD44, one culminating with ERK 1/2 activation and the other with 
cytoskeletal reorganisation via phosphorylation of the cytoskeletal protein filamin. 
CaMKII is responsible for activating filamin and similarly in this chapter I 
demonstrated that it is required for myofibroblastic differentiation. It is interesting to 
speculate that such a mechanism described by Bourguignon et al could provide a 
signalling function for my own model. That is, HA-CD44-EGF-R interacts with 
cytoskeletal proteins and regulates cytoskeletal reorganisation required for cellular 
differentiation. Whether this is an event downstream of, or as Bourguignon et al propose 
is separate to ERK1/2 activation remains unknown and further investigation is required.
In the previous chapter, and consistent with previous observations [264], Smad2 but not 
Smad3 activation was demonstrated to be essential for TGF-P 1-mediatedcellular 
activation. As mentioned earlier, TGF-pl mobilizes both Smad-dependent and Smad- 
independent signalling [140]. In the current study I have demonstrated that activation 
of Smad2 and EGF-R/ERK1/2 pathways work in a complimentary way to coordinate 
TGF-pl mediated a-S M A  induction. Phosphorylation of Smad2 was not affected by 
anti-EGF antibody, AG1478, or HA disruption by Hyal and 4MU, signifying that TGF- 
pi-directed Smad2 signalling is independent of EGF-R signalling and its modulation by
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HA. Consistent with this, Smad2 was efficiently phosphorylated in young (EGF-R 
present) and aged (EGF-R not present) dermal fibroblasts. These pathways also display 
differential responses to in-vitro aging; TGF-P 1 dependent activation of Smad is 
unaffected by cellular aging whilst TGF-P 1 dependent EGF-R/HAS2 signalling is 
suppressed with aging.
My data demonstrates that the loss of TGF-P 1 responsiveness in aged cells is not due to 
global but to specific deficits (i.e. EGF-R and HAS2). Signalling from some surface 
receptors is decreased in aging [353], and this decrease is likely controlled separately 
from global cell dysfunction. To support this, I found that the receptor CD44 levels 
were relatively unchanged in aged cells. Furthermore, Smad phosphorylation did not 
change with age proving that at least some signalling pathways were intact in aged cells.
The salient findings of this chapter are summarised in figure 5.27. In addition to 
HAS2 there was loss o f EGF-R in aged cells and both are required for normal fibroblast 
functionality. Analysis of molecular events revealed that in young cells, TGF-P 1 
dependent phenotypic activation utilises two distinct but cooperating pathways that 
involve TGF-Rp/Smad2 activation and EGF mediated EGF-R/ERK1/2 signalling and 
the latter is compromised with in-vitro aging. I present evidence that the HA receptor, 
CD44 co-localises with the EGF-R following activation by TGF-P 1 . This interaction is 
HA-dependent as disruption of HA synthesis abrogates this association and inhibits 
subsequent downstream signalling of ERK 1/2. In aged fibroblasts this association is 
lost with resultant suppression of ERK1/2 activation. Forced over-expression of EGF-R 
and HAS2 in aged cells restored TGF-pl-mediated HA-CD44/EGF-R association and 
a-SMA induction.
In summary, the data suggests that HA serves as a signal integrator and facilitates the 
capacity for CD44 to physically associate with EFG-R. This complex is necessary for 
propagating TGF-pl intracellular signals via EGF-R-dependent transduction pathways 
necessary for myofibroblastic differentiation. It would appear that as important as HA is 
in orchestrating fibroblast behaviour, a functional relationship between CD44 and EGF- 
R is vital to transduce the HA signal. This explains why recovery of HAS2-induced HA
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levels in aged cells is insufficient to restore TGF-pi responsiveness in the aged 
phenotype without combined restoration of EGF-R apparatus.
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Figure 5,27 Comparison o f young and in-vitro aged fibroblast phenotype,
A comparison of cell morphology, HA generation and phenotype o f patient matched young 
(A&C) and aged (B&D&E&F) dermal fibroblasts based on the analysis compacted from this 
results chapter. In response to TGF-pi young fibroblasts (A) readily differentiate into 
myofibroblastic cells (C), which incorporate prominent stress fibres and a-SMA and is 
mediated via activation o f EGF-R by EGF. Accordingly phenotypic activation is impaired by 
the EGF-R inhibitor AG1478 and anti-EGF antibody. HAS2-dependent HA synthesis is 
regulated by EGF-R signalling since AG1478 prevents HAS2 induction by TGF-pi. 
Stimulation with TGF-pi drives CD44-EGF-R co-localisation and inhibition with either 4MU 
or Hyal confers this association is HA dependent. In addition, TGF-pi mediated 
myofibroblastic differentiation is dependent on activation of ERK1/2 and accordingly is 
attenuated by ERK1/2 inhibitor PD98059. Furthermore, TGF-pl-mediated ERK activation 
was dependent on EGF-R signalling and CD44-HA modulation since AG1478, anti-EGF 
antibody, 4MU, Hyal and anti-CD44 antibody all hindered ERK activation. Smad2 
phosphorylation was unaltered using the same pharmacological inhibition suggesting a 
dissociation in intracellular signalling events (red text). In-vitro aged fibroblasts (B) 
demonstrate reduced EGF-R levels and fail to reach phenotypic maturity in response to TGF- 
p i associated with reduced induction of EGF and a failure of CD44-EGF-R co-localisation
(D). CD44 expression is identical in young and aged phenotype but in response to TGF-pi 
young cells demonstrate CD44 re-location whereas aged cells do not. Restoration of EGF-R 
levels in aged cells failed to restore the potential for phenotypic activation by TGF-pi (E). 
Restoration o f EGF-R levels and co-stimulation with TGF-pi and EGF in aged fibroblasts led 
to augmented phenotypic activation characterised by up-regulated a-SMA and induction of 
HAS2 and TSG-6. (F) Restoration of both EGF-R and HAS2 allowed for TGFpi mediated 
myofibroblastic differentiation without the need for exogenous EGF (F). This was also 
associated with restoration o f CD44-EGF-R co-localisation.
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Chapter 6 
General Discussion
The data presented herein provide a mechanism to explain age dependent resistance of 
dermal fibroblasts to phenotypic activation. Figure 6.1 illustrates my current proposed 
model. Synergy between TGF-pl-dependent pathways and competent EGF-R-signalling 
pathways are required for TGF-pi-dependent fibroblast-myofibroblast differentiation. 
This contains at least two distinct but cooperating pathways that involve TGF-pl - 
Smad2 activation (step 1) and HA dependent EGF-R-ERK1/2 signalling (steps 2-8) and 
the latter is compromised during in-vitro aging. In a young cell TGF-pl-mediated 
synthesis of EGF (step 2) phosphorylates the EGF-R (step 3). Activation of the EGF-R 
signalling pathway is required for elevated transcription of HAS2 induced HA 
accumulation (step 4) and its assembly into a pericellular coat (step 5). The HA-binding 
protein TSG-6 has been shown to be critical in facilitating this step. I propose that 
binding of HA to its receptor CD44 orchestrates its association with EGF-R, (step 6) 
while signalling downstream of this complex triggers phosphorylation of the p42/p44 
MAP kinases, ERK1 and ERK2 (step 7) and cytoskeletal activation via calmodulin- 
dependent kinase II (step 8). Activation of these pathways together with Smad 
dependent transcriptional regulation of a-SMA is then responsible for reorganisation of 
the actin cytoskeleton required for phenotypic activation (step 9).
With in-vitro aging, numerous aspects of this signalling cascade (highlighted in red) are 
impaired, including decreased expression of EGF-R, suppression of TGF-pl dependent 
EGF synthesis and the resultant failure of induction of HAS2 dependent HA and its 
assembly into a pericellular coat. The result of this is loss of CD44-EGF-R co­
localisation leading to selective impairment of the ERK 1/2 signalling pathway and 
resistance to phenotypic maturation. This model has the potential to be a major 
advancement in the field o f wound healing and to change the way TGF-pl promoted 
myofibroblast differentiation is viewed; however there remain a number of uncertainties 
relating to the proposed mechanism which are now discussed for each step.
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F igure 6.1 Proposed m odel f o r  the signal transduction pathw ays involved in TG F-fll-m ediated  
fibroblast-m yofibroblast differentiation. The age-related defects in this pathway (highlighted 
red) confer resistance to m yofibroblastic differentiation.
(1) Sm ad phosphory lation  causes d issociation  from  the recep tor and stim ulation o f  
assem bly  o f  heterom eric  com plexes betw een the phosphory la ted  R -Sm ad and the Co- 
Sm ad, Sm ad4. T his results in nuclear accum ulation  o f  th is com plex  and subsequent 
transcrip tional ac tiva tion  o f  target genes. In turn, th is  cascade activates the transcrip tion  
o f  an  inhibitory Sm ad (Sm ad 7), w hich can in teract w ith  the  T G F-p receptor to block 
Sm ad activation. W hilst the data  suggests that T G F signalling  m achinery  is intact 
fo llow ing in-vitro  aging w e cannot exclude potential age-related  differences 
dow nstream  o f  Sm ad phosphorylation. It w ould  be in teresting  to further investigate 
Sm ad4 and Sm ad7 expression  in young and aged cells.
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Furthermore, autocrine generation of TGF-P 1 levels remained constant in young and 
aged fibroblasts. Collectively these results suggested that deficits in TGF-P 1 
responsiveness by aged cells could not be attributed to a global deficit in TGF-P 1 
signalling. It could be argued, however, that the interpretation that young and aged cells 
share identical autocrine TGF-P 1 signalling would have been more convincing had 
examination of TGF-pl at the level of transcription been combined with measurement 
of protein synthesis by ELISA. Furthermore, TGF-pl is generated in a biologically 
inactive form, requiring activation before subsequent signalling can occur [354, 355]. 
Therefore, since the activity of any generated TGF-P was not assessed by bioassay it is 
also worth considering that the activity of TGF-pl generated by young and aged cells 
could have varied despite apparent similar generation.
(2) The data suggests that activation of EGF-R by TGF-pl was mediated through 
synthesis of EGF. The mechanism regulating induction of EGF by TGF-P 1 was not 
investigated. Transcriptional control o f human EGF is poorly understood. It has been 
shown that 5.5 kb of the 5’- 6 flanking region of the mouse EGF gene is sufficient to 
direct reporter gene expression [356, 357]. In addition, studies of the mouse EGF 5’ 
UTR have shown an element located between 51 and 35 bases upstream of the EGF 
transcription start site is required for basal activity of the EGF promoter [358]. Three 
proteins bind to this region, one of which is either Spl or a closely related protein [359]. 
In a recent study using 2085 bp of the human EGF promoter in pull-down assays of 
extracts from human keratinocytes, the CREB, Sp-1, NFkB and AP-1 transcription 
factors were all implicated in EGF transcriptional control [360]. The elements involved 
with the TGF-pl-dependent induction of EGF, however, were not examined. It would 
be interesting to analyse the human EGF promoter in more detail and investigate the 
intracellular signalling initiated by TGF-P 1 to define the mechanisms of EGF induction 
by TGF-pl.
(3) Consistent with previous studies [35]. I demonstrated a decrease in EGF-R 
expression as cells age. Matrisian et al [256] argue that decreased responsiveness to 
EGF associated with aging is dependent solely on loss of receptor, however this is not
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always reported. Tran et al [1] observed that as fibroblasts near senescence not only is 
there less receptors for EGF, the remaining receptors face upregulated signal attenuation 
as the dephosphorylating protein tyrosine phosphatase activity is increased. Furthermore 
age-associated delay in the rate of receptor phosphorylation after EGF stimulation and 
impairment in receptor/ligand trafficking has been reported [361]. Specifically Reenstra 
et al add there is an age-associated decrease and delay in the number of occupied 
receptors that are transported intracellularly and in their rate of clearance from the 
plasma membrane [361]. Whilst I have demonstrated aging-related downregulation of 
EGF-R levels, combined upregulation of protein phosphatases, and/or deficits in EGF- 
R-processing mechanisms cannot be dismissed and could contribute to tipping the 
kinase/phosphatase balance in favour of de-phosphorylated EGF-R. It would be 
interesting therefore to investigate whether specific tyrosine phophatases and altered 
receptor activation and trafficking attenuates EGF-R signalling in an aging manner. In 
retrospect, the number of binding sites should have been assessed [35] to ensure a 
decrease in EGF binding sites correlated with aging, this would rule out that fewer 
EGF-R were differentially presented.
An important question is what mechanisms could be responsible for age-dependent 
reduction in EGF-R transcription? Basal EGF-R expression is reported to be tightly 
regulated by microRNA-7 [362]. MicroRNAs (miRs) are small, endogenous, non­
coding RNAs that bind to target mRNA inducing translational repression of the target 
gene, or degradation of the target mRNA. A single miR can regulate many targets and 
miR-7 over-expression in cancer cells down-regulates both EGF-R expression and the 
expression of EGF-R signalling pathway intermediates [362]. My pilot data, using 
QPCR for the mature miR-7, have demonstrated that reduced expression of EGF-R in 
aged fibroblasts is associated with an increased expression of miR-7. To date, however, 
the relationship between mi-R-7 expression and dysregulation of EGF-R has not been 
examined in dermal fibroblasts. It would be interesting to use miR-7 over-expression 
[362] in young cells and miR-7 antagomirs in aged cells to determine whether miR- 7 is 
the key regulator of EGF-R expression.
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The EGF-R is a transmembrane glycoprotein that constitutes one o f four closely related 
members of the erbB family of tyrosine kinase receptors: EGF-R (ErbB-1), HER2/c-neu 
(ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4) [363]. Whilst this study has focused on 
EGF-R (ErbB-1) its potential for interaction with other members of the erbB 
superfamily has been demonstrated [319]. There is growing evidence that in glioma cell 
lines for example there is dual interaction with CD44 by both EGF-R and ErbB2 that is 
comparable to the mechanism proposed in this communication [326]. Furthermore 
ErbB2-ERK signalling and FIAS regulation are functionally coupled in human ovarian 
tumour cells [205]. HA may play an important role in activating CD44-associated 
p i85her2 kinase activity required for the onset of human ovarian tumour cell growth
[364]. It would therefore be interesting to extend the present data to investigate the 
regulation of fibroblast phenotype by HER2/ ErbB-2.
(4) HAS2 expression and induction are essential to the differentiation process. An 
important question is how do EGF-R and TGFpRl synergise to control HAS2 
expression. Work in ION has identified the transcription start site of the HAS2 gene
[365], and subsequent in silico analysis of the 3 kb of genomic DNA upstream of HAS2 
identified a number of putative transcription factor binding sites (TFBSs) of potential 
functional significance in EGF and TGF-pl-signalling. These include multiple 
recognition motifs for the binding of activator protein 1 (API), extracellular signal- 
regulated kinases (ERKs), signal transducers and activator of transcription (STAT)l and 
3, and the Smad family of transcription factors. It has also been shown that specificity 
protein (Sp)l and Sp3 are required for HAS2 mRNA synthesis in renal proximal tubular 
epithelial cells (PTC) [365, 366]. In addition, recent preliminary data demonstrated that 
siRNA knockdown of Spl and Sp3 inhibits HAS2 up-regulation stimulated by IL-lp in 
these cells. It would be interesting therefore to investigate the involvement of Spl/Sp3 
in the HAS2 transcriptional responses to TGF- pi-driven differentiation.
The posttranscriptional regulation of HAS2 mRNA by its natural antisense RNA, 
HAS2AS, has recently been described in osteosarcoma cells [367]. Preliminary work in 
ION has demonstrated that stimulation with TGF-p 1 in PTC induced coordinated 
temporal profiles of HAS2AS and HAS2 transcription, and it was postulated that
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transcription of the antisense RNA stabilises or augments HAS2 mRNA expression in 
these cells. It is interesting to speculate therefore that a modification in HASAS 
expression in aged dermal fibroblasts could contribute to diminished HAS2 induction 
by TGF-P 1 associated with the aged phenotype.
(5) One of the principle differences between young and aged dermal fibroblast was 
the inability of the latter to form pericellular HA coats which was demonstrated to be 
necessary for driving the myofibroblastic phenotype. Resistance to myofibroblastic 
conversion coupled with failure to synthesis HA coats was also reported for oral 
fibroblasts [159]. Despite its obvious involvement, the functional role of the HA coat in 
phenotypic conversion has however remained elusive. Myofibroblasts are controlled by 
the mechanical microenvironment, in particular, by the organisation and stiffness of the 
ECM [368]. Whilst increasing the matrix ridgity has been shown to increase a-SMA 
expression [369] stress release leads to reduced a-SMA [370]. Even though TGF-pi is 
always present following wounding the mechanical characteristics of the environment 
appear to modulate its action to induce either migration or contraction [68]. The role of 
the pericellular matrix in mechanotransduction and cell response to strain has been 
described in several studies. It has been postulated that structured HA may form the 
basis of a dynamic and changing network through which cells may communicate and 
respond to external forces. Several studies provide evidence that in response to 
mechanical strain, cells can respond by synthesising a matrix that allows the cells to 
adapt to the new mechanical environment. For example an increase in pericellular HA 
has been described in human cervical fibroblasts [371], smooth muscle cells [372] and 
lung fibroblasts [373] in response to cyclic stretch. It is therefore interesting to speculate 
that the pericellular HA coat can acts as a mechano-sensor in response to cellular injury, 
triggering and maintaining the contractile phenotype through mechanical cues from the 
surrounding tissue. By this rational one can see why the failure of aged fibroblasts to 
synthesis a HA coat could be detrimental to the progression of wound closure and scar 
formation.
Interestingly one study demonstrated that exogenous HA can act as a scavenger of 
reactive oxygen species (ROS) and confer protection from oxidative damage in
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fibroblasts [374] during which it undergoes degradation [375]. Injury by ROS has been 
shown to play a critical role in the degenerative changes that are characterised by a 
decline in cell numbers and viability which occurs with aging. Cells may undergo 
premature senescence in response to a variety of external stimuli, for example oxidative 
stress and the accumulation of senescent fibroblasts within age-related chronic wounds 
have been explained by oxidative stress [94]. It is therefore interesting to speculate that 
the HA coat plays a protective role and as cells age excess ROS could induce shedding 
of pericellular HA. This could theoretically explain loss of pericellular HA with aging. 
An increase in low-molecular-weight HA due to depolymerisation of HA might be 
expected but this was clearly not the case in my in-vitro aging model.
Versican expression hampers HA pericellular coat formation [193]. In a recent paper , 
Suwan et al [248] generated mice whose versican demonstrated decreased HA binding 
affinity, thereby exhibiting fibroblasts with a disorganised HA matrix. They make the 
convincing argument that disruption of the HA network structure caused constitutive 
ERK 1/2 phosphorylation via CD44 and led to premature senescence. It is interesting to 
speculate that modifications in HA (i.e. loss of coat), could be the catalyst for initiating 
cells to undergo cellular aging and senescence as opposed to my model where 
diminished HA levels are a consequence of cellular aging. It would be interesting to 
test these hypothesises further; fibroblast populations could be cultured through to 
senescence in varying HA concentrations to establish if a reduced HA environment 
confers protection against premature senescence i.e. can we prolong the proliferative 
lifespan of fibroblasts and hence extend senescence?
There is a current focus on the role of hyaladherins, such as Ial, TSG-6 and versican, in 
regulating HA pericellular coat formation. Recent published data suggests that the 
balance between theses hyaladherins maintains an equilibrium that regulars the 
assembly of the pericellular coat [193, 194, 248]. Mechanisms which regulate HA 
binding proteins like TSG-6 may present alternative therapeutic targets for the control 
of HA coat formation and regulation of TGF-P 1-dependent wound healing responses.
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(6) The data indicate that the affect of TGF-pl on myofibroblast differentiation 
and HA generation is mediated through EGF-R signalling. Our data suggest that EGF-R 
activation can occur through either of two mechanisms. The first involves direct 
interaction with EGF leading to HAS2 induction. The second involves interaction with 
CD44 and is mediated by HA. Previous workers from this laboratory have shown that 
the accumulation of HA that occurs alongside fibroblast to myofibroblast differentiation 
was associated with re-localisation of CD44, from a punctuate distribution to a more 
diffuse staining pattern [266]. The functional consequences of these observations were 
not determined. Here I have shown that in addition to re-localisation, CD44 physically 
associates with EGF-R. Redistribution of cell surface CD44 may well facilitate this 
process. Accordingly age-dependent failure of CD44-EGF-R interaction was associated 
with age-dependent failure of CD44 localisation. Webber et al. demonstrated in lung 
fibroblasts that CD44 re-localisation coincided with a redistribution of ALK5 (TGFRI) 
from lipid rafts [161]. In HeLa, A431 and Hep2 cells, EGF-R localises to lipid-rafts on 
the cell-surface and this sequesters a fraction of the receptors in a state inaccessible to 
ligand binding [376]. Furthermore, cholesterol depletion of the plasma membrane of 
HaCaT cells releases EGF-R to discrete areas on the membrane where they become 
activated [377]. Which (if any) o f these mechanisms are operative in primary dermal 
fibroblasts and myofibroblasts, is not known. It would be interesting to investigate the 
cellular localisation (lipid-raft, non-raft or cytoskeletal-associated) o f CD44 and EGF-R 
associated with the young and aged phenotypes to test the theory that CD44 re­
localisation coincides with increased trafficking to lipid raft-associated pools where it 
associates with EGF-R [209].
Mature human EGF-R is a 170-kDa transmembrane glycoprotein composed of a single 
polypeptide chain o f 1186 amino acid residues [378]. Alteration in EGF-R expression is 
frequently associated with malignant transformation of epithelial tissues, including oral 
mucosa. It was revealed that there is a truncated EGF-R mRNA (~1.5-kb) in oral 
squamous cell carcinoma cell lines and in all keratinocyte cell lines [378]. The potential 
biological relevance o f the truncated receptor are currently being explored. One 
potential mechanism is that the truncated EGF-R may be able to form inactive 
heterodimers with the cell surface EGF-R and interfere with signal transduction. In
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A431 cells, soluble truncated EGF-R has been shown to inhibit tyrosine kinase activity 
of the transmembrane receptor [379]. If this hypothesis is true, then it is interesting to 
speculate that the full-length EGF-R/truncated EGF-R ratio would be critical in EGF-R 
activation. This truncated EGF-R has been reported to span 53 kDa - 100 kDa [378]. I 
have demonstrated in young dermal fibroblasts that anti-CD44-mediated 
immunoprecipitation followed by anti-EGF-R immunoblotting revealed a single band at 
~160kDa with no additional lower molecular weight bands so it is safe to presume this 
corresponded with the full length EGF-R. Whilst immunoprecipitation of CD44 and 
EGF-R was not performed in aged cells, it is interesting to predict detection of a lower 
molecular weight band corresponding to truncated EGF-R. An age-dependent increase 
in truncated EGF-R could provide an additional mechanism for diminished EGF-R 
activity.
(7) When phosphorylated, ERK can either phosphorylate a number of cytoplasmic 
targets or may translocate to the nucleus and activate transcription factors such as c-fos, 
Elk-1 [343] and STAT3. STAT3 activation by ERK has been reported to facilitate 
expression of HAS2, hyaluronan synthesis, and CD44 expression in epidermal 
keratinocytes [343, 380]. It is interesting to speculate that transcription of factors such 
as STAT3 downstream from ERK activation may be partly responsible for EGF-R 
dependent HAS2 induction (stage 4). This could provide an explanation for the rapid 
activation of ERK that was observed in chapter 5.
Preliminary work in this laboratory has demonstrated that in a HA-rich environment 
early and late ERK1/2 activation results in a proliferative response to TGF-pi, whilst in 
a non-HA rich environment only early ERK1/2 activation occurs resulting in an anti­
proliferative response to TGF-pl. Further investigation is needed therefore to decipher 
the biphasic nature of ERK 1/2 activation in my system. It is interesting to speculate that 
early activation of ERK 1/2 is involved in HAS2 induction leading to a HA-rich 
environment which facilitates further activation of ERK 1/2 (late) required for TGF-P 1 
mediated responses.
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(8) Several studies indicate that the intracellular domain of CD44 selectively 
interacts with the intracellular actin cytoskeleton [207] which provides a direct 
transmembrane linkage between HA and the cytoskeleton. Much of the interest in HA 
has arisen from its association with pathological processes, particularly cancer [214]. 
HA-mediated transmembrane interactions between CD44 isoforms and cytoskeletal 
proteins such as ankyrin [203], filamin [205, 206] and cortactin [336] have been 
reported to play a pivotal role in regulating tumour cell behaviour. The work from this 
thesis has described that phenotypic activation is dependent on at least one signalling 
pathway downstream of HA-CD44 targets (i.e. CaMKII) which can regulate 
cytoskeletal organisation. Whilst still inconclusive, the current data does supports a 
functional role of the HA coat in regulating the actin cytoskeletal activities in my 
model. In Chapters 3 & 4 I demonstrated that changes in HA modulate fibroblast 
phenotype and in Chapter 5 I show that an intact cytoskeleton is important for 
maintenance of the HA pericellular coat. Collectively these data enables us to speculate 
that both inside-out and outside-in communication patterns are likely to be occurring 
such that there is a constant flow o f information to and from the cell and its surrounding 
HA matrix. Admittedly, further clarification is needed to elucidate what other signalling 
pathways are involved in HA-CD44-EGF-R modulation of the cytoskeleton and how 
these may be altered with in-vitro aging.
(9) Work by ION, and others have demonstrated that cross-talk between ERK MAP 
kinase and Smad signalling pathways may enhance TGF-(31 dependent responses in 
other cell systems [315, 381]. The mitogen-activated protein kinases, ERK are involved 
in TGF-P 1 signalling via cross-talking with the Smad pathway required for fibroblast 
differentiation [382] and migration [383]. To my knowledge this is the first time that the 
synergistic involvement of these signalling pathways has been implicated in the 
impaired regulation o f dermal fibroblast-myofibroblast activation in the context of 
cellular aging. This raises the question how ERK 1/2 signalling and Smad signalling 
finally converge on the gene level to up-regulate a-SMA and phenotypic activation? 
Proteins from the MAP Kinase pathway have been shown to modify the outcome of 
Smad signalling through several means. They are capable of altering phosphorylation of 
the Smads [384]. However, this is unlikely to occur in my system as I have previously
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shown that Smad phosphorylation is similar in young and aged fibroblast phenotypes. 
They may serve to regulate the capacity o f Smad proteins to translocate to the nucleus 
[385]. They are also capable o f physically interacting with transcription factors, thus 
regulating transcription o f Smad target proteins in the nucleus [386, 387]. Further 
investigation is therefore required to elucidate potential interaction between the 
MAPK/Smad pathways, and to determine signalling events downstream of Smad2 and 
ERK1/2 phosphorylation to delineate the kinetics involved in the regulation of 
fibroblast differentiation by TGF-pl.
This data indicates that decreased functioning in aged cells is not due to a global deficit 
but to specific deficits and the results highlight EGF-R and HAS2 expression as markers 
o f age-related alterations in the fibroblast cell proteome. This begs the question as to 
why cellular activities and proteome makeup are altered such that EGF-R levels for 
example are diminished in the face of in-vitro aging whilst Smad proteins for example 
remain constant. If it was a senescent-associated mechanism, i.e. to prevent replication, 
it would be more advantageous to alter cyclin activation at a key point of convergence 
further downstream. Thus, it seems there is a need to suppress immediate postreceptor 
signalling at the EGF-R and limit both genetic and epigenetic responses. Although a 
general mechanism for the limited responsiveness of aged cells has yet to be 
established, this body of work ascribes to the ‘gate theory’ of aging [388], which states 
that the membrane might play the role as the ‘gate’ to modulate the signals for the aging 
phenotype. Hence in my model, EGF-R and HAS2 can be thought of as ‘gatekeeper’ 
molecules in this respect because they represent potential targets for modulating the 
aging process. Accordingly, the results clearly demonstrate the possibility of reversing 
the aged phenotype, to the functionally active young phenotype, by restoration of 
membrane signalling apparatus i.e. EGF-R and HAS2.
What are the actual ramifications of these findings for age related wound healing? 
During aging dermal fibroblasts lose both proliferative and basal migrative capacity 
[67] and to this we can now add capacity for myofibroblastic differentiation. The end 
result is delayed or incomplete wound healing in aged adults. To compensate, in the 
past, growth factors have been used in clinical trials as adjuvants in non-healing
199
wounds, but as I alluded to in my opening paragraph, with limited success [35]. Such 
findings are not surprising having demonstrated in this body of work that age-related 
resistance to myofibroblastic conversion can be explained not by impaired growth factor 
availability but by intrinsic cellular defects. These data demonstrate that reduced 
responsiveness to TGF-P 1 results from deficits in the apparatus required for cell surface 
receptor-mediated signal transduction (EGF-R) and matrix remodelling (HAS2). Hence 
one can imagine that in a wound environment as fibroblasts rapidly approach 
senescence upon mitogenesis the addition of growth factors like TGF-pl would not 
compensate for inherent impaired cellular activities. One must be careful in applying the 
results of the findings from in-vitro experiments to in vivo clinical problems however 
the implications o f this study are that interventions to improve healing in aged skin need 
to be targeted toward improving cell responsiveness by enhancing cell signalling and 
augmenting the cell response. My data thus support the use of EGF-R and HAS2 gene 
transfer to non-healing wounds in the elderly as a more rationale therapy than 
application of growth factors, since the rate limiting step is receptor/synthase signalling 
and not factor availability (although EGF was shown to be reduced in aged cells).
Because the duration of aging in humans makes it almost impossible to perform in-vivo 
studies, for now fibroblast cultures remain a powerful model for aging-related studies 
[35, 55, 284]. However, perhaps alternative methodologies to cellular senescence are 
necessary to study the essence of cellular changes with age, for example an association 
appears to exist between cellular stress resistance and organismal aging (reviewed in 
[54]. Probably the biggest difference between in-vivo and in-vitro conditions is that cells 
in culture are deprived of interactions with other cell types and the release of growth 
factors and hormones. For instance differences in cell behaviour have been reported 
between 2-D and 3-D culture systems, showing how the microenvironment is essential 
to cell behaviour and function [389]. The next logical step would be to apply this in- 
vitro model into a 3-D culture system. The use of fibroblast-populated collagen lattices 
and organotypic models for example have proved effective in providing a more in-vivo 
like environment whilst avoiding some of the uncontrollable variables associated with 
whole animal studies [222, 390]. Loss of capacity for senescence is, of course, a 
necessary step for immortalization and, ultimately, transformation into a malignant
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phenotype [54]. Beyond the context of age-related wound healing this model may also 
prove useful in studies o f the relationship between replicative aging, HA and 
tumorigenesis.
The work outlined in this thesis has identified a novel functional relationship between 
CD44 and EGF-R in dermal fibroblasts that is mediated through interactions with the 
HA dependent pericellular coat. The obvious implication of this system is the capacity 
for HA to regulate cellular phenotype. The data suggests this may be achieved through 
interactions with the actin cytoskeleton. The proposed model provides new insights not 
only into the mode by which HA may facilitate cellular differentiation but also how 
modifying their matrix environment with aging, dermal fibroblasts can acquire a more 
susceptible phenotype that promotes defective wound healing. In conclusion, this work 
demonstrates intrinsic deficits in EGF-R signalling are responsible for the changes in 
HA synthesis, organisation and assembly observed with in-vitro aging and ultimately 
this confers resistance to TGF-P 1 mediated fibroblast-myofibroblast differentiation. The 
proposed mechanism should not be considered as an endpoint, but rather, one that 
provides a blueprint for future investigations. Further studies to elucidate details of 
these pathways should provide new opportunities for modifying the wound healing 
response and for ameliorating clinical conditions that involve age-related complications.
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Appendix 1: Buffers and Reagents
Block Buffer:
Guanidine Buffer (4 M):
Hyaluronidase Buffer:
PAGE Reducing Buffer (3 x):
PAGE Reducing Buffer (5 x):
PCR Loading Buffer:
Phosphate Buffered Saline (PBS):
Pronase Buffer:
Reagent Diluent:
Running Buffer:
5 % (vol/vol) Tween-20, 0.05 % (wt/vol) NaN3 in 
PBS
4 M guanidine, 50 mM sodium acetate, 0.5 % 
(vol/vol) triton X-100, 0.05 % (wt/vol) sodium 
azide, pH 6
20 mM sodium acetate, 0.15 M NaCl, 0.05 % 
(wt/vol) sodium azide, pH 6
62.5 mM Tris (pH 6.8), 30 % (vol/vol) glycerol, 6 
% (wt/vol) SDS, 0.03 % (vol/vol) bromophenol 
blue, 15 % (vol/vol) 2p mercaptoethanol
62.5 mM Tris (pH 6.8), 50 % (vol/vol) glycerol, 
10 % (wt/vol) SDS, 0.05 % (vol/vol) bromophenol 
blue, 25 % (vol/vol) 2p mercaptoethanol
30 % (vol/vol) glycerol, 0.1 % (wt/vol) Orange G 
2.68 mM KC1, 1.47 mM KH2P 0 4, 137 mM NaCl, 
8.1 mM Na2H P04
100 mM Tris, 0.05 % (wt/vol) sodium azide, pH 
8.0
1.4 % (wt/vol) BSA, 0.05 % (vol/vol) Tween-20 in 
PBS, pH 1.2-1 A
25 mM Tris, 192 mM glycine, 3.5 mM SDS, pH 
8.3
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Stripping Buffer:
TAE Buffer:
Transfer Buffer:
Tris Buffered Saline (TBS): 
Triton Buffer (0.2 %):
Triton Buffer (1 %):
Urea Buffer (8 M):
Wash Buffer:
64 mM Tris, 69 mM SDS, 0.7 % (vol/vol) 20 
mercaptoethanol
40 mM Tris, 40 mM acetic acid, 10 mM EDTA 
25 mM Tris, 192 mM glycine, 20 % (vol/vol) 
methanol
20 mM Tris, 137 mM NaCl, pH 7.6
25 mM Tris, 0.2 % (vol/vol) Triton X-100, 56 mM
caproic acid, 13 mM EDTA, pH 7.5
25 mM Tris, 1 % (vol/vol) Triton X-100, 0.4 M
guanidine, 56 mM caproic acid, 13 mM EDTA,
pH 7.5
8 M urea, 20 mM Bis-Tris buffer, pH 6, 0.2 % 
(vol/vol) Triton X-100
0.05 % (vol/vol) Tween-20 in PBS, pH 7.2-7.4
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